Original Article
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
N Engl J Med 2005; 353:123-132July 14, 2005
- Abstract
Background
We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non–small-cell lung cancer after the failure of first-line or second-line chemotherapy.
Methods
Patients with stage IIIB or IV non–small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens. The patients were stratified according to center, performance status, response to prior chemotherapy, number of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo.
Results
The median age of the 731 patients who underwent randomization was 61.4 years; 49 percent had received two prior chemotherapy regimens, and 93 percent had received platinum-based chemotherapy. The response rate was 8.9 percent in the erlotinib group and less than 1 percent in the placebo group (P<0.001); the median duration of the response was 7.9 months and 3.7 months, respectively. Progression-free survival was 2.2 months and 1.8 months, respectively (hazard ratio, 0.61, adjusted for stratification categories; P<0.001). Overall survival was 6.7 months and 4.7 months, respectively (hazard ratio, 0.70; P<0.001), in favor of erlotinib. Five percent of patients discontinued erlotinib because of toxic effects.
Conclusions
Erlotinib can prolong survival in patients with non–small-cell lung cancer after first-line or second-line chemotherapy.
Media in This Article
Figure 1
Kaplan–Meier Curves for Overall Survival (Panel A) and Progression-free Survival (Panel B) among All Patients Randomly Assigned to Erlotinib or Placebo.Table 1
Baseline Characteristics of the Patients.Article Activity
- Article
Lung cancer is the leading cause of cancer death among men and women in North America.1 In advanced non–small-cell lung cancer, chemotherapy offers symptomatic relief and modest improvement in survival2; responses are brief, with a median time to progression of three to five months. Second-line chemotherapy with docetaxel can prolong survival after platinum-based therapy for non–small-cell lung cancer.3,4 However, there is at present no defined role for third-line chemotherapy. The futility of offering third-line chemotherapy was demonstrated by Massarelli et al.,5 who reported a response rate of only 2 percent and a median survival of four months. Shepherd et al.6 showed that among patients treated with docetaxel after the failure of two or more chemotherapy regimens, survival was identical to that among patients treated with supportive care.
The epidermal growth factor receptor (EGFR) family is part of a complex signal-transduction network that is central to several critical cellular processes. Since EGFR is often found in non–small-cell lung cancer cells,7,8 it has been the focus of efforts to develop new agents that target the EGFR pathway. Erlotinib (Tarceva, OSI Pharmaceuticals) and gefitinib (Iressa, AstraZeneca) inhibit the tyrosine kinase activity of EGFR and have been studied extensively.9-12 In randomized phase 2 trials of gefitinib (Iressa Dose Evaluation in Advanced Lung Cancer [IDEAL] 1 and 2),10,11 the tumors of 10 to 20 percent of patients who were previously treated with platinum-based regimens responded, and in a phase 2 trial of erlotinib among previously treated patients with non–small-cell lung cancer in which 10 percent or more of the cells expressed EGFR, the response rate was 12.3 percent.12 These promising rates are perhaps higher than those possible with other forms of chemotherapy,3-6 but it is unknown whether treatment with an EGFR inhibitor prolongs survival. For this reason, the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) conducted a trial (BR.21) to compare erlotinib with placebo after the failure of standard chemotherapy for non–small-cell lung cancer. The inclusion of a control group receiving placebo was considered ethical in view of the lack of benefit from further chemotherapy after the failure of standard treatment.5,6
Methods
Study Design
This international, phase 3, randomized, double-blind, placebo-controlled trial of erlotinib after the failure of first-line or second-line chemotherapy for non–small-cell lung cancer was designed by the NCIC CTG. Patients were randomly assigned in a 2:1 ratio to receive oral erlotinib at a dose of 150 mg daily or placebo. Randomization was performed centrally by Applied Logic Associates (Houston), with the use of the minimization method.13 Patients were stratified according to center, Eastern Cooperative Oncology Group performance status (0 or 1 vs. 2 or 3, with higher scores indicating greater impairment), best response to prior therapy (complete or partial response vs. stable disease vs. progressive disease), number of prior regimens received (one vs. two), and exposure to prior platinum therapy (yes vs. no).
The primary end point was overall survival. Secondary end points included progression-free survival, overall response rate (complete and partial), duration of response, toxic effects, and quality of life. Responses were assessed with the use of the Response Evaluation Criteria in Solid Tumors (RECIST),14 and toxic effects were assessed according to the Common Toxicity Criteria of the National Cancer Institute (version 2.0). The European Organization for Research and Treatment of Cancer (EORTC) quality-of-life questionnaire (QLQ-C30) and the quality-of-life questionnaire for patients with lung cancer (QLQ-LC13) were used to evaluate patients' quality of life.
The protocol was approved by the ethics review boards at all participating institutions, and all patients provided written informed consent. Support was provided by the NCIC and OSI Pharmaceuticals. Data were collected, managed, and analyzed by the NCIC CTG, and the manuscript was written by members of the NCIC CTG. OSI Pharmaceuticals reviewed the final manuscript and provided comments on it. Confidentiality was maintained by both the NCIC CTG and OSI Pharmaceuticals. The study chair, Dr. Shepherd, and the physician coordinator, Dr. Seymour, reviewed all the data and confirmed their completeness and accuracy.
Eligibility Criteria
Patients 18 years of age or older with an Eastern Cooperative Oncology Group (ECOG) performance status between 0 and 3 were eligible in the presence of documented pathological evidence of non–small-cell lung cancer. The patients had to have received one or two regimens of combination chemotherapy and not be eligible for further chemotherapy. Patients 70 years of age or older may have received therapy with one or two single agents. Patients had to have recovered from any toxic effects of therapy and were randomly assigned to the study treatment at least 21 days after chemotherapy (14 days after treatment with vinca alkaloids or gemcitabine) and 7 days after radiation. Adequate hematologic and biochemical values were required.
Patients with prior breast cancer, melanoma, or hypernephroma were ineligible, as were those with other malignant diseases (except basal-cell skin cancers) within the preceding five years. Other exclusion criteria were symptomatic brain metastases, clinically significant cardiac disease within one year, ventricular arrhythmias requiring medication, and clinically significant ophthalmologic or gastrointestinal abnormalities.
Study Procedures
Within seven days before randomization, a history and physical examination were obtained and hematologic and biochemical testing, chest radiography, and assessments of toxic effects and quality of life were obtained. Computed tomographic scans of the chest and abdomen were obtained within 28 days before randomization. For a patient to be evaluated for a response, at least one measurable lesion was required, but measurable disease was not mandatory for eligibility. Only patients with measurable disease were included in the analyses of complete or partial response.
Administration of the study medication was to start within two days after randomization. For grade 2 diarrhea, loperamide was recommended without reduction of the dose of erlotinib. For grade 3 diarrhea, the study treatment was withheld until the diarrhea was grade 1 or less, and then erlotinib at a dose of 100 mg daily was started. For grade 1 or 2 rash, treatment modification was not recommended. For grade 3 rash, treatment was withheld, the rash was treated symptomatically, and erlotinib at a dose of 100 mg daily was restarted when the rash was grade 1 or less.
History taking, physical examination, and hematologic and biochemical testing were performed every four weeks, and radiologic investigations every eight weeks. Patients' quality of life was evaluated every four weeks in countries with validated versions of the questionnaires.
EGFR Expression
Separate written consent for optional tissue banking and correlative studies was obtained. EGFR expression was determined with the use of immunohistochemistry in a central laboratory that used Dako kits (DakoCytomation). Positivity was defined as more than 10 percent of cells staining at any intensity for EGFR.
Statistical Analysis
The trial was designed to detect, with 90 percent power and a two-sided type I error of 5 percent, a 33 percent improvement in median survival from four months as estimated in the placebo group. For the final analysis, 582 deaths were required and were projected to occur with a sample size of 700 patients enrolled over a period of 14 months with 6 months of follow-up. The required number of deaths had occurred by January 2004, and the database was locked as of April 23, 2004. There was no interim analysis. Tumor responses were validated centrally for the first 333 patients in the trial.
The stratified log-rank test, accounting for stratification factors at randomization (except center) and EGFR protein expression (positive vs. negative vs. unknown), was used to compare progression-free survival and overall survival between treatment groups. Exploratory forward stepwise regression analyses with the use of the Cox model were performed to adjust for treatment effect and to identify prognostic factors for progression-free survival and overall survival. Candidate covariates included EGFR expression, stratification factors (except center), sex, age (60 years or less vs. more than 60 years), race or ethnic group (Asian vs. others), prior radiotherapy (yes vs. no), histologic subtype of cancer (adenocarcinoma vs. others), and smoking status (smoker vs. nonsmoker vs. unknown). Race was self-reported or determined by study personnel and was not based on country of domicile. Fisher's exact test was used to compare response rates between levels of potential predictors and rates of toxic effects between treatments. Times to deterioration (a 10-point increase from the baseline score) for cough, dyspnea, and pain were identified prospectively as the primary end points for the analysis of quality of life15 and were analyzed with the use of the log-rank test, with adjustment according to the Hochberg method16 for the comparison of multiple end points. All P values were two-sided.
Results
Patient Characteristics
Between August 2001 and January 2003, 731 patients were randomly assigned to erlotinib (488) or placebo (243). Twenty-two patients (12 assigned to erlotinib and 10 assigned to placebo) were ineligible for the following reasons: three prior chemotherapy regimens (9); single-agent chemotherapy for patients less than 70 years of age (2); inadequate time since the last treatment (5); abnormal biochemistry results (4); and symptomatic brain metastases (2). All 731 patients were included in the efficacy analyses, and 727 treated patients (485 assigned to erlotinib and 242 assigned to placebo) were included in the safety analyses. Eight patients assigned to erlotinib (1.6 percent) and 18 assigned to placebo (7.4 percent) received other EGFR inhibitors after study medication was discontinued. The groups were balanced with respect to baseline characteristics and important prognostic variables (Table 1Table 1
Baseline Characteristics of the Patients.).Response and Survival
In patients with at least one target lesion, the lesions were evaluated according to RECIST (427 patients assigned to erlotinib and 211 assigned to placebo). In the erlotinib group, the rates of complete response and partial response were 0.7 percent and 8.2 percent, respectively (median duration, 7.9 months); in the placebo group, the rate of partial response was less than 1 percent (P<0.001), but these responses were not externally validated. In an intention-to-treat analysis of all patients randomly assigned to treatment, the disease-control rate (i.e., the rate of complete or partial responses and stable disease) in the erlotinib group was 45 percent; 38 percent of the patients had progressive disease, and among the remaining 17 percent progression was not confirmed. The likelihood of a response to erlotinib (Table 2Table 2
Analysis of Responses to the Study Treatment.) among patients with non–small-cell lung cancer was not significantly altered by performance status, prior treatments, prior response, or age, but it was higher among women (P=0.006), nonsmokers (P<0.001), Asians (P=0.02), patients with adenocarcinoma (P<0.001), and patients in whom 10 percent or more of the tumor cells expressed EGFR (P=0.10). In multiple logistic-regression analyses, never having smoked (P<0.001), the presence of adenocarcinoma (P=0.01), and EGFR expression (P=0.03) were associated with responsiveness to erlotinib.At the time of analysis, 587 deaths had occurred (378 in the erlotinib group and 209 in the placebo group). Figure 1Figure 1
Kaplan–Meier Curves for Overall Survival (Panel A) and Progression-free Survival (Panel B) among All Patients Randomly Assigned to Erlotinib or Placebo. shows Kaplan–Meier curves for overall survival and progression-free survival. Median overall survival in the erlotinib group was 6.7 months, and in the placebo group it was 4.7 months (adjusted hazard ratio, 0.70; 95 percent confidence interval, 0.58 to 0.85; P<0.001). In the Cox regression analysis, erlotinib remained associated with longer survival (P=0.002), as did Asian origin (P=0.01), adenocarcinoma on histologic examination (P=0.004), and never having smoked (P=0.048 vs. current or past smoking). Table 3Table 3
Analysis of Survival. shows the exploratory subgroup analyses. Although the sample sizes may be inadequate to detect small or moderate differences, a benefit from erlotinib was apparent in most of the subgroups. The interaction between treatment and the covariate defining the subgroup was statistically significant only for smoking status. At the time of analysis, 682 patients had had progression of disease (450 in the erlotinib group and 232 in the placebo group). Median progression-free survival was 2.2 months in the erlotinib group and 1.8 months in the placebo group (adjusted hazard ratio, 0.61; 95 percent confidence interval, 0.51 to 0.74; P<0.001). In the Cox model, treatment with erlotinib (P<0.001) and never having smoked (P<0.01 for the comparison with current or past smoking) were associated with longer progression-free survival.Toxic Effects
Four patients who underwent randomization did not receive treatment. Table 4Table 4
Toxic Effects and Dose Modifications among 727 Patients Receiving the Study Drugs. shows that 19 percent of the erlotinib group required dose reductions because of drug-related toxic effects, as compared with 2 percent of the placebo group, most frequently because of rash (12 percent) and diarrhea (5 percent); 26 patients (5 percent) discontinued erlotinib because of drug-related toxic effects, as compared with 4 patients (2 percent) receiving placebo. There was a higher incidence of infection among the erlotinib patients, which may reflect longer follow-up (P<0.001). There were similar rates of pneumonitis and pulmonary fibrosis in the two groups. Two patients died of pneumonitis (one in each group).Quality of Life
Compliance was similar in the two groups. Patients who had responded to the quality-of-life questionnaire at baseline and had one follow-up assessment were included in the analysis. The median time to deterioration with regard to cough (4.9 months among patients receiving erlotinib and 3.7 months among those receiving placebo, P=0.04 with Hochberg adjustment), dyspnea (4.7 months and 2.9 months, respectively; adjusted P=0.03), and pain (2.8 months and 1.9 months, respectively; adjusted P=0.04) in favor of erlotinib. These results are consistent with response-based analyses of the quality of life, which found that more patients receiving erlotinib had improvement in cough, pain, and dyspnea and in the domain of overall physical function (further information is in the Supplementary Appendix, available with the complete text of this article at www.nejm.org).
Discussion
Docetaxel is the only agent known to prolong survival among patients with disease progression after cisplatin-based chemotherapy for non–small-cell lung cancer.3,4,17 Few options are available for the treatment of patients with disease progression after docetaxel or those who are not eligible for second-line chemotherapy.5,6 Clearly, new treatments are needed for such patients.
Expression of EGFR is common in non–small-cell lung cancer.18-20 Several agents that target EGFR are in various phases of clinical evaluation.9,21 The orally active EGFR tyrosine kinase inhibitors gefitinib and erlotinib have been evaluated in several trials. In the IDEAL 1 trial,10 patients with non–small-cell lung cancer with disease progression after platinum-based chemotherapy were randomly assigned to receive gefitinib, at a dose of 250 mg or 500 mg daily. There were no differences between the two doses with respect to response rate, time to progression, or median survival. The response rates were also similar whether gefitinib was used as second-line treatment (17.9 percent of patients) or third-line treatment (19.8 percent of patients). In the IDEAL 2 trial,11 which enrolled symptomatic patients in whom two or more chemotherapy regimens containing platinum and docetaxel had failed, the response rates were 12 percent and 9 percent, respectively, for the two dose levels. More adverse events were seen with the dose of 500 mg in both trials, but discontinuation of treatment because of toxic effects was uncommon at either dose. In a phase 2 trial of erlotinib, the response rate was 12 percent, and response did not correlate with level of EGFR in the tumor.12
In our trial, the response rate of 8.9 percent was similar to rates reported for erlotinib and gefitinib.10-12 Some investigators have reported that responsiveness to EGFR inhibitors correlates with sex, histologic type, race or ethnic origin, and smoking status.10,11,21 We also found that response was higher among Asians, women, patients with adenocarcinoma, and lifetime nonsmokers. Contrary to previous reports,12 the response rate in our trial was higher when 10 percent or more of tumor cells expressed EGFR.
Activating mutations in the EGFR gene have been found to predict a response to gefitinib.22-27 The results of our assays for the number of copies and mutation status of the EGFR gene are published in this issue of the Journal.28 Higher response rates were found among patients with high numbers of gene copies and mutations, but the difference was significant only for gene copies.
Because none of the early trials10-12 had a placebo control group, it is not possible to determine whether EGFR-inhibitor therapy was superior to palliative treatment. In our placebo-controlled trial, erlotinib did provide clinically meaningful prolongation of survival. According to the Kaplan–Meier estimates, the median survival was prolonged by two months, and 31 percent of patients treated with erlotinib were alive at one year, as compared with 22 percent in the placebo group. The two-month prolongation of survival is similar to that achieved with docetaxel in the setting of second-line chemotherapy,3,4 even though half the patients in our trial were treated after both first-line and second-line chemotherapy. In this trial and another trial,3 a significant prolongation of survival was achieved despite response rates of less than 10 percent, perhaps because a high proportion of the patients had durable stable disease while receiving treatment. Survival in this trial appears to be longer than what was achieved in a similar trial of gefitinib, although the response rates were similar in both studies. The characteristics of the patients in these two trials, however, may have differed somewhat.29
Exploratory multivariate analyses showed that only Asian origin, adenocarcinoma on histologic examination, and a history of not smoking were significant independent predictors of survival after adjustment for treatment and other potential predictors. Erlotinib had a beneficial effect on survival in almost all subgroups tested, but only the interaction between smoking status and treatment was significantly predictive of a differential effect on survival. Notably, the presence of EGFR gene mutations was not predictive of a survival benefit from erlotinib in our study.28
In the IDEAL 2 trial,11 gefitinib rapidly reduced symptoms in 35 percent to 43 percent of patients. In our trial, significantly more patients in the erlotinib group than in the placebo group had reductions in dyspnea, pain, and cough. Furthermore, the time to exacerbation of these symptoms was significantly longer in the erlotinib group. The analysis of the quality of life showed that symptom improvement was also associated with significantly improved physical function.
Rash30 and diarrhea are the main toxic effects of EGFR inhibitors.9 They led to dose reduction in 12 percent and 5 percent of patients, respectively, in our trial. Pneumonitis has been reported mainly in Japan following treatment with gefitinib.31 However, four trials of gefitinib or erlotinib combined with chemotherapy for non–small-cell lung cancer reported similar rates of pneumonitis in active-treatment and placebo groups.32-35 We rarely encountered pneumonitis or pulmonary fibrosis.
In summary, this trial shows that erlotinib, an oral tyrosine kinase inhibitor of EGFR, prolongs survival and decreases symptoms, as compared with placebo, in previously treated patients with non–small-cell lung cancer.
Supported in part by a grant from OSI Pharmaceuticals to the National Cancer Institute of Canada Clinical Trials Group.
We are indebted to Dr. Joseph Pater and Dr. Keyue Ding for their contribution to the trial; to T. Masterson, W. Gollogly, S. Melinyshyn, A. Sadura, M. Whitehead, L. Lafond, K. Hann, J. Ottaway, D. Voskoglou-Nomikos, D. Jones-Moar, T. Boyd, M. Savoie, A. Urton, T. Hanna, T. Feener, and S. Virk of the National Cancer Institute of Canada Clinical Trials Group; and to M. Ptaszynski and B. Geiger of OSI Pharmaceuticals.
Source Information
From the Departments of Medical Oncology and Hematology (F.A.S.) and Radiation Oncology (A.B.), the University Health Network, Princess Margaret Hospital Site, and the University of Toronto (F.A.S., A.B.) — both in Toronto; the Instituto de Cancer Arnaldo Vieira de Carvalho, São Paulo (J.R.P.); the Oncological Institute Ion Chiricuta, Cluj-Napoca, Romania (T.C.); the Department of Medical Oncology, National Cancer Centre, Singapore (E.H.T.); the Department of Oncology, McGill University, Montreal (V.H.); the Faculty of Medicine, Chiangmai University, Chiangmai, Thailand (S.T.); the Confidence Medical Center, San Isidro, Argentina (D.C.); Pramongkutklao Hospital, Bangkok, Thailand (S.M.); Cross Cancer Institute, Edmonton, Alta., Canada (M.S.); the Instituto Nacional de Cancer, Praça da Cruz Vermelha, Rio de Janeiro, Brazil (R.M.); the Instituto Medico Alexander Fleming, Buenos Aires (M.K.); the Oncology Institute, Bucharest, Romania (M.D.); Hôtel Dieu Health Sciences Hospital, St. Catharines, Ont., Canada (B.F.); the National Cancer Institute of Canada Clinical Trials Group, Kingston, Ont., Canada (D.T., D.J., L.S.); and OSI Pharmaceuticals, Boulder, Colo. (G.C., P.S.).
The investigators and centers participating in this National Cancer Institute of Canada Clinical Trials Group study are listed in the Appendix.
Appendix
The following investigators and centers participated in this National Cancer Institute of Canada Clinical Trials Group study: A.M. Alvarez, J.L. Martinez, M. Varela, M. Van Kooten, S. Jovtis, Buenos Aires; M. Freue, Lanus, Argentina; M. Rosenthal, Parkville, Australia; D. Yip, Garran, Australia; R. De Boer, Footscray, Australia; S. Ackland, Waratah, Australia; P. Clingan, Wollongong, Australia; D. Campos, San Isidro, Argentina; A. del Giglio, Santo Andre, Brazil; C. Mathias, Bahia, Brazil; I.L Santoro, J.R. Pereira, São Paulo; A.M. Murad, Belo Horizonte, Brazil; R.D.A. Ribeiro, Ceara, Brazil; S. Lago, Porto Alegre, Brazil; J. Vinholes, Porto Alegre, Brazil; R. Martins, Rio de Janeiro; S. Rorke, St. John's, Canada; W. Morzycki, Halifax, Canada; F. Laberge, R. Whittom, Ste.-Foy, Canada; V. Hirsh, J. Ayoub, Montreal; R.W. Gregg, Kingston, Canada; S. Laurie, Ottawa; F. Wierzbicki, Oshawa, Canada; B. Findlay, St. Catharines, Canada; A. Arnold, Hamilton, Canada; L.A. Zibdawi, Newmarket, Canada; J. Meharchand, F. Shepherd, R.L. Burkes, Y.C. Ung, Toronto; J.J. Wilson, Weston, Canada; B. Pressnail, Barrie, Canada; R. Myers, Mississauga, Canada; J. Noble, Sudbury, Canada; D. Walde, Sault Ste. Marie, Canada; S. Navaratnam, Winnipeg, Canada; H.I. Chalchal, Regina, Canada; D.G. Morris, Calgary, Canada; M. Smylie, Edmonton, Canada; D. Fenton, Kelowna, Canada; H. Martins, Victoria, Canada; J. Gutierrez, Las Condes, Chile; U. Gatzemeier, Grobhansdorf, Germany; J. von Pawel, Gauting, Germany; R. Loddenkemper, Berlin; A. Gerogianni, Athens; R. Chan, Pokfulam, Hong Kong; D. Flex, Petach Tikva, Israel; D. Loven, Afula, Israel; M.C. Wollner, Haifa, Israel; H. Biran, Rehovot, Israel; M. Levitt, Tel Hashomer, Israel; A. Cyjon, Zerifin, Israel; J. Lopez, Dviango, Mexico; J. Robles, Mexico City; G. Calderillo, Tlalpan, Mexico; T. Christmas, Auckland, New Zealand; A.B. Simpson, Wellington, New Zealand; M. Dediu, Bucharest, Romania; T.-E. Ciuleanu, Cluj-Napaca, Romania; M. Patran, Sibiu, Romania; L. Miron, Lasi, Romania; L. Ek, Lund, Sweden; B. Bergman, Gothenburg, Sweden; R. Soo, E.H. Tan, Singapore; S. Maoleekoonpairoj, A. Cheirsilpa, Bangkok, Thailand; S. Thongprasert, Chiangmai, Thailand; C.M. Rudin, Chicago; P. Ruff, Johannesburg, South Africa; D.J. Hacking, Westridge, South Africa; S.J. Fourie, Pretoria, South Africa; C. Jacobs, Port Elizabeth, South Africa; C.F. Slabber, Brooklyn Square, South Africa; D.A. Vorobiof, Parklands, South Africa; K. Chi-Hei, Pokfulam, Hong Kong; W. Arpornwirat, Bangkok, Thailand; M. Zukin, Rio de Janeiro.
- References
References
1
Jemal A ,Tiwan RC ,Murray T , et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29
CrossRef | Web of Science | Medline2
Non-small Cell Lung Cancer Collaborative Group
CrossRef | Web of Science3
Shepherd FA ,Dancey J ,Ramlau R , et al. A prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103
Web of Science | Medline4
Fossella FV ,DeVore R ,Kerr RN , et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18:2354-2362[Erratum, J Clin Oncol 2004;22:209.]
Web of Science | Medline5
Massarelli E ,Andre F ,Liu DD , et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003;39:55-61
CrossRef | Web of Science | Medline6
Shepherd FA ,Dancey J ,Ramlau R , et al. Prospective randomized trial of docetaxel versus best support care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Classic Pap Curr Comment 2001;6:87-967
Rusch V ,Klimstra D ,Venkatraman E ,Pisters PW ,Langenfeld J ,Dmitrovsky E . Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer, but does not predict tumor progression. Clin Cancer Res 1997;3:515-522
Web of Science | Medline8
Brabender J ,Danenberg KD ,Metzger R , et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001;7:1850-1855
Web of Science | Medline9
Sridhar SS ,Seymour L ,Shepherd FA . Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 2003;4:397-406
CrossRef | Web of Science | Medline10
Fukuoka M ,Yano S ,Giaccone G , et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL Trial). J Clin Oncol 2003;21:2237-2246[Erratum, J Clin Oncol 2004;22:4811.]
CrossRef | Web of Science | Medline11
Kris MG ,Natale RB ,Herbst RS , et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158
CrossRef | Web of Science | Medline12
Perez-Soler R ,Chachoua A ,Hammond LA , et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247
CrossRef | Web of Science | Medline13
Tu D. Minimization procedure. In: Chow SC, ed. Encyclopedia of biopharmaceutical statistics. New York: Marcel Dekker, 2003:614-8.
14
Therasse P ,Arbuck SG ,Eisenhauer EA , et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216
CrossRef | Web of Science | Medline15
Osoba D ,Rodrigues G ,Myles J ,Zee B ,Pater J . Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-144
Web of Science | Medline16
Hochberg Y . A sharper Bonferroni's procedure for multiple tests of significance. Biometrika 1988;75:800-803
CrossRef | Web of Science17
Pfister DG ,Johnson DH ,Azzoli CG , et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353
CrossRef | Web of Science | Medline18
Salomon DS ,Brandt R ,Ciardiello F ,Normanno N . Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232
CrossRef | Web of Science | Medline19
Fontanini G ,De Laurentiis M ,Vignati S , et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998;4:241-249
Web of Science | Medline20
Grunwald V ,Hidalgo M . Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003;95:851-867
CrossRef | Web of Science | Medline21
Rusch V ,Baselga J ,Cordon-Cardo C , et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993;53:Suppl:2379-2385
Web of Science | Medline22
Miller VA ,Kris MG ,Shah N , et al. Bronchioalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-1109
CrossRef | Web of Science | Medline23
Lynch TJ ,Bell DW ,Sordella R , et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139
Full Text | Web of Science | Medline24
Paez JG ,Janne PA ,Lee JC , et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500
CrossRef | Web of Science | Medline25
Pao W ,Miller V ,Zakowski M , et al. EGF receptor mutations are common in lung cancers from “never smokers“ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311
CrossRef | Web of Science | Medline26
Huang S-F ,Liu H-P ,Li L-H , et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-8203
CrossRef | Web of Science | Medline27
Han S-W ,Kim T-Y ,Hwang PG , et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-2501
CrossRef | Web of Science | Medline28
Tsao M-S ,Sakurada A ,Cutz J-C , et al. Erlotinib in lung cancer -- molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144
Full Text | Web of Science | Medline29
Thatcher N, Chang A, Parikh P, Pemberton K, Archer V. Results of a Phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care (BSC) in patients with advanced non-small-cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens. In: Proceedings of the 96th Annual Meeting of the American Association for Cancer Research, Anaheim, Calif., April 16–20, 2005:4. abstract.
30
Perez-Soler R . Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Huntingt) 2003;17:Suppl 12:23-28
Medline31
Inoue A ,Saijo Y ,Maemondo M , et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-139
CrossRef | Web of Science | Medline32
Giaccone G ,Herbst RS ,Manegold C , et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial -- INTACT 1. J Clin Oncol 2004;22:777-784
CrossRef | Web of Science | Medline33
Herbst RS ,Giaccone G ,Schiller JH , et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial -- INTACT 2. J Clin Oncol 2004;22:785-794
CrossRef | Web of Science | Medline34
Herbst RS ,Prager D ,Hermann R , et al. TRIBUTE -- a phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;23:617-617 abstract.35
Gatzemeier U ,Pluzanska A ,Szczesna A , et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;23:617-617 abstract.
- Citing Articles (1214)
Citing Articles
1
Charu Aggarwal, Corey J. Langer. (2012) Older age, poor performance status and major comorbidities. Current Opinion in Oncology 24:2, 130-136
CrossRef2
Amelia M. Wnorowski, Aieska de Souza, Abraham Chachoua, David E. Cohen. (2012) The management of EGFR inhibitor adverse events: a case series and treatment paradigm. International Journal of Dermatology 51:2, 223-232
CrossRef3
J. De Grève, E. Teugels, C. Geers, L. Decoster, D. Galdermans, J. De Mey, H. Everaert, I. Umelo, P. In’t Veld, D. Schallier. (2012) Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer
CrossRef4
Karen L. Reckamp. (2012) Antiangiogenic Agents as Second-line Therapy for Advanced Non-Small Cell Lung Cancer. Cancer Letters
CrossRef5
Liang Cheng, Riley E Alexander, Gregory T MacLennan, Oscar W Cummings, Rodolfo Montironi, Antonio Lopez-Beltran, Harvey M Cramer, Darrell D Davidson, Shaobo Zhang. (2012) Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology
CrossRef6
Naoyuki Nogami, Katsuyuki Hotta, Yoshihiko Segawa, Nagio Takigawa, Shinobu Hosokawa, Isao Oze, Masanori Fujii, Eiki Ichihara, Takuo Shibayama, Atsuhiko Tada, Noboru Hamada, Masatoshi Uno, Akihiko Tamaoki, Shoichi Kuyama, Genyo Ikeda, Masahiro Osawa, Saburo Takata, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura. (2012) Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402. Acta Oncologica1-6
CrossRef7
Takashi Kobayashi, Tomonobu Koizumi, Toshihide Agatsuma, Masanori Yasuo, Kenji Tsushima, Keishi Kubo, Seiichiro Eda, Hiroshi Kuraishi, Shigeru Koyama, Tsutomu Hachiya, Nariaki Ohura. (2012) A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology
CrossRef8
Guus A. M. S. Dongen, Alex J. Poot, Danielle J. Vugts. (2012) PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumor Biology
CrossRef9
Wei-Xiang Qi, Li-Na Tang, Ai-Na He, Zan Shen, Yang Yao. (2012) Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology
CrossRef10
D Sanoudou, G Mountzios, D A Arvanitis, D Pectasides. (2012) Array-based pharmacogenomics of molecular-targeted therapies in oncology. The Pharmacogenomics Journal
CrossRef11
T Doi, H Takiuchi, A Ohtsu, N Fuse, M Goto, M Yoshida, N Dote, Y Kuze, F Jinno, M Fujimoto, T Takubo, N Nakayama, R Tsutsumi. (2012) Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients. British Journal of Cancer
CrossRef12
Parthasarathy Seshacharyulu, Moorthy P Ponnusamy, Dhanya Haridas, Maneesh Jain, Apar K Ganti, Surinder K Batra. (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets15-31
CrossRef13
Jared Weiss, Thomas E Stinchcombe. (2012) Treatment of elderly patients with stage IV non-small-cell lung cancer. Expert Review of Anticancer Therapy 12:1, 111-120
CrossRef14
Athanasios G. Pallis, Kostas Syrigos. (2012) Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: Current status and future challenges. Cancer Treatment Reviews
CrossRef15
Ian Cromwell, Kimberly van der Hoek, Suzanne C. Malfair Taylor, Barbara Melosky, Stuart Peacock. (2012) Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis. Lung Cancer
CrossRef16
L. Greillier, F. Barlesi. (2012) Traitements de deuxième ligne du cancer bronchique non à petites cellules métastatique : quels choix aujourd’hui ? Quelles perspectives demain ?. Revue des Maladies Respiratoires 29:1, 4-6
CrossRef17
Sai-Hong Ignatius Ou. (2012) Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence. Critical Reviews in Oncology/Hematology
CrossRef18
Luis Paz-Ares. (2012) Beyond first-line NSCLC therapy: chemotherapy or erlotinib?. The Lancet Oncology
CrossRef19
Tudor Ciuleanu, Lilia Stelmakh, Saulius Cicenas, Skaidrius Miliauskas, Alexandru Calin Grigorescu, Carina Hillenbach, Hrefna Kristin Johannsdottir, Barbara Klughammer, Emilio Esteban Gonzalez. (2012) Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. The Lancet Oncology
CrossRef20
Corey J. Langer. (2012) Individualized therapy for patients with non-small cell lung cancer: Emerging trends and challenges. Critical Reviews in Oncology/Hematology
CrossRef21
Yonglan Zheng, Mengyuan Kan, Lan Yu, Xiaomin Niu, Daizhan Zhou, Lin He, Shun Lu, Yun Liu. (2012) GPC5 rs2352028 Polymorphism and Risk of Lung Cancer in Han Chinese. Cancer Investigation 30:1, 13-19
CrossRef22
Roman Thomas, Jürgen Wolf. (2012) Personalized Therapy of Lung Cancer. Onkologie 35:s1, 14-19
CrossRef23
Takanori Ayabe, Tetsuya Shimizu, Masaki Tomita, Toshio Onitsuka. (2012) A surgical intervention followed by adjuvant treatment of erlotinib for a 85-year-old elderly advanced lung cancer. Annals of Cancer Research and Therapy 20:1, 01-06
CrossRef24
Haruhiro Saito, Haruhiro Saito, Shuji Murakami, Shuji Murakami, Tetsuro Kondo, Tetsuro Kondo, Fumihiro Oshita, Fumihiro Oshita, Kazumasa Noda, Kazumasa Noda, Kouzo Yamada, Kouzo Yamada. (2012) Effectiveness of Erlotinib in Advanced Non-Small Cell Lung Cancer in Cases of Gefitinib Resistance after Treatment of More Than 6 Months. Onkologie 35:1-2, 18-22
CrossRef25
Seiji Niho, Hideo Kunitoh, Hiroshi Nokihara, Takeshi Horai, Yukito Ichinose, Toyoaki Hida, Nobuyuki Yamamoto, Masaaki Kawahara, Tetsu Shinkai, Kazuhiko Nakagawa, Kaoru Matsui, Shunichi Negoro, Akira Yokoyama, Shinzoh Kudoh, Katsuyuki Kiura, Kiyoshi Mori, Hiroaki Okamoto, Hiroshi Sakai, Koji Takeda, Soichiro Yokota, Nagahiro Saijo, Masahiro Fukuoka. (2012) Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer
CrossRef26
Rosalie Fisher, James Larkin, Charles Swanton. (2011) Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. The EPMA Journal
CrossRef27
M. Wada, M. Yamamoto, S. Ryuge, Y. Nagashima, N. Hayashi, S. Maki, S. Otani, K. Katono, A. Takakura, T. Yanaihara, S. Igawa, M. Yokoba, H. Mitsufuji, M. Kubota, M. Katagiri, N. Masuda. (2011) Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology
CrossRef28
Geoffrey Y. Ku, Benjamin A. Haaland, Gilberto de Lima Lopes. (2011) Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials. Lung Cancer 74:3, 469-473
CrossRef29
Cesare Gridelli, Andrea Ardizzoni, Sandro Barni, Lucio Crinò, Alberto Caprioli, Elena Piazza, Vito Lorusso, Santi Barbera, Nicoletta Zilembo, Vittorio Gebbia, Vincenzo Adamo, Riccardo Pela, Maurizio Marangolo, Raffaella Morena, Gianfranco Filippelli, Calogero Buscarino, Oscar Alabiso, Paolo Maione, Paola Venturino, Filippo De Marinis. (2011) Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: Results from the Italian observational “SUN” (Survey on the lUng cancer maNagement) study. Lung Cancer 74:3, 462-468
CrossRef30
Scott Gettinger, Thomas Lynch. (2011) A Decade of Advances in Treatment for Advanced Non–Small Cell Lung Cancer. Clinics in Chest Medicine 32:4, 839-851
CrossRef31
Takanori Tsuchiya, Takashi Fukuda, Masashi Furuiye, Koichi Kawabuchi. (2011) Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancer. Lung Cancer 74:3, 521-528
CrossRef32
Flora Zagouri, Christos A. Papadimitriou, Meletios-Athanassios Dimopoulos, Dimitrios Pectasides. (2011) Molecularly targeted therapies in unresectable-metastatic gastric cancer. A systematic review. Cancer Treatment Reviews 37:8, 599-610
CrossRef33
W. Jeffrey Petty, William R. Voelzke, James J. Urbanic, Victor A. Varela, Lynsay L. Waller, Catherine B. Swift, R. Matthew Graham, Vincent A. Memoli, Konstantin H. Dragnev. (2011) High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer. Lung Cancer 74:3, 384-391
CrossRef34
Emilio Esteban Gonzalez, Noemi Villanueva, Joaquin Fra, Jose Pablo Berros, Paula Jimenez, María Luque, Isabel Muñiz, Pilar Blay, Yolanda Fernandez, José María Vieitez, Carolina Muriel, Miguel Sanmamed, Pablo Pardo Coto, Marta Izquierdo, Enrique Estrada, Angel J. Lacave. (2011) Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study. Investigational New Drugs 29:6, 1459-1464
CrossRef35
Evangelia Skoura, Ioannis E. Datseris, Ioannis Platis, Georgios Oikonomopoulos, Konstantinos N. Syrigos. (2011) Role of Positron Emission Tomography in the Early Prediction of Response to Chemotherapy in Patients With Non–Small-Cell Lung Cancer. Clinical Lung Cancer
CrossRef36
Mathilda L. Bongers, Veerle M.H. Coupé, Elise P. Jansma, Egbert F. Smit, Carin A. Uyl-de Groot. (2011) Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer. PharmacoEconomics1
CrossRef37
Paul Mitchell, Tony Mok, Helen Barraclough, Alena Strizek, Rebecca Lew, Maximiliano van Kooten. (2011) Smoking History As a Predictive Factor of Treatment Response in Advanced Non–Small-Cell Lung Cancer: A Systematic Review. Clinical Lung Cancer
CrossRef38
Thanyanan Reungwetwattana, Saravut J. Weroha, Julian R. Molina. (2011) Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non-Small-Cell Lung Cancer (NSCLC). Clinical Lung Cancer
CrossRef39
Nichole T. Tanner, Nicholas J. Pastis, Carol Sherman, George R. Simon, David Lewin, Gerard A. Silvestri. (2011) The role of molecular analyses in the era of personalized therapy for advanced NSCLC. Lung Cancer
CrossRef40
Kai Wang, Jin Wei. (2011) Multi-targeted therapies in non-small cell lung cancer. Clinical Oncology and Cancer Research 8:4, 220-223
CrossRef41
Fang Wang, Gui-fang Guo, Hui-juan Qiu, Xu-xian Chen, Pi-li Hu, Fei-fei Zhou, Wen-zhuo He, Bei Zhang, Liang-ping Xia. (2011) Pemetrexed monotherapy and pemetrexed plus platinum combination therapy as non-first-line treatments for advanced non-small cell lung cancer. Clinical Oncology and Cancer Research 8:4, 235-241
CrossRef42
M. Fiegl, C. Thöni, M. Hochleitner. (2011) Gender aspects in haematology and oncology: Overview and own observations in lung cancer. memo - Magazine of European Medical Oncology 4:4, 209-216
CrossRef43
, H. Popper, F. Wrba, U. Gruber-Mösenbacher, W. Hulla, R. Pirker, W. Hilbe, M. Studnicka, A. Mohn-Staudner, F. Ploner. (2011) A histology-based algorithm in the molecular diagnosis of mutations of the epidermal growth factor receptor (EGFR)–in non-small-cell lung cancer (NSCLC)*. memo - Magazine of European Medical Oncology 4:4, 248-253
CrossRef44
C. Jungels, T. Berghmans, A.-P. Meert, J.-J. Lafitte, A. Scherpereel, J.-P. Sculier. (2011) Traitement de rattrapage par pémétrexed pour les CBNPC : étude rétrospective d’implémentation. Revue des Maladies Respiratoires
CrossRef45
Jan Nyrop Jakobsen, Jens Benn Sørensen. (2011) Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer. Cancer Chemotherapy and Pharmacology
CrossRef46
Deepak Kilari, Supriya Gupta Mohile. (2011) Management of Cancer in the Older Adult. Clinics in Geriatric Medicine
CrossRef47
Tingting Hong, Ruxia Zhang, Dongyan Cai, Xiaohong Wu, Dong Hua. (2011) Second-line epidermal growth factor receptor inhibitors followed by third-line pemetrexed or the reverse sequence: a retrospective analysis of 83 Chinese patients with advanced lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology
CrossRef48
P. Hofman, M. Ilie, V. Hofman, S. Roux, A. Valent, A. Bernheim, M. Alifano, F. Leroy-Ladurie, F. Vaylet, I. Rouquette, P. Validire, M. Beau-Faller, L. Lacroix, J. C. Soria, P. Fouret. (2011) Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Annals of Oncology
CrossRef49
M J Fidler, L E Morrison, S Basu, L Buckingham, K Walters, M Batus, K K Jacobson, S S Jewell, J Coon, P D Bonomi. (2011) PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. British Journal of Cancer
CrossRef50
A A Memon, B Weber, M Winterdahl, S Jakobsen, P Meldgaard, H H T Madsen, S Keiding, E Nexo, B S Sorensen. (2011) PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer. British Journal of Cancer
CrossRef51
Bohuslav Melichar, Mario Plebani. (2011) Cancer diagnosis: from dogs to DNA or from DNA to dogs?. Clinical Chemistry and Laboratory Medicine---
CrossRef52
H. Murakami, T. Tamura, T. Takahashi, H. Nokihara, T. Naito, Y. Nakamura, K. Nishio, Y. Seki, A. Sarashina, M. Shahidi, N. Yamamoto. (2011) Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemotherapy and Pharmacology
CrossRef53
Shiro Tanaka, Kazuhiro Yanagihara, Satoshi Tamaru, Satoshi Teramukai, Toshiyuki Kitano, Masanori Fukushima. (2011) Difference in survival and prognostic factors between smokers and never-smokers with advanced non-small-cell lung cancer. International Journal of Clinical Oncology
CrossRef54
Sera Tort, Dolores Gallardo, Fergus Macbeth, Maria Cinta Pallarès, Ivan Solà, Sera Tort. 2011. Erlotinib for advanced non-small cell lung cancer. .
CrossRef55
E. F. Smit. (2011) Medicatie bij longcarcinoom. Huisarts en wetenschap
CrossRef56
A. Hata, N. Katakami, K. Kunimasa, H. Yoshioka, S. Fujita, R. Kaji, R. Tachikawa, K. Tomii, Y. Imai, M. Iwasaku, T. Ishida. (2011) Erlotinib for Pretreated Squamous Cell Carcinoma of the Lung in Japanese Patients. Japanese Journal of Clinical Oncology
CrossRef57
Patrick Micke, Karolina Edlund, Lars Holmberg, Hanna Göransson Kultima, Larry Mansouri, Simon Ekman, Michael Bergqvist, Lena Scheibenflug, Kristina Lamberg, Gunnar Myrdal, Anders Berglund, Annsofie Andersson, Mats Lambe, Fredrik Nyberg, Andrew Thomas, Anders Isaksson, Johan Botling. (2011) Gene Copy Number Aberrations Are Associated with Survival in Histologic Subgroups of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:11, 1833-1840
CrossRef58
Anthony B Daniels, Matt L Miller, Amy Kotecha, David H Abramson. (2011) UVEAL METASTASIS FROM NONSMALL CELL LUNG CARCINOMA WITH DRAMATIC RESPONSE TO ERLOTINIB. Retinal Cases & Brief Reports 4:4, 390-393
CrossRef59
A. Vergnenègre, I. Monnet, C. Chouaïd, J. Hureaux, J. Mazières, G. Quéré, J.N. Lombard, I. Cumin, S. Abdiche, C. Nocent Ejnaini, H. Bonnabau, Ch. Decroisette. (2011) Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: A GFPC study. Lung Cancer 74:2, 264-267
CrossRef60
Akshay Sudhindra, Roberto Ochoa, Edgardo S. Santos. (2011) Biomarkers, Prediction, and Prognosis in Non–Small-Cell Lung Cancer: A Platform for Personalized Treatment. Clinical Lung Cancer 12:6, 360-368
CrossRef61
Vijay Agarwal, Michael J. Lind, Lynn Cawkwell. (2011) Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?. Cancer Treatment Reviews 37:7, 533-542
CrossRef62
Fausto Petrelli, Karen Borgonovo, Mary Cabiddu, Sandro Barni. (2011) Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer. Anti-Cancer Drugs 22:10, 1010-1019
CrossRef63
A. Becker, L. Crombag, D.A.M. Heideman, F.B. Thunnissen, A.W. van Wijk, P.E. Postmus, E.F. Smit. (2011) Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. European Journal of Cancer 47:17, 2603-2606
CrossRef64
Jing Wang, Ting-Yi Xia, Ying-Jie Wang, Hong-Qi Li, Ping Li, Ji-Dong Wang, Dong-Shu Chang, Liy-Yuan Liu, Yu-Peng Di, Xuan Wang, Wei-Zhang Wu. (2011) Prospective Study of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Concurrent With Individualized Radiotherapy for Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 81:3, e59-e65
CrossRef65
Makoto Nishio, Takeharu Yamanaka, Kazuko Matsumoto, Hideharu Kimura, Kazuko Sakai, Asao Sakai, Takashi Sone, Atsushi Horiike, Fumiaki Koizumi, Kazuo Kasahara, Tatsuo Ohira, Norihiko Ikeda, Nagahiro Saijo, Tokuzo Arao, Kazuto Nishio. (2011) Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma. Journal of Thoracic Oncology 6:11, 1889-1894
CrossRef66
Tommaso De Pas, Francesca Toffalorio, Michela Manzotti, Caterina Fumagalli, Gianluca Spitaleri, Chiara Catania, Angelo Delmonte, Monica Giovannini, Lorenzo Spaggiari, Filippo de Braud, Massimo Barberis. (2011) Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations. Journal of Thoracic Oncology 6:11, 1895-1901
CrossRef67
Akito Hata, Nobuyuki Katakami, Hiroshige Yoshioka, Shiro Fujita, Kei Kunimasa, Shigeki Nanjo, Kyoko Otsuka, Reiko Kaji, Keisuke Tomii, Masahiro Iwasaku, Akihiro Nishiyama, Hidetoshi Hayashi, Satoshi Morita, Tadashi Ishida. (2011) Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection. Lung Cancer 74:2, 268-273
CrossRef68
Hye-Suk Han, Dae-Woon Eom, Joo Heon Kim, Kyung-Hee Kim, Hyang-Mi Shin, Jin Young An, Ki Man Lee, Kang Hyeon Choe, Ki Hyeong Lee, Seung Taik Kim, Ji Hae Koo, Ho-chang Lee, Ok-Jun Lee. (2011) EGFR Mutation Status in Primary Lung Adenocarcinomas and Corresponding Metastatic Lesions: Discordance in Pleural Metastases. Clinical Lung Cancer 12:6, 380-386
CrossRef69
Britta Weber, Boe S. Sorensen, Marianne Marquard Knap, Hans Henrik Madsen, Ebba Nexo, Peter Meldgaard. (2011) Complete Pathologic Response in Lung Tumors in Two Patients with Metastatic Non-small Cell Lung Cancer Treated with Erlotinib. Journal of Thoracic Oncology 6:11, 1946-1949
CrossRef70
David F. Heigener, Yi-Long Wu, Nico van Zandwijk, Pekka Mali, Keith Horwood, Martin Reck. (2011) Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study. Lung Cancer 74:2, 274-279
CrossRef71
Domenico Galetta, Salvatore Pisconti, Saverio Cinieri, Giovanni Luigi Pappagallo, Vittorio Gebbia, Nicola Borsellino, Evaristo Maiello, Antonio Rinaldi, Michele Montrone, Pietro Rizzo, Nicola Marzano, Nicola Sasso, Antonio Febbraro, Giuseppe Colucci. (2011) Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life–Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (ERACLE). Clinical Lung Cancer 12:6, 402-406
CrossRef72
Yoshikazu Hasegawa, Tomoya Kawaguchi, Akihito Kubo, Masahiko Ando, Junji Shiraishi, Shun-ichi Isa, Taisuke Tsuji, Kazuyuki Tsujino, Sai-Hong I. Ou, Kazuhiko Nakagawa, Minoru Takada. (2011) Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy. Journal of Thoracic Oncology 6:11, 1881-1888
CrossRef73
Nathan A. Pennell. (2011) Integration of EGFR Inhibitors and Conventional Chemotherapy in the Treatment of Non–Small-cell Lung Cancer. Clinical Lung Cancer 12:6, 350-359
CrossRef74
Young Hak Kim, Michiaki Mishima. (2011) Maintenance chemotherapy for non-small-cell lung cancer. Cancer Treatment Reviews 37:7, 505-510
CrossRef75
LACHLAN STANDFIELD, ADÈLE R. WESTON, HELEN BARRACLOUGH, MAXIMILIANO VAN KOOTEN, NICK PAVLAKIS. (2011) Histology as a treatment effect modifier in advanced non-small cell lung cancer: A systematic review of the evidence. Respirology 16:8, 1210-1220
CrossRef76
Jennifer Nam Choi. (2011) Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts. Clinics in Dermatology 29:6, 587-601
CrossRef77
David Hughes, Shane Doheny. (2011) Deliberating Tarceva: A case study of how British NHS managers decide whether to purchase a high-cost drug in the shadow of NICE guidance. Social Science & Medicine 73:10, 1460-1468
CrossRef78
Laurie L. Carr, James H. Finigan, Jeffrey A. Kern. (2011) Evaluation and Treatment of Patients with Non–Small Cell Lung Cancer. Medical Clinics of North America 95:6, 1041-1054
CrossRef79
Ian Cromwell, Kimberly van der Hoek, Barbara Melosky, Stuart Peacock. (2011) Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef80
Ezra E.W. Cohen, Janakiraman Subramanian, Feng Gao, Livia Szeto, Mark Kozloff, Leonardo Faoro, Theodore Karrison, Ravi Salgia, Ramaswamy Govindan, Everett E. Vokes. (2011) Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non–Small-Cell Lung Cancer, A Phase II Trial. Clinical Lung Cancer
CrossRef81
Peter Goldstraw, David Ball, James R Jett, Thierry Le Chevalier, Eric Lim, Andrew G Nicholson, Frances A Shepherd. (2011) Non-small-cell lung cancer. The Lancet 378:9804, 1727-1740
CrossRef82
Humberto Lara-Guerra, Catherine T. Chung, Joerg Schwock, Melania Pintilie, David M. Hwang, Natasha B. Leighl, Thomas K. Waddell, Ming-Sound Tsao. (2011) Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer. Lung Cancer
CrossRef83
M.E.R. O’Brien, J.S. Myerson, J.I.G. Coward, M. Puglisi, L. Trani, A. Wotherspoon, B. Sharma, G. Cook, S. Ashley, R. Gunapala, S. Chua, S. Popat. (2011) A phase II study of 18F-fluorodeoxyglucose PET–CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12weeks. European Journal of Cancer
CrossRef84
Jean-Charles Soria, Tony S. Mok, Federico Cappuzzo, Pasi A. Jänne. (2011) EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. Cancer Treatment Reviews
CrossRef85
Peter Mazzone, Tarek Mekhail. (2011) Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists. Respiratory Medicine
CrossRef86
Eric Nadler, Michael Forsyth, Sacha Satram-Hoang, Carolina Reyes. (2011) Costs and Clinical Outcomes among Patients with Second-Line Non-small Cell Lung Cancer in the Outpatient Community Setting. Journal of Thoracic Oncology1
CrossRef87
Giulia M. Stella, Maurizio Luisetti, Simona Inghilleri, Francesca Cemmi, Roberta Scabini, Michele Zorzetto, Ernesto Pozzi. (2011) Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies. Respiratory Medicine
CrossRef88
Mi-Sook Kim. (2011) Future Cancer Therapy with Molecularly Targeted Therapeutics: Challenges and Strategies. Biomolecules and Therapeutics 19:4, 371-389
CrossRef89
H. Hayashi, I. Okamoto, S. Morita, M. Taguri, K. Nakagawa. (2011) Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Annals of Oncology
CrossRef90
P. S. Choi, J. van Riggelen, A. J. Gentles, P. Bachireddy, K. Rakhra, S. J. Adam, S. K. Plevritis, D. W. Felsher. (2011) Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proceedings of the National Academy of Sciences 108:42, 17432-17437
CrossRef91
Wei-Xiang Qi, Li-Na Tang, Ai-Na He, Zan Shen, Yang Yao. (2011) The Role of Vandetanib in the Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Four Randomized Controlled Trials. Lung
CrossRef92
Hiroki Nagai, Shiro Tanaka, Miyuki Niimi, Nanae Seo, Takahiko Sasaki, Hiroshi Date, Michiaki Mishima, Hiroyasu Yasuda, Kazuhiro Yanagihara. (2011) Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan. International Journal of Clinical Oncology 16:5, 560-567
CrossRef93
Martin Reck, Andreas Hermes, Eng-Huat Tan, Enriqueta Felip, Barbara Klughammer, José Baselga. (2011) Tissue sampling in lung cancer: A review in light of the MERIT experience. Lung Cancer 74:1, 1-6
CrossRef94
Alice T Shaw, Beow Y Yeap, Benjamin J Solomon, Gregory J Riely, Justin Gainor, Jeffrey A Engelman, Geoffrey I Shapiro, Daniel B Costa, Sai-Hong I Ou, Mohit Butaney, Ravi Salgia, Robert G Maki, Marileila Varella-Garcia, Robert C Doebele, Yung-Jue Bang, Kimary Kulig, Paulina Selaru, Yiyun Tang, Keith D Wilner, Eunice L Kwak, Jeffrey W Clark, A John Iafrate, D Ross Camidge. (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. The Lancet Oncology 12:11, 1004-1012
CrossRef95
Hui-li Wong, Richard H de Boer. (2011) Vandetanib for the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy 12:14, 2271-2278
CrossRef96
Yosuke Togashi, Katsuhiro Masago, Shiro Fujita, Yukimasa Hatachi, Akiko Fukuhara, Hiroki Nagai, Yuichi Sakamori, Young Hak Kim, Tadashi Mio, Michiaki Mishima. (2011) Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer. Lung Cancer 74:1, 98-102
CrossRef97
Antonio Passaro, Enrico Cortesi, Filippo de Marinis. (2011) Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?. Expert Review of Anticancer Therapy 11:10, 1587-1597
CrossRef98
S. Rivera, L. Quéro, S. Wong Hee Kam, C. Maylin, É. Deutsch, C. Hennequin. (2011) Thérapies ciblées et radiothérapie dans les cancers bronchiques non à petites cellules. Cancer/Radiothérapie 15:6-7, 527-535
CrossRef99
Rabab M. Gaafar, Veerle F. Surmont, Giorgio V. Scagliotti, Rob J. Van Klaveren, Demetris Papamichael, John J. Welch, Baktiar Hasan, Valter Torri, Jan P. van Meerbeeck. (2011) A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). European Journal of Cancer 47:15, 2331-2340
CrossRef100
Aminah Jatoi, Shaker R. Dakhil, Jeff A. Sloan, John W. Kugler, Kendrith M. Rowland, Paul L. Schaefer, Paul J. Novotny, Donald B. Wender, Howard M. Gross, Charles L. Loprinzi. (2011) Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Supportive Care in Cancer 19:10, 1601-1607
CrossRef101
Sofiya Reicher, Fatih Z. Boyar, Maher Albitar, Vladimira Sulcova, Sally Agersborg, Visal Nga, Ying Zhou, Gang Li, Rose Venegas, Samuel W. French, David S. Chung, Bruce E. Stabile, Viktor E. Eysselein, Arturo Anguiano. (2011) Fluorescence In Situ Hybridization and K-ras Analyses Improve Diagnostic Yield of Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Solid Pancreatic Masses. Pancreas 40:7, 1057-1062
CrossRef102
D. Rottlaender, S. Reda, L.J. Motloch, U.C. Hoppe. (2011) Neue Tyrosinkinase- und EGFR-Inhibitoren in der Tumortherapie. Der Internist 52:10, 1245-1255
CrossRef103
Robert Pirker, Martin Filipits. (2011) Monoclonal antibodies against EGFR in non-small cell lung cancer. Critical Reviews in Oncology/Hematology 80:1, 1-9
CrossRef104
Athanasios G. Pallis, Alexandra Voutsina, Nikolaos Kentepozidis, Stylianos Giassas, Pavlos Papakotoulas, Sofia Agelaki, Kostas Tryfonidis, Athanasios Kotsakis, Lambros Vamvakas, Nikolaos Vardakis, Vassilis Georgoulias. (2011) A Phase II Trial of Erlotinib As Front-Line Treatment in Clinically Selected Patients With Non–Small-Cell Lung Cancer. Clinical Lung Cancer
CrossRef105
Hui Gao, Xin Ding, Dong Wei, Peng Cheng, Xiaomei Su, Huanyi Liu, Fahad Aziz, Daoyuan Wang, Tao Zhang. (2011) Efficacy of erlotinib in patients with advanced non-small cell lung cancer. Anti-Cancer Drugs 22:9, 842-852
CrossRef106
Hajime Sunagozaka, Masao Honda, Taro Yamashita, Ryuhei Nishino, Hajime Takatori, Kuniaki Arai, Tatsuya Yamashita, Yoshio Sakai, Shuichi Kaneko. (2011) Identification of a secretory protein c19orf10 activated in hepatocellular carcinoma. International Journal of Cancer 129:7, 1576-1585
CrossRef107
M. Luu, S. L. Boone, J. Patel, P. Sullivan, A. W. Rademaker, Y. Balagula, M. E. Lacouture. (2011) Higher severity grade of erlotinib-induced rash is associated with lower skin phototype. Clinical and Experimental Dermatology 36:7, 733-738
CrossRef108
Bohuslav Melichar, Mario Plebani. (2011) Laboratory medicine: an essential partner in the care of cancer patients. Clinical Chemistry and Laboratory Medicine 49:10, 1575-1578
CrossRef109
Szilvia Torok, Balazs Hegedus, Viktoria Laszlo, Mir Alireza Hoda, Bahil Ghanim, Walter Berger, Walter Klepetko, Balazs Dome, Gyula Ostoros. (2011) Lung cancer in never smokers. Future Oncology 7:10, 1195-1211
CrossRef110
Erin M. McCartney, Nicholas S. Eyre, Michael R. Beard, Kris Kowdley, Geoffrey McCaughan, Christian Trautwein. (2011) Border patrol intensifies for hepatitis C virus entry. Hepatology 54:4, 1472-1475
CrossRef111
F. Wang, L.D. Wang, B. Li, Z.X. Sheng. (2011) Gefitinib Compared with Systemic Chemotherapy as First-line Treatment for Chemotherapy-naive Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of Randomised Controlled Trials. Clinical Oncology
CrossRef112
Jean Boucher, Linnea Olson, Bilal Piperdi. (2011) Preemptive Management of Dermatologic Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors. Clinical Journal of Oncology Nursing 15:5, 501-508
CrossRef113
Daxian Luo, Meijuan Huang, Xinxing Zhang, Min Yu, Bingwen Zou, Yanying Li, Jianlin Long, Jin Wang, Feng Peng, Yong Xu, Lu Li, Li Ren, Mei Hou, You Lu. (2011) Salvage treatment with erlotinib after gefitinib failure in advanced non-small cell lung cancer patients with poor performance status: A matched-pair case-control study. Thoracic Cancerno-no
CrossRef114
A C Mita, K Papadopoulos, M J A de Jonge, G Schwartz, J Verweij, M M Mita, A Ricart, Q S-C Chu, A W Tolcher, L Wood, S McCarthy, M Hamilton, K Iwata, B Wacker, K Witt, E K Rowinsky. (2011) Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. British Journal of Cancer 105:7, 938-944
CrossRef115
Cindy L. O’Bryant, Paul Haluska, Lee Rosen, Ramesh K. Ramanathan, Balaji Venugopal, Stephen Leong, Ramesh Boinpally, Amy Franke, Karsten Witt, Jeffry Evans, Chandra Belani, S. Gail Eckhardt, Suresh Ramalingam. (2011) An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemotherapy and Pharmacology
CrossRef116
T. Brodowicz, T. Ciuleanu, J. Crawford, M. Filipits, J. R. Fischer, V. Georgoulias, C. Gridelli, F. R. Hirsch, J. Jassem, P. Kosmidis, M. Krzakowski, C. Manegold, J. L. Pujol, R. Stahel, N. Thatcher, J. Vansteenkiste, C. Minichsdorfer, S. Zochbauer-Muller, R. Pirker, C. C. Zielinski, . (2011) Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Annals of Oncology
CrossRef117
Julie Bauman, Claire Verschraegen, Steven Belinsky, Carolyn Muller, Teresa Rutledge, M. Fekrazad, Meera Ravindranathan, Sang-Joon Lee, Dennie Jones. (2011) A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies. Cancer Chemotherapy and Pharmacology
CrossRef118
Ana Custodio, Javier de Castro. (2011) Strategies for maintenance therapy in advanced non-small cell lung cancer: Current status, unanswered questions and future directions. Critical Reviews in Oncology/Hematology
CrossRef119
Filip Janku, Ignacio Garrido-Laguna, Lubos B. Petruzelka, David J. Stewart, Razelle Kurzrock. (2011) Novel Therapeutic Targets in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:9, 1601-1612
CrossRef120
Amandine Hurbin, Marie Wislez, Benoît Busser, Martine Antoine, Corine Tenaud, Nathalie Rabbe, Sandrine Dufort, Florence de Fraipont, Denis Moro-Sibilot, Jacques Cadranel, Jean-Luc Coll, Elisabeth Brambilla. (2011) Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. The Journal of Pathology 225:1, 83-95
CrossRef121
Thomas J. Semrad, Philip C. Mack. (2011) Fibroblast Growth Factor Signaling in Non–Small Cell Lung Cancer. Clinical Lung Cancer
CrossRef122
Katsuhiro Masago, Yosuke Togashi, Masahide Fukudo, Tomohiro Terada, Kaoru Irisa, Yuichi Sakamori, Young Hak Kim, Tadashi Mio, Ken-ichi Inui, Michiaki Mishima. (2011) Plasma and Pleural Fluid Pharmacokinetics of Erlotinib and its Active Metabolite OSI-420 in Patients With Non–Small-Cell Lung Cancer With Pleural Effusion. Clinical Lung Cancer 12:5, 307-312
CrossRef123
David P. Carbone, Enriqueta Felip. (2011) Adjuvant Therapy in Non–Small Cell Lung Cancer: Future Treatment Prospects and Paradigms. Clinical Lung Cancer 12:5, 261-271
CrossRef124
Filippo de Marinis, Serena Ricciardi. (2011) Second-line treatment options in advanced non-small cell lung cancer. European Journal of Cancer 47, S258-S271
CrossRef125
Yaping Xu, Yiping Zhang, Shenglin Ma. (2011) EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer 73:3, 249-255
CrossRef126
Paola Claudia Sacco, Paolo Maione, Antonio Rossi, Maria Anna Bareschino, Clorinda Schettino, Cesare Guida, Massimo Elmo, Rita Ambrosio, Valentina Barbato, Rosario Zeppa, Giovanni Palazzolo, Cesare Gridelli. (2011) Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer. Targeted Oncology 6:3, 171-180
CrossRef127
Peter P. Luk, Peter Galettis, Matthew Links. (2011) ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478. Lung Cancer 73:3, 274-282
CrossRef128
Marco Platania, Francesco Agustoni, Barbara Formisano, Milena Vitali, Monika Ducceschi, Filippo Pietrantonio, Nicoletta Zilembo, Francesco Gelsomino, Sara Pusceddu, Roberto Buzzoni. (2011) Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. Targeted Oncology 6:3, 181-186
CrossRef129
Feng Pan, Jing Tian, Xuchao Zhang, Ying Zhang, Yueyin Pan. (2011) Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non–small lung cancer with EGFR TKIs-resistant mutation. Journal of Cancer Research and Clinical Oncology 137:9, 1397-1408
CrossRef130
Johan Vansteenkiste, Benjamin Solomon, Michael Boyer, Jürgen Wolf, Neil Miller, Lilla Di Scala, Ilona Pylvaenaeinen, Katarina Petrovic, Sasa Dimitrijevic, Beatrijs Anrys, Eckart Laack. (2011) Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy. Journal of Thoracic Oncology1
CrossRef131
Randeep Sangha, Angela M. Davies, Primo N. Lara, Philip C. Mack, Laurel A. Beckett, Paul J. Hesketh, Derick Lau, Tianhong Li, Natasha Perkins, David R. Gandara. (2011) Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation. Journal of Thoracic Oncology1
CrossRef132
R. Veillon, J. Mazières. (2011) Résultats des stratégies ciblées des cancers bronchiques non à petites cellules en 2011. Revue des Maladies Respiratoires Actualités 3:4, 423-427
CrossRef133
L. Teixeira, L. Staudacher, E. Kempf, C. Durand, G. Bussac, J.-L. Jagot, C. Beuzelin, S. Salmeron, J. Trédaniel. (2011) Cancer bronchique non à petites cellules: la 2e ligne et au-delà. Revue des Maladies Respiratoires Actualités 3:4, 372-375
CrossRef134
Chiara Lazzari, Anna Spreafico, Angela Bachi, Heinrich Roder, Irene Floriani, Daniela Garavaglia, Angela Cattaneo, Julia Grigorieva, Maria Grazia Viganò, Cristina Sorlini, Domenico Ghio, Maxim Tsypin, Alessandra Bulotta, Luca Bergamaschi, Vanesa Gregorc. (2011) Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology1
CrossRef135
Etienne Giroux Leprieur, Armelle Lavole, Anne-Marie Ruppert, Valérie Gounant, Marie Wislez, Jacques Cadranel, Bernard Milleron. (2011) Factors associated with long-term survival of patients with advanced non-small cell lung cancer. Respirologyno-no
CrossRef136
Hajime Asahina, Ikuo Sekine, Hidehito Horinouchi, Hiroshi Nokihara, Noboru Yamamoto, Kaoru Kubota, Tomohide Tamura. (2011) Retrospective Analysis of Third-Line and Fourth-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer
CrossRef137
Alexander I. Spira, Nicholas O. Iannotti, Michael A. Savin, Marcus Neubauer, Nashat Y. Gabrail, Ronald H. Yanagihara, Edith A. Zang, Patricia E. Cole, Dale Shuster, Asha Das. (2011) A Phase II Study of Eribulin Mesylate (E7389) in Patients With Advanced, Previously Treated Non–Small-Cell Lung Cancer. Clinical Lung Cancer
CrossRef138
J.R. Fischer, F. Griesinger, T. Fink, T. Salm, A. Marseille, M. Wolf. (2011) Docetaxel–carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)—Results of the nonrandomised phase II study TaxErb. Lung Cancer
CrossRef139
Tony S. K. Mok. (2011) Personalized medicine in lung cancer: what we need to know. Nature Reviews Clinical Oncology 8:11, 661-668
CrossRef140
Shan Liu, Deqiang Wang, Bo Chen, Yan Wang, Weihong Zhao, Jianqing Wu. (2011) The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status. Lung Cancer 73:2, 203-210
CrossRef141
A. M. Horgan, P. A. Bradbury, E. Amir, R. Ng, J. Y. Douillard, E. S. Kim, F. A. Shepherd, N. B. Leighl. (2011) An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. Annals of Oncology 22:8, 1805-1811
CrossRef142
Eng-Huat Tan, Glenwood D. Goss, Ravi Salgia, Benjamin Besse, David R. Gandara, Nasser H. Hanna, James Chih-Hsin Yang, Raymond Thertulien, Michael Wertheim, Julien Mazieres, Thomas Hensing, Christa Lee, Neeraj Gupta, Rajendra Pradhan, Jiang Qian, Qin Qin, Frank A. Scappaticci, Justin L. Ricker, Dawn M. Carlson, Ross A. Soo. (2011) Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:8, 1418-1425
CrossRef143
Isabelle Ray-Coquard, Axel Le Cesne. (2011) A role for maintenance therapy in managing sarcoma. Cancer Treatment Reviews
CrossRef144
Caicun Zhou, Yi-Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lu, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiuyi Zhi, Yiping Zhang, Qingyu Xiu, Jun Ma, Li Zhang, Changxuan You. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology 12:8, 735-742
CrossRef145
Peter M. Ellis, Normand Blais, Dennis Soulieres, Diana N. Ionescu, Meenakshi Kashyap, Geoff Liu, Barb Melosky, Tony Reiman, Phillippe Romeo, Frances A. Shepherd, Ming-Sound Tsao, Natasha B. Leighl. (2011) A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:8, 1379-1391
CrossRef146
Xiao-Hang Zhang, Cheng Li, Chen-Fei Dai, Bao-Sen Zhou. (2011) Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: A meta-analysis. Thoracic Cancer 2:3, 101-108
CrossRef147
Kazuhiro Asami, Masaaki Kawahara, Shinji Atagi, Tomoya Kawaguchi, Kyoichi Okishio. (2011) Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib. Lung Cancer 73:2, 211-216
CrossRef148
Howard West. (2011) The Evolving Role of Targeted Therapy in Early-Stage and Locally Advanced Non-small Cell Lung Cancer. Current Oncology Reports 13:4, 280-289
CrossRef149
Virginia Arrazubi, Roberto Pazo, Dolores Isla, José Luis Pérez Gracia. (2011) SEOM clinical guidelines for using molecular markers in clinical practice. Clinical and Translational Oncology 13:8, 587-591
CrossRef150
F. Tanaka, H. Wada, Y. Fukui, M. Fukushima. (2011) Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. Annals of Oncology 22:8, 1791-1797
CrossRef151
S. Matsuura, N. Inui, Y. Ozawa, Y. Nakamura, M. Toyoshima, K. Yasuda, T. Yamada, T. Shirai, H. Suganuma, K. Yokomura, T. Suda, K. Chida. (2011) Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations. Japanese Journal of Clinical Oncology 41:8, 959-963
CrossRef152
Anastasios Dimou, Seema Agarwal, Valsamo Anagnostou, Hollis Viray, Stephen Christensen, Bonnie Gould Rothberg, Vassiliki Zolota, Konstantinos Syrigos, David L. Rimm. (2011) Standardization of Epidermal Growth Factor Receptor (EGFR) Measurement by Quantitative Immunofluorescence and Impact on Antibody-Based Mutation Detection in Non–Small Cell Lung Cancer. The American Journal of Pathology 179:2, 580-589
CrossRef153
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Shaw, Alice T., Forcione, David G., Digumarthy, Subba R., Iafrate, A. John, . (2011) Case 21-2011. New England Journal of Medicine 365:2, 158-167
Full Text154
Filippo de Marinis, Antonio Rossi, Massimo Di Maio, Serena Ricciardi, Cesare Gridelli. (2011) Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer 73:1, 1-10
CrossRef155
Britta Weber, Michael Winterdahl, Ashfaque Memon, Boe S. Sorensen, Susanne Keiding, Leif Sorensen, Ebba Nexo, Peter Meldgaard. (2011) Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor. Journal of Thoracic Oncology 6:7, 1287-1289
CrossRef156
E. Felip, C. Gridelli, P. Baas, R. Rosell, R. Stahel, . (2011) Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Annals of Oncology 22:7, 1507-1519
CrossRef157
Shannon Otsuka, Alexander C. Klimowicz, Karen Kopciuk, Stephanie K. Petrillo, Mie Konno, Desiree Hao, Huong Muzik, Erin Stolte, William Boland, Don Morris, Anthony M. Magliocco, D. Gwyn Bebb. (2011) CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:7, 1169-1178
CrossRef158
S. John Weroha, Ann L. Oberg, Katie L. Allen Ziegler, Shaker R. Dakhilm, Kendrith M. Rowland, Lynn C. Hartmann, Dennis F. Moore, Gary L. Keeney, Prema P. Peethambaram, Paul Haluska. (2011) Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecologic Oncology 122:1, 116-120
CrossRef159
Dolores Isla, Nuria González-Rojas, Diana Nieves, Max Brosa, Henrik W. Finnern. (2011) Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clinical and Translational Oncology 13:7, 460-471
CrossRef160
V. Zietemann, T. Duell. (2011) Prevalence and effectiveness of first-, second-, and third-line systemic therapy in a cohort of unselected patients with advanced non-small cell lung cancer. Lung Cancer 73:1, 70-77
CrossRef161
A. Cortot, E. Dansin, A. Scherpereel. (2011) Oncologie thoracique. Revue des Maladies Respiratoires Actualités 3:6, 158-165
CrossRef162
E.Y. Romero-Ventosa, A. Mucientes-Molina, E. Pedrido-Reino, N. Lago-Rivero, L. Constenla-Caramés, I. Arias-Santos. (2011) Efectividad y toxicidad de erlotinib en la farmacoterapia del cáncer de pulmón no microcítico. Farmacia Hospitalaria
CrossRef163
Jaclyn Yoong, Michael Michael, Trevor Leong. (2011) Targeted Therapies for Gastric Cancer. Drugs 71:11, 1367-1384
CrossRef164
Nagahiro Saijo. (2011) Problems involved in the clinical trials for non-small cell lung carcinoma. Cancer Treatment Reviews
CrossRef165
P. La Rosée. (2011) Tyrosinkinaseinhibitoren. Der Onkologe 17:7, 641-650
CrossRef166
Marco Pizzi, Matteo Fassan, Mariangela Balistreri, Alessandra Galligioni, Federico Rea, Massimo Rugge. (2011) Anterior Gradient 2 Overexpression in Lung Adenocarcinoma. Applied Immunohistochemistry and Molecular Morphology1
CrossRef167
Shirish M. Gadgeel, Percy Ivy, Wei Chen, Joan Mauer, Daryn Smith, Patricia LoRusso. (2011) Analysis of Lung Cancer Patients Enrolled in CTEP (Cancer Therapy Evaluation Program)-Sponsored Phase I Trials. Clinical Lung Cancer 12:4, 218-223
CrossRef168
A G Pallis, D A Fennell, E Szutowicz, N B Leighl, L Greillier, R Dziadziuszko. (2011) Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. British Journal of Cancer 105:1, 1-8
CrossRef169
(2011) Erlotinib or Gefitinib for Non–Small-Cell Lung Cancer. New England Journal of Medicine 364:24, 2367-2368
Full Text170
Alfredo Tartarone, Rose Lerose, Giuseppina Gallucci, Raffaele Ardito, Michele Aieta. (2011) Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer. Medical Oncology
CrossRef171
Mariacarmela Santarpia, Giuseppe Altavilla, Maria F Salazar, Ignacio Magri, Giuseppe Pettineo, Sara Benecchi, Rafael Rosell. (2011) Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. Expert Review of Respiratory Medicine 5:3, 413-424
CrossRef172
B. Besse, G. Zalcman. (2011) Quelle séquence de traitement chez les patients EGFR mutés ?. Revue de Pneumologie Clinique 67, S24-S29
CrossRef173
Kanwal Pratap Singh Raghav, George R Blumenschein. (2011) Motesanib and advanced NSCLC: experiences and expectations. Expert Opinion on Investigational Drugs 20:6, 859-869
CrossRef174
X Ning, Z Sun, Y Wang, J Zhou, S Chen, D Chen, H Zhang. (2011) Docetaxel plus trans-tracheal injection of adenoviral-mediated p53 versus docetaxel alone in patients with previously treated non-small-cell lung cancer. Cancer Gene Therapy 18:6, 444-449
CrossRef175
Victoria J. Muir, Sohita Dhillon. (2011) Erlotinib. BioDrugs 25:3, 139-146
CrossRef176
Mark Murphy, Britta Stordal. (2011) Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: A systematic review. Drug Resistance Updates 14:3, 177-190
CrossRef177
Alain Makinson, Jean-Charles Tenon, Sabrina Eymard-Duvernay, Jean-Louis Pujol, Clotilde Allavena, Lise Cuzin, Isabelle Poizot-Martin, Xavier de la Tribonnière, André Cabié, Pascal Pugliese, Jacques Reynes, Vincent Le Moing. (2011) Human Immunodeficiency Virus Infection and Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:6, 1022-1029
CrossRef178
C.P. Belani, G. Goss, G. Blumenschein. (2011) Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treatment Reviews
CrossRef179
Tony SK MOK, Te-Chun HSIA, Chun-Ming TSAI, Kenneth TSANG, Gee-Chen CHANG, John Wen-Cheng CHANG, Sirisinha THITIYA, Virote SRIURANPONG, Sumitra THONGPRASERT, Daniel TT CHUA, Nicola MOORE, Christian MANEGOLD. (2011) Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial. Asia-Pacific Journal of Clinical Oncology 7, 4-12
CrossRef180
Wilson Gonsalves, Apar Kishor Ganti. (2011) Targeted anti-cancer therapy in the elderly. Critical Reviews in Oncology/Hematology 78:3, 227-242
CrossRef181
A.L. Watters, J.B. Epstein, M. Agulnik. (2011) Oral complications of targeted cancer therapies: A narrative literature review. Oral Oncology 47:6, 441-448
CrossRef182
Matthias Scheffler, Paola Di Gion, Oxana Doroshyenko, Jürgen Wolf, Uwe Fuhr. (2011) Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics 50:6, 371-403
CrossRef183
Zhi-jie Wang, Tong-tong An, Tony Mok, Lu Yang, Hua Bai, Jun Zhao, Jian-chun Duan, Mei-na Wu, Yu-yan Wang, Ping-ping Li, Hong Sun, Ping Yang, Jie Wang. (2011) Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer. Chinese Journal of Cancer Research 23:2, 112-117
CrossRef184
Yuh-Min Chen, Wen-Chien Fan, Chun-Ming Tsai, Shih-Hao Liu, Jen-Fu Shih, Teh-Ying Chou, Chieh-Hung Wu, Kun-Ta Chou, Yu-Chin Lee, Reury-Perng Perng, Jacqueline Whang-Peng. (2011) A Phase II Randomized Trial of Gefitinib Alone or with Tegafur/Uracil Treatment in Patients with Pulmonary Adenocarcinoma Who had Failed Previous Chemotherapy. Journal of Thoracic Oncology 6:6, 1110-1116
CrossRef185
Hai T. Tran, Ralph G. Zinner, George R. Blumenschein, Yun W. Oh, Vassiliki A. Papadimitrakopoulou, Edward S. Kim, Charles Lu, Mubashira Malik, Bert L. Lum, Roy S. Herbst. (2011) Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Investigational New Drugs 29:3, 499-505
CrossRef186
Chenguang Li, Yihua Sun, Zhaoyuan Fang, Xiangkun Han, Rong Fang, Yang Zhang, Yunjian Pan, Wenjing Zhang, Yan Ren, Hongbin Ji, Haiquan Chen. (2011) Comprehensive Analysis of Epidermal Growth Factor Receptor Gene Status in Lung Adenocarcinoma. Journal of Thoracic Oncology 6:6, 1016-1021
CrossRef187
Michèle Beau-Faller, Armelle Degeorges, Estelle Rolland, Mounia Mounawar, Martine Antoine, Virginie Poulot, Audrey Mauguen, Véronique Barbu, Florence Coulet, Jean-Luc Prétet, Ivan Bièche, Hélène Blons, Jean-Christophe Boyer, Marie-Pierre Buisine, Florence de Fraipont, Sarab Lizard, Sylviane Olschwang, Patrick Saulnier, Delphine Prunier-Mirebeau, Nicolas Richard, Claire Danel, Elisabeth Brambilla, Christos Chouaid, Gérard Zalcman, Pierre Hainaut, Stefan Michiels, Jacques Cadranel. (2011) Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples. Journal of Thoracic Oncology 6:6, 1006-1015
CrossRef188
Shang-Gin Wu, Chih-Hsin Yang, Chong-Jen Yu, Jih-Hsiang Lee, Ya-Chieh Hsu, Yih-Leong Chang, Jin-Yuan Shih, Pan-Chyr Yang. (2011) Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer 72:3, 333-339
CrossRef189
Paul Schwarzenberger, Anna Fariss, Louis Linares, Lucien Nedzi, Omar M. Salazar. (2011) Dose Escalation of Once Weekly Oral Vinorelbine Concurrent With Weekly Split Dose Hypofractionated Chest Radiation for Palliation of Advanced Non–Small Cell Lung Cancer: A Phase I/II Study. The American Journal of the Medical Sciences 341:6, 454-459
CrossRef190
Guanghui Wang, Wei Dong, Hongchang Shen, Xueru Mu, Zhenxiang Li, Xiaoyan Lin, Ying Liu, Jiajun Du. (2011) A comparison of Twist and E-cadherin protein expression in primary non-small-cell lung carcinoma and corresponding metastases. European Journal of Cardio-Thoracic Surgery 39:6, 1028-1032
CrossRef191
Chun-Ming Tsai, Joseph Siu-kie Au, Gee-Chen Chang, Ashley Chi-kin Cheng, Caicun Zhou, Yi-long Wu. (2011) Safety and Efficacy of First-Line Bevacizumab with Chemotherapy in Asian Patients with Advanced Nonsquamous NSCLC. Journal of Thoracic Oncology 6:6, 1092-1097
CrossRef192
F. Barlesi. (2011) Prise en charges des patients présentant une résistance aux TKI de l’EGFR. Revue de Pneumologie Clinique 67, S30-S35
CrossRef193
Anil K Arora. (2011) Erlotinib-induced Hepatotoxicity—Clinical Presentation and Successful Management: A Case Report. Journal of Clinical and Experimental Hepatology 1:1, 38-40
CrossRef194
F. Lokiec, J.-Y. Douillard. (2011) Inhibiteurs de tyrosine kinase (TKI) de l’EGFR : similitudes et différences. Revue de Pneumologie Clinique 67, S15-S19
CrossRef195
Seung Tae Kim, Ji Eun Uhm, Jeeyun Lee, Jong-mu Sun, Insuk Sohn, Seon Woo Kim, Sin-Ho Jung, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. (2011) Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer
CrossRef196
T. C. Gauler, B. Besse, A. Mauguen, J. B. Meric, V. Gounant, B. Fischer, T. R. Overbeck, H. Krissel, D. Laurent, M. Tiainen, F. Commo, J. C. Soria, W. E. E. Eberhardt. (2011) Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). Annals of Oncology
CrossRef197
B. Coudert, T. Ciuleanu, K. Park, Y.-L. Wu, G. Giaccone, W. Brugger, P. Gopalakrishna, F. Cappuzzo, . (2011) Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Annals of Oncology
CrossRef198
J.-C. Soria, J. Cortes, C. Massard, J.-P. Armand, D. De Andreis, S. Ropert, E. Lopez, A. Catteau, J. James, J.-F. Marier, M. Beliveau, R. E. Martell, J. Baselga. (2011) Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. Annals of Oncology
CrossRef199
Rajasubramaniam Shanmugam, Praveen Kusumanchi, Hitesh Appaiah, Liang Cheng, Peter Crooks, Sundar Neelakantan, Tyler Peat, James Klaunig, William Matthews, Harikrishna Nakshatri, Christopher J. Sweeney. (2011) A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen species. International Journal of Cancer 128:10, 2481-2494
CrossRef200
Herbert H. Loong, Jia Wei, Tony S. Mok. (2011) Ethnic variation in response to EGFR inhibitors. Drug Discovery Today: Therapeutic Strategies
CrossRef201
Roy S Herbst, Rafat Ansari, Frederique Bustin, Patrick Flynn, Lowell Hart, Gregory A Otterson, Gordana Vlahovic, Chang-Heok Soh, Paula O'Connor, John Hainsworth. (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. The Lancet 377:9780, 1846-1854
CrossRef202
Jane Fridlyand, Lee D. Kaiser, Gwen Fyfe. (2011) Analysis of tumor burden versus progression-free survival for Phase II decision making. Contemporary Clinical Trials 32:3, 446-452
CrossRef203
Jenn-Yu Wu, Shang-Gin Wu, Chih-Hsin Yang, Yih-Leong Chang, Yeun-Chung Chang, Ya-Chieh Hsu, Jin-Yuan Shih, Pan-Chyr Yang. (2011) Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. Lung Cancer 72:2, 205-212
CrossRef204
Christos Chouaid, Faith Nathan, Kristine Pemberton, Thomas Morris. (2011) A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 67:5, 1203-1208
CrossRef205
David Berz, Harold Wanebo. (2011) Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumors. Journal of Surgical Oncology 103:6, 574-586
CrossRef206
Cesar Moran. (2011) Importance of Molecular Features of Non–Small Cell Lung Cancer for Choice of Treatment. The American Journal of Pathology 178:5, 1940-1948
CrossRef207
T. Zander, M. Hallek. (2011) Thyrosinkinaseinhibitoren in der Onkologie. Der Internist 52:5, 595-600
CrossRef208
, Helmut Popper, Fritz Wrba, Ulrike Gruber-Mösenbacher, Wolfgang Hulla, Robert Pirker, Wolfgang Hilbe, Michael Studnicka, Andrea Mohn-Staudner, Ferdinand Ploner. (2011) Histologie-basierter Algorithmus der molekularen Diagnostik des epidermalen Wachstumsfaktor-Rezeptorgens (Epidermal Growth Factor Receptor, EGFR) beim nicht-kleinzelligen Lungenkarzinom (non-small cell lung cancer, NSCLC)*. Wiener klinische Wochenschrift 123:9-10, 316-321
CrossRef209
Shannon E. OʼMahar, Toby C. Campbell, Tien Hoang, Songwon Seo, KyungMann Kim, Martha M. Larson, Sarah M. Marcotte, Noelle K. LoConte, Anne M. Traynor. (2011) Phase I Study of Sunitinib and Erlotinib in Advanced Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:5, 951-953
CrossRef210
Joachim Lupberger, Mirjam B Zeisel, Fei Xiao, Christine Thumann, Isabel Fofana, Laetitia Zona, Christopher Davis, Christopher J Mee, Marine Turek, Sebastian Gorke, Cathy Royer, Benoit Fischer, Muhammad N Zahid, Dimitri Lavillette, Judith Fresquet, François-Loïc Cosset, S Michael Rothenberg, Thomas Pietschmann, Arvind H Patel, Patrick Pessaux, Michel Doffoël, Wolfgang Raffelsberger, Olivier Poch, Jane A McKeating, Laurent Brino, Thomas F Baumert. (2011) EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nature Medicine 17:5, 589-595
CrossRef211
Jean-Paul Sculier, Anne-Pascal Meert, Thierry Berghmans. (2011) Salvage with erlotinib plus bevacizumab: not in NSCLC. The Lancet 377:9780, 1810-1812
CrossRef212
João Paulo da Silveira Nogueira Lima, Ricardo Akiyoshi Nakamura, Lucas Vieira dos Santos. (2011) Japanese patients equally likely to benefit from aprepitant for chemotherapy-induced nausea and vomiting prevention. Cancer Science 102:5, 1112-1112
CrossRef213
W.A. Weber. (2011) Molekulare Bildgebung in der Tumortherapie. Der Onkologe 17:5, 395-404
CrossRef214
Robert Amato. (2011) Everolimus for the treatment of advanced renal cell carcinoma. Expert Opinion on Pharmacotherapy 12:7, 1143-1155
CrossRef215
Denise A. Chan, Amato J. Giaccia. (2011) Harnessing synthetic lethal interactions in anticancer drug discovery. Nature Reviews Drug Discovery 10:5, 351-364
CrossRef216
Yuh-Min Chen, Jen-Fu Shih, Wen-Chien Fan, Chieh-Hung Wu, Kun-Ta Chou, Chun-Ming Tsai, Yu-Chin Lee, Reury-Perng Perng, Jacqueline Whang-Peng. (2011) Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status. Journal of the Chinese Medical Association 74:5, 209-214
CrossRef217
Christian Hessler, Eik Vettorazzi, Juergen Madert, Carsten Bokemeyer, Jens Panse. (2011) Actual and Predicted Survival Time of Patients With Spinal Metastases of Lung Cancer. Spine 36:12, 983-989
CrossRef218
Niels Reinmuth, Michael Thomas. (2011) An approach to personalized medicine: the BATTLE trial. Clinical Investigation 1:5, 699-705
CrossRef219
Vikram K. Jain, Eliza A. Hawkes, David Cunningham. (2011) Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer
CrossRef220
Ana Custodio, Míriam Méndez, Mariano Provencio. (2011) Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications. Cancer Treatment Reviews
CrossRef221
Gilda da Cunha Santos, Mauro Ajaj Saieg, William Geddie, Natasha Leighl. (2011) EGFR gene status in cytological samples of nonsmall cell lung carcinoma. Cancer Cytopathology 119:2, 80-91
CrossRef222
Shahreen Billah, John Stewart, Gregg Staerkel, Su Chen, Yun Gong, Ming Guo. (2011) EGFR and KRAS mutations in lung carcinoma. Cancer Cytopathology 119:2, 111-117
CrossRef223
Antonin Levy, Laurence Albiges-Sauvin, Christophe Massard, Hassan Izzedine, Stéphane Edhery, Ratio Bahleda, Carlos Gomez-Roca, Cyrus Chargari, Isabelle Brocheriou-Spelle, Jean-Charles Soria. (2011) Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. Investigational New Drugs
CrossRef224
Giulio Metro, R. Chiari, M. Mare, D. Giannarelli, F. R. Tofanetti, V. Minotti, M. Ferraldeschi, D. Giuffrida, L. Marcomigni, C. Bennati, M. J. Fischer, M. Meacci, R. Bellavita, L. Pistola, V. Ludovini, L. Crinò. (2011) Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer Chemotherapy and Pharmacology
CrossRef225
Ramaswamy Govindan, Daniel Morgensztern, Michael D. Kommor, Roy S. Herbst, Paul Schaefer, Jitendra Gandhi, Kaku Saito, Christopher Zergebel, Joan Schiller. (2011) Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:4, 790-795
CrossRef226
Joaquim Bellmunt, Timothy Eisen, Mayer Fishman, David Quinn. (2011) Experience with sorafenib and adverse event management. Critical Reviews in Oncology/Hematology 78:1, 24-32
CrossRef227
E. Szutowicz, K. Konopa, J. Jassem. (2011) Targeted therapies in advanced non-small cell lung cancer: success or failure?. memo - Magazine of European Medical Oncology 4:1, 23-26
CrossRef228
S. I. Rothschild, O. Gautschi. (2011) Maintenance therapy for patients with advanced non-small cell lung cancer: Who to treat and how to treat?. memo - Magazine of European Medical Oncology 4:1, 19-22
CrossRef229
, David S. Binns, Andrea Pirzkall, Wei Yu, Jason Callahan, Linda Mileshkin, Peter Conti, Andrew M. Scott, David Macfarlane, Bernard M. Fine, Rodney J. Hicks. (2011) Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging 38:4, 642-650
CrossRef230
Fernanda Salazar, Miguel Angel Molina, Maria Sanchez-Ronco, Teresa Moran, Jose Luis Ramirez, Jose Miguel Sanchez, Rolf Stahel, Pilar Garrido, Manuel Cobo, Dolores Isla, Jordi Bertran-Alamillo, Bartomeu Massuti, Felipe Cardenal, Christian Manegold, Pilar Lianes, Jose Manuel Trigo, Jose Javier Sanchez, Miquel Taron, Rafael Rosell. (2011) First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer 72:1, 84-91
CrossRef231
Mizuki Nishino, David M. Jackman, Hiroto Hatabu, Pasi A. Jänne, Bruce E. Johnson, Annick D. Van den Abbeele. (2011) Imaging of Lung Cancer in the Era of Molecular Medicine. Academic Radiology 18:4, 424-436
CrossRef232
Y. Koh, B. Jang, Y. K. Jeon, T. M. Kim, S.-H. Lee, D.-W. Kim, D. H. Chung, Y. T. Kim, Y. W. Kim, D. S. Heo. (2011) EGFR Gene Copy Number Gain is Related to High Tumor SUV and Frequent Relapse after Adjuvant Chemotherapy in Resected Lung Adenocarcinoma. Japanese Journal of Clinical Oncology 41:4, 548-554
CrossRef233
Liang Cheng, Shaobo Zhang, Riley Alexander, Yongxue Yao, Gregory T MacLennan, Chong-xian Pan, Jiaoti Huang, Mingsheng Wang, Rodolfo Montironi, Antonio Lopez-Beltran. (2011) The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncology 7:4, 519-541
CrossRef234
Antonio Garofalo, Laurence Goossens, Perrine Six, Amélie Lemoine, Séverine Ravez, Amaury Farce, Patrick Depreux. (2011) Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 21:7, 2106-2112
CrossRef235
C. Gridelli, F. De Marinis, M. Di Maio, D. Cortinovis, F. Cappuzzo, T. Mok. (2011) Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues. Lung Cancer 72:1, 3-8
CrossRef236
Yongzheng Wang, Jiandong Zhang, Hairong Liu, Shuanghu Yuan, Fuli Wang, Kang Ning, Fengjun Liu, Jinming Yu. (2011) Erlotinib Resistance is Altered after Gemcitabine Chemotherapy for Recurrent Non-Small-Cell Lung Cancer. Clinical Drug Investigation 31:4, 279-283
CrossRef237
Ari VanderWalde, Sumanta Kumar Pal, Karen L. Reckamp. (2011) Management of non-small-cell lung cancer in the older adult. Maturitas 68:4, 311-321
CrossRef238
Gwyn Bebb, Colum Smith, Stewart Rorke, William Boland, Leonardo Nicacio, Ryan Sukhoo, Anthony Brade. (2011) Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemotherapy and Pharmacology 67:4, 837-845
CrossRef239
Vienna Ludovini, Fortunato Bianconi, Lorenza Pistola, Rita Chiari, Vincenzo Minotti, Renato Colella, Dario Giuffrida, Francesca Romana Tofanetti, Annamaria Siggillino, Antonella Flacco, Elisa Baldelli, Daniela Iacono, Maria Grazia Mameli, Antonio Cavaliere, Lucio Crinò. (2011) Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:4, 707-715
CrossRef240
I. Stenger, C. Tomala, M. Pietsch, U. Olgemoeller, W. Koerber, B. Fischer, M. Sebastian, L. Truemper, T. Overbeck, F. Griesinger. (2011) Mitomycin C in combination with vinorelbine or cisplatin and erythropoietin in pretreated patients with in field relapse after radiation therapy of non-small cell lung cancer: a phase II trial of the AIO. memo - Magazine of European Medical Oncology 4:1, 31-37
CrossRef241
Yasunari Oki, Takashi Hirose, Toshimitsu Yamaoka, Sojiro Kusumoto, Takao Shirai, Tomohide Sugiyama, Kentaro Okuda, Masanao Nakashima, Yasunori Murata, Tohru Ohmori, Mitsuru Adachi. (2011) Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 67:4, 791-797
CrossRef242
Sanghui Park, Seung Yeon Ha, Hyun Yee Cho, Dong Hae Chung, Na Rae Kim, Junshik Hong, Eun Kyung Cho. (2011) Prognostic implications of hypoxia-inducible factor-1α in epidermal growth factor receptor-negative non-small cell lung cancer. Lung Cancer 72:1, 100-107
CrossRef243
A.-M. Ruppert, M. Wislez, V. Poulot, R. Lacave, M. Antoine, J. Cadranel. (2011) Un regard simple sur la biologie du cancer bronchique : EGFR. Revue des Maladies Respiratoires 28:4, 565-577
CrossRef244
Cataldo, Vince D., Gibbons, Don L., Pérez-Soler, Román, Quintás-Cardama, Alfonso, . (2011) Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib. New England Journal of Medicine 364:10, 947-955
Full Text245
Ying Yuan, Hong Shen, Xiao-Ye Hu, Fei-Ying Gu, Mo-Dan Li, Xian Zhong. (2011) Multidisciplinary treatment with chemotherapy, targeted drug, and high-intensity focused ultrasound in advanced pancreatic carcinoma. Medical Oncology
CrossRef246
Deepa S Subramaniam, Jimmy Hwang. (2011) BIBW 2992 in non-small cell lung cancer. Expert Opinion on Investigational Drugs 20:3, 415-422
CrossRef247
Oscar Arrieta, Cynthia Villarreal-Garza, Digna Pachuca, Rosa M. Michel Ortega, Luis Martinez-Barrera, Diana Flores-Estrada, Alma Astorga. (2011) High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy. Medical Oncology 28:1, 300-306
CrossRef248
Qian-Ze Dong, Yang Wang, Xin-Jun Dong, Zi-Xuan Li, Zhong-Ping Tang, Quan-Ze Cui, En-Hua Wang. (2011) CIP2A is Overexpressed in Non-Small Cell Lung Cancer and Correlates with Poor Prognosis. Annals of Surgical Oncology 18:3, 857-865
CrossRef249
Linda E. Coate, Natasha B. Leighl. (2011) How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?. Current Treatment Options in Oncology 12:1, 1-11
CrossRef250
Gabriella Farina, Flavia Longo, Olga Martelli, Ida Pavese, Andrea Mancuso, Luca Moscetti, Roberto Labianca, Alessandro Bertolini, Enrico Cortesi, Antonio Farris, Daniele Fagnani, Maria Cristina Locatelli, Giuseppe Valmadre, Antonio Ardizzoia, Maurizio Tomirotti, Eliana Rulli, Marina Chiara Garassino, Alberto Scanni. (2011) Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non–Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer 12:2, 138-141
CrossRef251
Satoshi Yoda, Kenzo Soejima, Hiroyuki Yasuda, Katsuhiko Naoki, Ichiro Kawada, Hideo Watanabe, Ichiro Nakachi, Ryosuke Satomi, Sohei Nakayama, Sinnosuke Ikemura, Hideki Terai, Takashi Sato, Maiko Morosawa, Koichiro Asano. (2011) A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients. Cancer Chemotherapy and Pharmacology 67:3, 717-722
CrossRef252
P. Forde, C. Murphy, C. O’Sullivan, D. Carney. (2011) Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer. Irish Journal of Medical Science 180:1, 283-284
CrossRef253
Julien Hadoux, Benjamin Besse, David Planchard. (2011) Cancers bronchiques des non-fumeurs : particularités épidémiologiques, thérapeutiques et moléculaires. La Presse Médicale
CrossRef254
Athanasios G. Pallis, Kostas Syrigos, Athanasios Kotsakis, Niki Karachaliou, Aris Polyzos, Vassilis Chandrinos, Ioannis Varthalitis, Charalambos Christophyllakis, Alexandros Ardavanis, Lambros Vamvakas, Nikolaos Vardakis, Zacharenia Saridaki, George Samonis, Stylianos Giassas, Vassilis Georgoulias, Sophia Agelaki. (2011) Second-line Paclitaxel/Carboplatin Versus Vinorelbine/Carboplatin in Patients Who Have Advanced Non–Small-Cell Lung Cancer Pretreated With Non–Platinum-Based Chemotherapy: A Multicenter Randomized Phase II Study. Clinical Lung Cancer 12:2, 100-105
CrossRef255
F. Cappuzzo, D. R. Camidge, M. Varella-Garcia. (2011) Is FISH floating or still swimming in the lung cancer ocean?. Annals of Oncology 22:3, 493-499
CrossRef256
Suresh S. Ramalingam, Taofeek K. Owonikoko, Fadlo R. Khuri. (2011) Lung cancer: New biological insights and recent therapeutic advances. CA: A Cancer Journal for Clinicians 61:2, 91-112
CrossRef257
Giannis Mountzios, Kostas N. Syrigos. (2011) A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer. Drug Safety 34:3, 175-186
CrossRef258
Qiong Luo, Yanhong Gu, Wei Zheng, Xingxin Wu, Fangyuan Gong, Liyun Gu, Yang Sun, Qiang Xu. (2011) Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway. Toxicology and Applied Pharmacology 251:2, 130-136
CrossRef259
Pei-pei Dong, Zhong-ze Fang, Yan-yan Zhang, Guang-bo Ge, Yu-xi Mao, Liang-liang Zhu, Yan-qing Qu, Wei Li, Li-ming Wang, Chang-xiao Liu, Ling Yang. (2011) Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib. Acta Pharmacologica Sinica 32:3, 399-407
CrossRef260
N. Mollberg, M. Surati, C. Demchuk, R. Fathi, A. K. Salama, A. N. Husain, T. Hensing, R. Salgia. (2011) Mind-mapping for lung cancer: Towards a personalized therapeutics approach. Advances in Therapy 28:3, 173-194
CrossRef261
Dennis A. Wigle. (2011) Personalized Therapy for Non–Small Cell Lung Cancer: Hype or Clinical Reality?. Seminars in Thoracic and Cardiovascular Surgery 23:1, 30-35
CrossRef262
Fenghua Wang, Yang Zhang, Hongyun Zhao, Likun Chen, Yan-Xia Shi, Li Zhang. (2011) Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib. Medical Oncology 28:1, 331-335
CrossRef263
A.- M. C. Dingemans, A. J. de Langen, V. van den Boogaart, J. T. Marcus, W. H. Backes, H. T. G. M. Scholtens, H. van Tinteren, O. S. Hoekstra, J. Pruim, B. Brans, F. B. Thunnissen, E. F. Smit, H. J. M. Groen. (2011) First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Annals of Oncology 22:3, 559-566
CrossRef264
Sumanta Kumar Pal, Robert A. Figlin. (2011) Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. Targeted Oncology 6:1, 5-16
CrossRef265
Yufan Zhao, Donglin Zeng, Mark A. Socinski, Michael R. Kosorok. (2011) Reinforcement Learning Strategies for Clinical Trials in Nonsmall Cell Lung Cancer. Biometricsno-no
CrossRef266
Gilda da Cunha Santos, Frances A. Shepherd, Ming Sound Tsao. (2011) EGFR Mutations and Lung Cancer. Annual Review of Pathology: Mechanisms of Disease 6:1, 49-69
CrossRef267
Karen Reckamp, Barbara Gitlitz, Lin-Chi Chen, Ravi Patel, Ginger Milne, Mary Syto, Deborah Jezior, Sara Zaknoen. (2011) Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer. Cancer 117:4, 809-818
CrossRef268
David J. Stewart, Carmen Behrens, Jack Roth, Ignacio I. Wistuba. (2011) Exponential decay nonlinear regression analysis of patient survival curves: Preliminary assessment in non-small cell lung cancer. Lung Cancer 71:2, 217-223
CrossRef269
Álvaro Taus, Iván Vollmer, Edurne Arriola. (2011) Mutaciones de sensibilidad y resistencia del gen epidermal growth factor receptor (EGFR) en el cáncer de pulmón de célula no pequeña: una realidad clínica. Archivos de Bronconeumología 47:2, 103-105
CrossRef270
Katsuhiro Masago, Shiro Fujita, Young Hak Kim, Yukimasa Hatachi, Akiko Fukuhara, Kaoru Irisa, Hiroki Nagai, Yuichi Sakamori, Yosuke Togashi, Tadashi Mio, Michiaki Mishima. (2011) Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer. Cancer Chemotherapy and Pharmacology 67:2, 325-330
CrossRef271
Mark H. Michalski, Xiaoyuan Chen. (2011) Molecular imaging in cancer treatment. European Journal of Nuclear Medicine and Molecular Imaging 38:2, 358-377
CrossRef272
Xin-Hua Xu, Jin Su, Xiang-Yang Fu, Feng Xue, Qiao Huang, Dao-Jun Li, Ming-Qian Lu. (2011) Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 67:2, 475-479
CrossRef273
David E. Gerber, Drew W. Rasco, Phat Le, Jingsheng Yan, Jonathan E. Dowell, Yang Xie. (2011) Predictors and Impact of Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer in the United States. Journal of Thoracic Oncology 6:2, 365-371
CrossRef274
Takayuki Shiroyama, Kiyoshi Komuta, Fumio Imamura, Tomonori Hirashima, Takashi Kijima, Isao Tachibana, Ichiro Kawase. (2011) Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer. Lung Cancer
CrossRef275
Fumihiro Shoji, Daigo Kawano, Kensaku Ito, Yosuke Morodomi, Tokujiro Yano, Yoshihiko Maehara. (2011) Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: Report of a case. Surgery Today 41:2, 255-257
CrossRef276
Paul Workman. (2011) Drugging the Cancer Genome. Annual Review of Pharmacology and Toxicology 52:1, 110301101444027
CrossRef277
A. Ocana, I. F. Tannock. (2011) When Are "Positive" Clinical Trials in Oncology Truly Positive?. JNCI Journal of the National Cancer Institute 103:1, 16-20
CrossRef278
Yuichi Takiguchi, Takashi Seto, Yukito Ichinose, Naoyuki Nogami, Tetsu Shinkai, Hiroaki Okamoto, Koichi Minato, Nobuhiko Seki, Kenji Eguchi, Kazuma Kishi, Masanori Nishikawa, Koshiro Watanabe. (2011) Long-Term Administration of Second-Line Chemotherapy with S-1 and Gemcitabine for Platinum-Resistant Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, 156-160
CrossRef279
Lauren E. Cipriano, Dorothy Romanus, Craig C. Earle, Bridget A. Neville, Elkan F. Halpern, G. Scott Gazelle, Pamela M. McMahon. (2011) Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value in Health 14:1, 41-52
CrossRef280
Daniel Spira, Michael Fenchel, Ulrich M. Lauer, Claus D. Claussen, Michael Gregor, Michael Bitzer, Marius Horger. (2011) Comparison of Different Tumor Response Criteria in Patients with Hepatocellular Carcinoma After Systemic Therapy with the Multikinase Inhibitor Sorafenib. Academic Radiology 18:1, 89-96
CrossRef281
Jesús García-Foncillas, Pilar Garrido, Javier Gómez, José Palacios, Miquel Tarón. (2011) Recomendaciones para la determinación de las mutaciones del gen EGFR en el carcinoma de pulmón no microcítico. Revista Española de Patología 44:1, 17-31
CrossRef282
Álvaro Taus, Iván Vollmer, Edurne Arriola. (2011) Activating and Resistance Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene and Non-Small Cell Lung Cancer: A Clinical Reality. Archivos de Bronconeumología (English Edition) 47:2, 103-105
CrossRef283
Antonio Garofalo, Laurence Goossens, Amélie Lemoine, Séverine Ravez, Perrine Six, Michael Howsam, Amaury Farce, Patrick Depreux. (2011) [4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl] carbamic acid esters: a novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors. MedChemComm 2:1, 65
CrossRef284
Penelope Bradbury, John Hilton, Lesley Seymour. (2011) Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress. Clinical Investigation 1:1, 33-44
CrossRef285
Valsamo K. Anagnostou, Anastasios T. Dimou, Taxiarchis Botsis, Elizabeth J. Killiam, Mark D. Gustavson, Robert J. Homer, Daniel Boffa, Vassiliki Zolota, Dimitrios Dougenis, Lynn Tanoue, Scott N. Gettinger, Frank C. Detterbeck, Konstantinos N. Syrigos, Gerold Bepler, David L. Rimm. (2011) Molecular classification of nonsmall-cell lung cancer using a 4-protein quantitative assay. Cancern/a-n/a
CrossRef286
Daniel J Lebovic, Alberto Chiappori, Jhanelle Gray. (2011) Maintenance therapies in advanced non-small-cell lung cancer. Therapy 8:1, 33-41
CrossRef287
Dae Ho Lee, Sang-We Kim, Cheolwon Suh, Yun Hee Han, Jung-Shin Lee. (2011) Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets. Cancer Chemotherapy and Pharmacology 67:1, 35-39
CrossRef288
Wen-Chien Fan, Chong-Jen Yu, Chun-Ming Tsai, Ming-Shyan Huang, Chun-Liang Lai, Te-Chun Hsia, Yin-Jing Tien, Shiang-Fen Huang, Chieh-Hung Wu, Kun-Ta Chou, Yu-Chin Lee, Reury-Perng Perng, Yuh-Min Chen. (2011) Different Efficacies of Erlotinib and Gefitinib in Taiwanese Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, 148-155
CrossRef289
Bruno R Bastos, Rogerio C Lilenbaum. (2011) Combining EGF receptor inhibitors with chemotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. Therapy 8:1, 9-14
CrossRef290
Myung Hee Chang, Hee Kyung Ahn, Jeeyun Lee, Chan-Kwon Jung, Yoon-La Choi, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. (2011) Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Cancer 117:1, 143-151
CrossRef291
Daniel S. Higginson, Ronald C. Chen, David E. Morris, Jan Halle, Julian G. Rosenman, Mark A. Socinski, Lawrence B. Marks. (2011) Predicting the need for palliative thoracic radiation after first-line chemotherapy for advanced nonsmall cell lung carcinoma. Cancern/a-n/a
CrossRef292
Hong-Joon Shin, Tae-Ok Kim, Hyun-Wook Kang, Su-Young Chi, Hee-Jung Ban, Soo-Ok Kim, Yong-Soo Kwon, In-Jae Oh, Kyu-Sik Kim, Yu-Il Kim, Sung-Chul Lim, Young-Chul Kim. (2011) Comparison of Therapeutic Efficacy of Gefitinib and Erlotinib in Patients with Squamous Cell Lung Cancer. Tuberculosis and Respiratory Diseases 71:1, 15
CrossRef293
Jinu Abraham, Laura D. Nelon, Courtney B. Kubicek, Aoife Kilcoyne, Sheila T. Hampton, Lee Ann Zarzabal, Francis J. Giles, Joel E. Michalek, Brian P. Rubin, Charles Keller. (2011) Preclinical Testing of Erlotinib in a Transgenic Alveolar Rhabdomyosarcoma Mouse Model. Sarcoma 2011, 1-5
CrossRef294
Hye Jin Choi, Joo Hyuk Sohn, Chang Geol Lee, Hyo Sub Shim, Ik-Jae Lee, Woo Ick Yang, Ji Eun Kwon, Se Kyu Kim, Moo-Suk Park, Ju Hee Lee, Joo Hang Kim. (2011) A phase I study of nimotuzumab in combination with radiotherapy in stages IIB–IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer 71:1, 55-59
CrossRef295
Gustavo Baretton, Stephan Grabbe, Ulrich Keilholz, Guido Sauter. (2011) Molekulare Diagnostik und Therapie in der Onkologie. Onkologie 34:s2, 5-9
CrossRef296
B. Geoerger, D. Hargrave, F. Thomas, A. Ndiaye, D. Frappaz, F. Andreiuolo, P. Varlet, I. Aerts, R. Riccardi, T. Jaspan, E. Chatelut, M.-C. Le Deley, X. Paoletti, C. Saint-Rose, P. Leblond, B. Morland, J.-C. Gentet, V. Meresse, G. Vassal, . (2011) Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro-Oncology 13:1, 109-118
CrossRef297
Derrek A. Heuveling, Remco de Bree, Guus A.M.S. van Dongen. (2011) The potential role of non-FDG-PET in the management of head and neck cancer. Oral Oncology 47:1, 2-7
CrossRef298
Alain Vergnenegre, Romain Corre, Henri Berard, Dominique Paillotin, Cecile Dujon, Gilles Robinet, Jacky Crequit, Suzanna Bota, Pascal Thomas, Christos Chouaid. (2011) Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, 161-168
CrossRef299
Yasuhiko Nishioka, Yoshinori Aono, Saburo Sone. (2011) Role of tyrosine kinase inhibitors in tumor immunology. Immunotherapy 3:1, 107-116
CrossRef300
Kenichiro Kudo, Keiichi Fujiwara, Mizuho Tsushima, Makoto Mizuta, Kiyoshi Matsuo, Toshiro Yonei, Toshio Sato. (2011) Toxicity manifesting as cosmetic hair alterations during erlotinib treatment. Acta Oncologica 50:1, 146-148
CrossRef301
Susanne Kilpinen, Thomas Spillmann, Pernilla Syrjä, Teresa Skrzypczak, Maria Louhelainen, Elias Westermarck. (2011) Effect of tylosin on dogs with suspected tylosin-responsive diarrhea: a placebo-controlled, randomized, double-blinded, prospective clinical trial. Acta Veterinaria Scandinavica 53:1, 26
CrossRef302
Chia-Chi Lin, James Chih-Hsin Yang. (2011) Optimal Management of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations. Drugs 71:1, 79-88
CrossRef303
Kamila Wojas-Krawczyk, Paweł Krawczyk, Radosław Mlak, Tomasz Kucharczyk, Dariusz M. Kowalski, Maciej Krzakowski, Janusz Milanowski. (2011) The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients. Respiration 82:4, 341-350
CrossRef304
Daniel Morgensztern, Ramaswamy Govindan. (2011) Best of the Month. Journal of Thoracic Oncology 6:1, 223-226
CrossRef305
Anastasios Dimou, Kevin Harrington, Kostas N. Syrigos. (2011) From the Bench to Bedside: Biological and Methodology Considerations for the Future of Companion Diagnostics in Nonsmall Cell Lung Cancer. Pathology Research International 2011, 1-8
CrossRef306
Efsevia Vakiani, David B Solit. (2011) KRAS and BRAF: drug targets and predictive biomarkers. The Journal of Pathology 223:2, 220-230
CrossRef307
Federico Longo, Alejandro Riquelme, Mercedes Rodríguez, María E. Olmedo, Pilar Garrido. (2011) Long-Term Survival in a Smoking Caucasian Male Patient Treated with Gefitinib for Spinal Cord Compression Secondary to Lung Cancer. Onkologie 34:6, 326-328
CrossRef308
Cesare Gridelli, Antonio Rossi, Paola Venturino, Filippo de Marinis. (2011) Treatment, Rationale, and Study Design of TALISMAN Study: A Randomized Phase II Open-Label Study of Second-line Erlotinib Versus Intermittent Erlotinib Dosing With Docetaxel in the Treatment of Former-Smoker Men Affected by Recurrent Squamous Non–Small-Cell Lung Cancer. Clinical Lung Cancer 12:1, 70-73
CrossRef309
Gérard Zalcman, Emmanuel Bergot, Christian Creveuil, Guénaëlle Levallet, Emmanuèle Lechapt. (2011) Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer. Current Opinion in Oncology 23:1, 106-111
CrossRef310
Shiro Tanaka, Yuichi Sakamori, Miyuki Niimi, Megumi Hazama, Young H Kim, Kazuhiro Yanagihara. (2011) Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST). Trials 12:1, 120
CrossRef311
Seong Ha Cheon, Kyung Seok Kim, Sehyun Kim, Hyun Sik Jung, Won Cheol Choi, Wan Kyu Eo. (2011) Efficacy and Safety of <i>Rhus verniciflua</i> Stokes Extracts in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. Forschende Komplementärmedizin / Research in Complementary Medicine 18:2, 2-2
CrossRef312
A. Bearz, M. Berretta, A. Lleshi, U. Tirelli. (2011) Target Therapies in Lung Cancer. Journal of Biomedicine and Biotechnology 2011, 1-5
CrossRef313
Kwok-Chi LAM, Tony S. MOK. (2011) Targeted therapy: An evolving world of lung cancer. Respirology 16:1, 13-21
CrossRef314
Dusan Kotasek, Niall Tebbutt, Jayesh Desai, Stephen Welch, Lillian L Siu, Sheryl McCoy, Yu-Nien Sun, Jessica Johnson, Adeboye H Adewoye, Timothy Price. (2011) Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. BMC Cancer 11:1, 313
CrossRef315
Heesue Kim, Ho Yeong Lim. (2011) Novel EGFR-TK Inhibitor EKB-569 Inhibits Hepatocellular Carcinoma Cell Proliferation by AKT and MAPK Pathways. Journal of Korean Medical Science 26:12, 1563
CrossRef316
Jill E. Larsen, Tina Cascone, David E. Gerber, John V. Heymach, John D. Minna. (2011) Targeted Therapies for Lung Cancer. The Cancer Journal 17:6, 512-527
CrossRef317
Tatsuya Nagano, Yoshikazu Kotani, Kazuyuki Kobayashi, Yukihisa Hatakeyama, Suya Hori, Daisuke Kasai, Yasuhiro Funada, Hideki Nishimura, Takeshi Kondoh, Yoshihiro Nishimura. (2011) Long-term Outcome after Multidisciplinary Approach for Leptomeningeal Carcinomatosis in a Non-small Cell Lung Cancer Patient with Poor Performance Status. Internal Medicine 50:24, 3019-3022
CrossRef318
Tatsuya Nagano, Yoshikazu Kotani, Kazuyuki Kobayashi, Masahiro Katsurada, Yukihisa Hatakeyama, Suya Hori, Daisuke Tamura, Daisuke Kasai, Yasuhiro Funada, Yoshihiro Nishimura. (2011) Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib. Case Reports in Pulmonology 2011, 1-4
CrossRef319
Azusa Hoshino-Yoshino, Motohiro Kato, Kohnosuke Nakano, Masaki Ishigai, Toshiyuki Kudo, Kiyomi Ito. (2011) Bridging from preclinical to clinical studies for tyrosine kinase inhibitors based on pharmacokinetics/pharmacodynamics and toxicokinetics/toxicodynamics. Drug Metabolism and Pharmacokinetics
CrossRef320
Dal Yong Kim, Dae Ho Lee, Sun-Joo Jang, Sang-We Kim, Cheolwon Suh, Jung Shin Lee. (2011) Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment. Cancer Research and Treatment 43:4, 212
CrossRef321
Fu-Tsai Chung, Kang-Yun Lee, Chih-Wei Wang, Chih-Chen Heh, Yao-Fei Chan, Huan-Wu Chen, Chih-Hsi Kuo, Po-Hao Feng, Ting-Yu Lin, Chun-Hua Wang, Chun-Liang Chou, Hao-Cheng Chen, Shu-Min Lin, Han-Pin Kuo. (2011) Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. International Journal of Cancern/a-n/a
CrossRef322
Guanghui Gao, Shengxiang Ren, Aiwu Li, Jianfang Xu, Qinghua Xu, Chunxia Su, Jian Guo, Qinfang Deng, Caicun Zhou. (2011) Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from 6 phase III randomized controlled trials. International Journal of Cancern/a-n/a
CrossRef323
Gilberto de Lima Lopes, Joel E. Segel, Daniel S. W. Tan, Young K. Do, Tony Mok, Eric A. Finkelstein. (2011) Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancern/a-n/a
CrossRef324
Grace K. Dy, Shauna L. Hillman, Kendrith M. Rowland, Julian R. Molina, Preston D. Steen, Donald B. Wender, Suresh Nair, Sumithra Mandrekar, Steven E. Schild, Alex A. Adjei. (2010) A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer. Cancer 116:24, 5686-5693
CrossRef325
Daniel Binder, Ann-Christin Buckendahl, Ralf-Harto Hübner, Peter Schlattmann, Bettina Temmesfeld-Wollbrück, Thomas Beinert, Norbert Suttorp. (2010) Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker. Medical Oncology
CrossRef326
Yoon Hee Choi, Jin Kyung Lee, Hye Jin Kang, Tae Sup Lee, Hye-Ryoun Kim, Cheol Hyeon Kim, Jae Soo Koh, Hee Jong Baek, Jae Cheol Lee, Im Il Na. (2010) Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:12, 1949-1952
CrossRef327
David Rossi, Donatella Dennetta, Marcello Ugolini, Vincenzo Catalano, Paolo Alessandroni, Paolo Giordani, Anna Maria Baldelli, Virginia Casadei, Francesco Graziano, S. Luzi Fedeli. (2010) Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial. Targeted Oncology 5:4, 231-235
CrossRef328
Joline S. W. Lind, Martijn R. Meijerink, Anne-Marie C. Dingemans, Cornelis Kuijk, Michel C. Öllers, Dirk Ruysscher, Pieter E. Postmus, Egbert F. Smit. (2010) Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?. European Radiology 20:12, 2890-2898
CrossRef329
Ilse Roodink, William P.J. Leenders. (2010) Targeted therapies of cancer: Angiogenesis inhibition seems not enough. Cancer Letters 299:1, 1-10
CrossRef330
Jean-François Morère, Jeanne-Marie Bréchot, Virginie Westeel, Valerie Gounant, Bernard Lebeau, Fabien Vaylet, Fabrice Barlési, Thierry Urban, Pierre-Jean Souquet, Didier Debieuvre, Laurence Baudrin, Gérard Zalcman, Franck Morin, Bernard Milleron, Denis Moro-Sibilot. (2010) Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer 70:3, 301-307
CrossRef331
Young Joo Lee, Hyo Sub Shim, Young Ae Kang, Su Jung Hong, Hyun Ki Kim, Hoguen Kim, Se Kyu Kim, Sung Ho Choi, Joo-Hang Kim, Byoung Chul Cho. (2010) Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 136:12, 1937-1944
CrossRef332
Joel W Neal. (2010) The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. Future Oncology 6:12, 1827-1832
CrossRef333
James F. Spicer, Sarah M. Rudman. (2010) EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Targeted Oncology 5:4, 245-255
CrossRef334
Patrick Adam, Stefanie Hahner, Martina Hartmann, Barbara Heinrich, Marcus Quinkler, Holger S Willenberg, Wolfgang Saeger, Silviu Sbiera, Sebastian Schmull, Hans-Ullrich Voelker, Philipp Ströbel, Bruno Allolio, Martin Fassnacht. (2010) Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Modern Pathology 23:12, 1596-1604
CrossRef335
J. C. Soria, C. Massard, T. Le Chevalier. (2010) Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?. Annals of Oncology 21:12, 2324-2332
CrossRef336
Stephanie V. Blank, Paul Christos, John P. Curtin, Noah Goldman, Carolyn D. Runowicz, Joseph A. Sparano, Leonard Liebes, Helen X. Chen, Franco M. Muggia. (2010) Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment. Gynecologic Oncology 119:3, 451-456
CrossRef337
B. Alt-Epping, F. Nauck. (2010) Tumorspezifische Therapien und ihr Einsatz in der Palliativmedizin. Der Schmerz 24:6, 633-641
CrossRef338
Alfredo Tartarone. (2010) Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature. Future Oncology 6:12, 1937-1940
CrossRef339
Joan H. Schiller, Joachim von Pawel, Philipp Schütt, Rafat H. Ansari, Michael Thomas, Mansoor Saleh, Robert D. McCroskey, Wolfgang Pfeifer, Thomas A. Marsland, Goetz H. Kloecker, Martin Sebastian, Robert Pirker, Raffael Kurek, Claire Beadman, Mark A. Socinski. (2010) Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:12, 1977-1985
CrossRef340
G. Maarten-Friso Ruinemans, Corinne Balemans, Vera Mattijssen, Anne J. Wiersma-van Tilburg, Hans J.M. Smit. (2010) Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib. Lung Cancer 70:3, 364-365
CrossRef341
Zhengbo Song, Yongfeng Yu, Zhiwei Chen, Shun Lu. (2010) Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients. Medical Oncology
CrossRef342
Joel W. Neal, Rebecca S. Heist, Panos Fidias, Jennifer S. Temel, Mark Huberman, J. Paul Marcoux, Alona Muzikansky, Thomas J. Lynch, Lecia V. Sequist. (2010) Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. Journal of Thoracic Oncology 5:11, 1855-1858
CrossRef343
M. Ranson, M. Reck, A. Anthoney, A.- R. Hanauske, E. Dean, I. Melezinek, G. Klingelschmitt, H. Kletzl, J. Blatter, C. Twelves. (2010) Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. Annals of Oncology 21:11, 2233-2239
CrossRef344
Amanda Psyrri, Barbara Burtness. (2010) Targeted therapies: Molecular selection for 'smart' study design in lung cancer. Nature Reviews Clinical Oncology 7:11, 621-622
CrossRef345
Inan Olmez, Bernadine R. Donahue, James S. Butler, Yiwu Huang, Philip Rubin, Yiqing Xu. (2010) Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis. Lung Cancer 70:2, 174-179
CrossRef346
Kouki Ohtsuka, Hiroaki Ohnishi, Takeshi Morii, Masachika Fujiwara, Tomonori Kishino, Wataru Ogura, Misaki Chiba, Satsuki Matsushima, Tomoyuki Goya, Takashi Watanabe. (2010) Downregulated ABCG2 Enhances Sensitivity to Topoisomerase I Inhibitor in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:11, 1726-1733
CrossRef347
Shivanni Kummar, Helen X. Chen, John Wright, Susan Holbeck, Myrtle Davis Millin, Joseph Tomaszewski, James Zweibel, Jerry Collins, James H. Doroshow. (2010) Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nature Reviews Drug Discovery 9:11, 843-856
CrossRef348
L. Trani, J. Myerson, S. Ashley, K. Young, A. Sheri, R. Hubner, M. Puglisi, S. Popat, M.E.R. O’Brien. (2010) Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations. Lung Cancer 70:2, 200-204
CrossRef349
Denis Moro-Sibilot, Alain Vergnenegre, Egbert F. Smit, Elisabeth Toy, Barbara Parente, Stephan Schmitz, Kees Kraaij, Carla Visseren-Grul, Victoria Soldatenkova, Jorge Arellano, Claudia Leteneux. (2010) Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study. Current Medical Research and Opinion 26:11, 2661-2672
CrossRef350
Nagahiro Saijo. (2010) Targeted therapies: Tyrosine-kinase inhibitors—new standard for NSCLC therapy. Nature Reviews Clinical Oncology 7:11, 618-619
CrossRef351
William Pao, Juliann Chmielecki. (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews Cancer 10:11, 760-774
CrossRef352
D. Barnes, C. Souza, J. Entwisle. (2010) The role of the percutaneous biopsy in the evolving diagnosis and treatment of lung cancer. Clinical Radiology 65:11, 951-952
CrossRef353
Jaya Sangodkar, Suzanna Katz, Heather Melville, Goutham Narla. (2010) Lung Adenocarcinoma: Lessons in Translation from Bench to Bedside. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:6, 597-605
CrossRef354
Eric B. Haura, Eric Sommers, Lanxi Song, Alberto Chiappori, Aaron Becker. (2010) A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance. Journal of Thoracic Oncology 5:11, 1806-1814
CrossRef355
Kyle E. Rusthoven, Steven J. Feigenberg, David Raben, Madeleine Kane, John I. Song, Nicos Nicolaou, Ranee Mehra, Barbara Burtness, John Ridge, Robyn Swing, Miriam Lango, Roger Cohen, Antonio Jimeno, Changhu Chen. (2010) Initial Results of a Phase I Dose-Escalation Trial of Concurrent and Maintenance Erlotinib and Reirradiation for Recurrent and New Primary Head-and-Neck Cancer. International Journal of Radiation Oncology*Biology*Physics 78:4, 1020-1025
CrossRef356
Giuseppe Bronte, Sergio Rizzo, Laura La Paglia, Vincenzo Adamo, Sergio Siragusa, Corrado Ficorella, Daniele Santini, Viviana Bazan, Giuseppe Colucci, Nicola Gebbia, Antonio Russo. (2010) Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treatment Reviews 36, S21-S29
CrossRef357
José Manuel Trigo Pérez, Pilar Garrido López, Enriqueta Felip Font, Dolores Isla Casado. (2010) SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. Clinical and Translational Oncology 12:11, 735-741
CrossRef358
S. Gütz. (2010) Fortgeschrittenes nichtkleinzelliges Bronchialkarzinom (NSCLC). Der Pneumologe 7:6, 448-449
CrossRef359
Liang-Ping Xia, Hui-Juan Qiu, Xu-Xian Chen, Pi-Li Hu, Gui-Fang Guo, Fang Wang, Fei-Fei Zhou, Wen-Zhuo He, Bei Zhang, Li Zhang. (2010) Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a report of 12 cases. Medical Oncology
CrossRef360
Nienke A. Vries, Tessa Buckle, Jin Zhao, Jos H. Beijnen, Jan H. M. Schellens, Olaf Tellingen. (2010) Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Investigational New Drugs
CrossRef361
Wilfried Eberhardt. (2010) Compassionate Use Programs or Phase IV Trials of Innovative Molecular Targeted Drugs in Lung Cancer. Journal of Thoracic Oncology 5:10, 1495-1497
CrossRef362
E. De Maio, C. Tibaldi, A. D'Incecco, S. Bursi, C. Barbara, S. Cupini, R. Di Marsico, M. D'Arcangelo, L. Landi, G. Minuti, F. Cappuzzo. (2010) Consequences of targeted treatments for second-line therapy. Annals of Oncology 21:Supplement 7, vii234-vii240
CrossRef363
Archontoula Stoffel. (2010) Targeted Therapies for Solid Tumors. BioDrugs 24:5, 303-316
CrossRef364
Tony Mok, Yi-long Wu, Joseph Siu-kie Au, Caicun Zhou, Li Zhang, Reury-Perng Perng, Keunchil Park. (2010) Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:10, 1609-1615
CrossRef365
Paolo Bidoli, Diego L. Cortinovis, Ilaria Colombo, Alessandra Crippa, Federica Cicchiello, Federica Villa, Marina E. Cazzaniga, Gianfranco Altomare. (2010) Isotretinoin Plus Clindamycin Seem Highly Effective Against Severe Erlotinib-Induced Skin Rash in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:10, 1662-1663
CrossRef366
Martin Reck, Nico van Zandwijk, Cesare Gridelli, Zoltan Baliko, Danny Rischin, Simon Allan, Maciej Krzakowski, David Heigener. (2010) Erlotinib in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:10, 1616-1622
CrossRef367
Kazuhiro Yanagihara, Kenichi Yoshimura, Miyuki Niimi, Hiroyasu Yasuda, Takahiko Sasaki, Takafumi Nishimura, Hiroshi Ishiguro, Shigemi Matsumoto, Toshiyuki Kitano, Masashi Kanai, Akiko Misawa, Harue Tada, Satoshi Teramukai, Tadashi Mio, Masanori Fukushima. (2010) Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 66:5, 913-918
CrossRef368
Tony S Mok, Qing Zhou, Linda Leung, Herbert H Loong. (2010) Personalized medicine for non-small-cell lung cancer. Expert Review of Anticancer Therapy 10:10, 1601-1611
CrossRef369
Sri Navaratnam, Erich V. Kliewer, Jim Butler, Alain A. Demers, Grace Musto, Ketan Badiani. (2010) Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death. Lung Cancer 70:1, 110-115
CrossRef370
Lynsay L Waller, Kathryn E Weaver, W Jeffrey Petty, Antonius A Miller. (2010) Effects of continued tobacco use during treatment of lung cancer. Expert Review of Anticancer Therapy 10:10, 1569-1575
CrossRef371
W. K. A. Yung, J. J. Vredenburgh, T. F. Cloughesy, P. Nghiemphu, B. Klencke, M. R. Gilbert, D. A. Reardon, M. D. Prados. (2010) Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro-Oncology 12:10, 1061-1070
CrossRef372
Gelenis Domingo, Cesar A Perez, Michel Velez, Jennifer Cudris, Luis E Raez, Edgardo S Santos. (2010) EGF receptor in lung cancer: a successful story of targeted therapy. Expert Review of Anticancer Therapy 10:10, 1577-1587
CrossRef373
Marta Batus, Mary Jo Fidler, Philip D Bonomi. (2010) Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Review of Anticancer Therapy 10:10, 1589-1599
CrossRef374
Hyeong Su Kim, Gyeong-Won Lee, Jung Han Kim, Ho Young Kim, Jung Hye Kwon, Hun Ho Song, Hyo Jung Kim, Joo Young Jung, Geundoo Jang, Dae Ro Choi, Sang Myeon Park, Tae Rim Shin, Hee-sung Lee, Dae Young Zang. (2010) A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. Lung Cancer 70:1, 71-76
CrossRef375
Chia-Chi Lin, Hsin-Hsin Hsu, Chia-Tung Sun, Jin-Yuan Shih, Zhong-Zhe Lin, Chong-Jen Yu, George G. Chen, Michael Kuan Yew Hsin, Kwok Chi Lam, Linda Leung, Chih-Hsin Yang, Tony Mok. (2010) Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors. Journal of Thoracic Oncology 5:9, 1424-1429
CrossRef376
Fang Wang, Liangping Xia, Guifang Guo, Huijuan Qiu, Feifei Zhou, Bei Zhang, Li Zhang. (2010) Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with non-small cell lung cancer: a report of 6 cases. The Chinese-German Journal of Clinical Oncology 9:9, 502-506
CrossRef377
Athanasios G. Pallis, Michalis V. Karamouzis, Panagiotis A. Konstantinopoulos, Athanasios G. Papavassiliou. (2010) Molecular networks in respiratory epithelium carcinomas. Cancer Letters 295:1, 1-6
CrossRef378
James S. Myerson, Syed A. Iqbal, Mary E. R. O'Brien, Sanjay Popat. (2010) Supersensitive Mutation: Two Case Reports of Non–Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Lung Cancer 11:5, E5-E8
CrossRef379
Deric L. Wheeler, Emily F. Dunn, Paul M. Harari. (2010) Understanding resistance to EGFR inhibitors—impact on future treatment strategies. Nature Reviews Clinical Oncology 7:9, 493-507
CrossRef380
H. Francis, B. Solomon. (2010) The current status of targeted therapy for non-small cell lung cancer. Internal Medicine Journal 40:9, 611-618
CrossRef381
Yoshihiko Segawa, Katsuyuki Kiura, Katsuyuki Hotta, Nagio Takigawa, Masahiro Tabata, Keitaro Matsuo, Hiroshige Yoshioka, Hidetoshi Hayashi, Haruyuki Kawai, Keisuke Aoe, Tadashi Maeda, Hiroshi Ueoka, Mitsune Tanimoto. (2010) A Randomized Phase II Study of a Combination of Docetaxel and S-1 versus Docetaxel Monotherapy in Patients with Non-small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy. Journal of Thoracic Oncology 5:9, 1430-1434
CrossRef382
Annemarie Becker, Atie van Wijk, Egbert F. Smit, Pieter E. Postmus. (2010) Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:9, 1477-1480
CrossRef383
Sara Caponi, Enrico Vasile, Laura Ginocchi, Carmelo Tibaldi, Francesca Borghi, Armida D'Incecco, Maurizio Lucchesi, Chiara Caparello, Michele Andreuccetti, Alfredo Falcone. (2010) Second-line Treatment for Non–Small-Cell Lung Cancer: One Size Does Not Fit All. Clinical Lung Cancer 11:5, 320-327
CrossRef384
Young-Hee Oh, Youngwook Kim, Young-Pil Kim, Soo-Won Seo, Tetsuya Mitsudomi, Myung-Ju Ahn, Keunchil Park, Hak-Sung Kim. (2010) Rapid Detection of the Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer for Analysis of Acquired Resistance Using Molecular Beacons. The Journal of Molecular Diagnostics 12:5, 644-652
CrossRef385
David J. Lee, Aarati Ranganathan, Bing-e Xu. (2010) The 2010 Meeting of the American Society of Clinical Oncology. Clinical Lung Cancer 11:5, 303-310
CrossRef386
Fengsheng Chen, Xi Luo, Jinbiao Zhang, Yang Lu, Rongcheng Luo. (2010) Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib. Medical Oncology 27:3, 950-957
CrossRef387
T T Zhao, B G Le Francois, G Goss, K Ding, P A Bradbury, J Dimitroulakos. (2010) Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins. Oncogene 29:33, 4682-4692
CrossRef388
T. Fojo, C. Grady. (2010) Response: Re: How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. JNCI Journal of the National Cancer Institute 102:15, 1207-1210
CrossRef389
Robert Pirker. (2010) Bevacizumab in lung cancer: hurdles in clinical development. The Lancet Oncology 11:8, 703-704
CrossRef390
W.A. Weber. (2010) Molekulare Bildgebung in der Tumortherapie. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 53:8, 810-817
CrossRef391
Rajiv Dua, Jianhuan Zhang, Phets Nhonthachit, Elicia Penuel, Chris Petropoulos, Gordon Parry. (2010) EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Research and Treatment 122:3, 685-697
CrossRef392
Sandra C Tomaszek, Marianne Huebner, Dennis A Wigle. (2010) Prospects for molecular staging of non-small-cell lung cancer from genomic alterations. Expert Review of Respiratory Medicine 4:4, 499-508
CrossRef393
Akito Hata, Nobuyuki Katakami, Shiro Fujita, Reiko Kaji, Yukihiro Imai, Yutaka Takahashi, Takashi Nishimura, Keisuke Tomii, Kyosuke Ishihara. (2010) Frequency of EGFR and KRAS Mutations in Japanese Patients with Lung Adenocarcinoma with Features of the Mucinous Subtype of Bronchioloalveolar Carcinoma. Journal of Thoracic Oncology 5:8, 1197-1200
CrossRef394
Yixing Jiang, Heath Mackley, Hua Cheng, Jaffer A Ajani. (2010) Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. Biomarkers in Medicine 4:4, 535-541
CrossRef395
Alvin S. Wong, Catherine Teo, Siew-Woon Lim, Eunice Wong, Ross A. Soo, Noreen Chan. (2010) Targeted Therapy at the End of Life for Patients with Lung Cancer. Journal of Palliative Medicine 13:8, 945-948
CrossRef396
P.A. Gerber, B.A. Buhren, S. Kürle, B. Homey. (2010) Therapie mit Inhibitoren des epidermalen Wachstumsfaktorrezeptors. Der Hautarzt 61:8, 654-661
CrossRef397
A.G. Pallis, C. Gridelli. (2010) Is age a negative prognostic factor for the treatment of advanced/metastatic non-small-cell lung cancer?. Cancer Treatment Reviews 36:5, 436-441
CrossRef398
Nicolas Girard, Françoise Mornex. (2010) Highlights of the 2nd European Lung Cancer Conference. Expert Review of Anticancer Therapy 10:7, 1023-1025
CrossRef399
Ariel Lopez-Chavez, Giuseppe Giaccone. (2010) Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer. Nature Reviews Clinical Oncology 7:7, 360-362
CrossRef400
Robert C. Doebele, Ana B. Oton, Nir Peled, D. Ross Camidge, Paul A. Bunn. (2010) New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer 69:1, 1-12
CrossRef401
Steven J. Edwards, John Borrill. (2010) Network Meta-Analysis: Importance of Appropriate Trial Selection. Value in Health 13:5, 681-682
CrossRef402
Roy S Herbst, Yan Sun, Wilfried EE Eberhardt, Paul Germonpré, Nagahiro Saijo, Caicun Zhou, Jie Wang, Longyun Li, Fairooz Kabbinavar, Yukito Ichinose, Shukui Qin, Li Zhang, Bonne Biesma, John V Heymach, Peter Langmuir, Sarah J Kennedy, Hiroomi Tada, Bruce E Johnson. (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. The Lancet Oncology 11:7, 619-626
CrossRef403
Lynette M. Sholl, Neal I. Lindeman. (2010) Molecular Diagnostics Testing for Lung Adenocarcinoma. Pathology Case Reviews 15:4, 103-110
CrossRef404
Shih-Chieh Chang, Cheng-Yu Chang, Chiung-Yu Chen, Chong-Jen Yu. (2010) Successful Erlotinib Rechallenge after Gefitinib-Induced Acute Interstitial Pneumonia. Journal of Thoracic Oncology 5:7, 1105-1106
CrossRef405
Filip Janku, David J. Stewart, Razelle Kurzrock. (2010) Targeted therapy in non-small-cell lung cancer—is it becoming a reality?. Nature Reviews Clinical Oncology 7:7, 401-414
CrossRef406
Yan Xu, Hongyu Liu, Jun Chen, Qinghua Zhou. (2010) Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009. Thoracic Cancer 1:2, 83-86
CrossRef407
Emma Guttman-Yassky, Alain Mita, Maja De Jonge, Lesley Matthews, Sean McCarthy, Kenneth K. Iwata, Jaap Verweij, Eric K. Rowinsky, James G. Krueger. (2010) Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. European Journal of Cancer 46:11, 2010-2019
CrossRef408
István Peták, Richárd Schwab, László Őrfi, László Kopper, György Kéri. (2010) Integrating molecular diagnostics into anticancer drug discovery. Nature Reviews Drug Discovery 9:7, 523-535
CrossRef409
Jong-Mu Sun, Myung-Ju Ahn, Min Jae Park, Jun Ho Yi, Tae Sung Kim, Myung Jin Chung, Yeon Hee Park, Jin Seok Ahn, Keunchil Park. (2010) Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Lung Cancer 69:1, 105-109
CrossRef410
Fabien Maldonado, James R Jett. (2010) Advances in the diagnosis of lung cancer: contribution of molecular biology to bronchoscopic diagnosis. Current Opinion in Pulmonary Medicine 16:4, 315-320
CrossRef411
Anne Mathieu, Birgit Weynand, Eric Verbeken, Susana Da Silva, Christine Decaestecker, Isabelle Salmon, Pieter Demetter. (2010) Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer. Lung Cancer 69:1, 46-50
CrossRef412
Patricia S Kho, Wei Chua, Melissa M Moore, Stephen J Clarke. (2010) Is it prime time for personalized medicine in cancer treatment?. Personalized Medicine 7:4, 387-397
CrossRef413
Maemondo, Makoto, Inoue, Akira, Kobayashi, Kunihiko, Sugawara, Shunichi, Oizumi, Satoshi, Isobe, Hiroshi, Gemma, Akihiko, Harada, Masao, Yoshizawa, Hirohisa, Kinoshita, Ichiro, Fujita, Yuka, Okinaga, Shoji, Hirano, Haruto, Yoshimori, Kozo, Harada, Toshiyuki, Ogura, Takashi, Ando, Masahiro, Miyazawa, Hitoshi, Tanaka, Tomoaki, Saijo, Yasuo, Hagiwara, Koichi, Morita, Satoshi, Nukiwa, Toshihiro, . (2010) Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. New England Journal of Medicine 362:25, 2380-2388
Full Text414
Seung Tae Kim, Jeeyun Lee, Jeong-hoon Kim, Young-Woong Won, Jong-Mu Sun, Jina Yun, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. (2010) Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. Cancer 116:12, 3025-3033
CrossRef415
Cesare Gridelli, Andrea Ardizzoni, Jean-Yves Douillard, Nasser Hanna, Christian Manegold, Francesco Perrone, Robert Pirker, Rafael Rosell, Frances A. Shepherd, Luigi De Petris, Massimo Di Maio, Filippo de Marinis. (2010) Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer 68:3, 319-331
CrossRef416
David S. Ettinger. (2010) Emerging profile of cetuximab in non-small cell lung cancer. Lung Cancer 68:3, 332-337
CrossRef417
Dong Xue, Amy P Abernethy. (2010) Management of dyspnea in advanced lung cancer: recent data and emerging concepts. Current Opinion in Supportive and Palliative Care 4:2, 85-91
CrossRef418
Wilson I. Gonsalves, Jamil Abuzetun, Peter T. Silberstein. (2010) Palliative Chemotherapy: An Outdated Term for Life-Prolonging Systemic Therapies for Incurable Malignancies. Journal of Palliative Medicine 13:6, 641-641
CrossRef419
Alejandro Forner, Carlos Rodríguez De Lope, María Reig, Jordi Bruix. (2010) Tratamiento del carcinoma hepatocelular avanzado. Gastroenterología y Hepatología 33:6, 461-468
CrossRef420
Els L. Persijn van Meerten, Hans Gelderblom, Johan L. Bloem. (2010) RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. European Radiology 20:6, 1456-1467
CrossRef421
Martin Sebastian, Martin Reck, Cornelius F. Waller, Cornelius Kortsik, Norbert Frickhofen, Martin Schuler, Holger Fritsch, Birgit Gaschler-Markefski, Gertraud Hanft, Gerd Munzert, Joachim von Pawel. (2010) The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy. Journal of Thoracic Oncology1
CrossRef422
Federico Cappuzzo, Tudor Ciuleanu, Lilia Stelmakh, Saulius Cicenas, Aleksandra Szczésna, Erzsébet Juhász, Emilio Esteban, Olivier Molinier, Wolfram Brugger, Ivan Melezínek, Gaëlle Klingelschmitt, Barbara Klughammer, Giuseppe Giaccone. (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. The Lancet Oncology 11:6, 521-529
CrossRef423
Martin Reck. (2010) A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond. Expert Review of Anticancer Therapy 10:6, 955-965
CrossRef424
A. Camerini, C. Valsuani, F. Mazzoni, O. Siclari, C. Puccetti, S. Donati, M. Rondini, G. Tartarelli, P. Puccinelli, F. Di Costanzo, D. Amoroso. (2010) Phase II trial of single-agent oral vinorelbine in elderly (>=70 years) patients with advanced non-small-cell lung cancer and poor performance status. Annals of Oncology 21:6, 1290-1295
CrossRef425
S. Jelic, I. Popov, V. H. Schartinger, G. M. Sprinzl. (2010) Head and neck cancer: a step forward. memo - Magazine of European Medical Oncology 3:2, 85-89
CrossRef426
Hyun Ju Lee, Xianhua Xu, Gheeyoung Choe, Doo Hyun Chung, Jeong-Wook Seo, Jae Ho Lee, Choon-Taek Lee, Sanghoon Jheon, Sook-Whan Sung, Jin-Haeng Chung. (2010) Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer 68:3, 375-382
CrossRef427
Jong-Mu Sun, Do-Youn Oh, Se-Hoon Lee, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Jong Seok Lee, Young-Whan Kim, Dae Seog Heo, Yung-Jue Bang. (2010) The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. Lung Cancer 68:3, 427-432
CrossRef428
Lucia Nogova, Matthias Scheffler, Christian Mattonet, Thomas Zander, Jürgen Wolf. (2010) Systemische Therapie des nichtkleinzelligen Bronchialkarzinoms. Onkopipeline 3:2, 113-117
CrossRef429
C. Ferte, B. Besse, E. Dansin, F. Parent, M. P. Buisine, M. C. Copin, N. Penel, J. C. Soria. (2010) Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. Annals of Oncology 21:6, 1385-1387
CrossRef430
Giorgio V. Scagliotti, Paul Germonpré, Leon Bosquée, Johan Vansteenkiste, R. Gervais, David Planchard, Martin Reck, Filippo De Marinis, Jin Soo Lee, Keunchil Park, Bonne Biesma, Steven Gans, R. Ramlau, Aleusandra Szczesna, A. Makhson, G. Manikhas, Bruno Morgan, Y. Zhu, Kai C. Chan, Joachim von Pawel. (2010) A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 68:3, 420-426
CrossRef431
L Xu, M B Nilsson, P Saintigny, T Cascone, M H Herynk, Z Du, P G Nikolinakos, Y Yang, L Prudkin, D Liu, J J Lee, F M Johnson, K-K Wong, L Girard, A F Gazdar, J D Minna, J M Kurie, I I Wistuba, J V Heymach. (2010) Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells. Oncogene 29:18, 2616-2627
CrossRef432
David M. Peereboom, Dale R. Shepard, Manmeet S. Ahluwalia, Cathy J. Brewer, Neeraj Agarwal, Glen H. J. Stevens, John H. Suh, Steven A. Toms, Michael A. Vogelbaum, Robert J. Weil, Paul Elson, Gene H. Barnett. (2010) Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. Journal of Neuro-Oncology 98:1, 93-99
CrossRef433
Alessandra Bearz, Isabella Garassino, Marcello Tiseo, Orazio Caffo, Hector Soto-Parra, Massimo Boccalon, Renato Talamini, Armando Santoro, Marco Bartolotti, Viviana Murgia, Massimiliano Berretta, Umberto Tirelli. (2010) Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. Lung Cancer 68:2, 264-268
CrossRef434
B. JACK, A. BOLAND, R. DICKSON, J. STEVENSON, C. MCLEOD. (2010) Best supportive care in lung cancer trials is inadequately described: a systematic review. European Journal of Cancer Care 19:3, 293-301
CrossRef435
G. D'Addario, M. Fruh, M. Reck, P. Baumann, W. Klepetko, E. Felip, . (2010) Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v116-v119
CrossRef436
Chiharu Tanai, Nobuyuki Yamamoto, Yuichiro Ohe, Toshiaki Takahashi, Hideo Kunitoh, Haruyasu Murakami, Noboru Yamamoto, Yukiko Nakamura, Hiroshi Nokihara, Takehito Shukuya, John R. Baldwin, Minori Koshiji, Tomohide Tamura. (2010) A Phase I Study of Enzastaurin Combined with Pemetrexed in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef437
Wee-Lee Yeo, Gregory J. Riely, Beow Y. Yeap, Michelle W. Lau, Jeremy L. Warner, Kelly Bodio, Mark S. Huberman, Mark G. Kris, Daniel G. Tenen, William Pao, Susumu Kobayashi, Daniel B. Costa. (2010) Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations. Journal of Thoracic Oncology1
CrossRef438
Mark A. Socinski. (2010) The Emerging Role of Biomarkers in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:3, 149-159
CrossRef439
Geoffrey Y. Ku, David H. Ilson. (2010) Esophagogastric cancer: Targeted agents. Cancer Treatment Reviews 36:3, 235-248
CrossRef440
Jörg J. Jacoby, Baruch Erez, Maria V. Korshunova, Ryan R. Williams, Kazuhisa Furutani, Osamu Takahashi, Lynn Kirkpatrick, Scott M. Lippman, Garth Powis, Michael S. OʼReilly, Roy S. Herbst. (2010) Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice. Journal of Thoracic Oncology1
CrossRef441
R. Honeywell, K. Yarzadah, E. Giovannetti, N. Losekoot, E.F. Smit, M. Walraven, J.S.W. Lind, C. Tibaldi, H.M. Verheul, G.J. Peters. (2010) Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. Journal of Chromatography B 878:15-16, 1059-1068
CrossRef442
Richard L. Schilsky. (2010) Personalized medicine in oncology: the future is now. Nature Reviews Drug Discovery 9:5, 363-366
CrossRef443
Yoshio Tomizawa, Yuka Fujita, Atsuhisa Tamura, Masahiro Shirai, Satoshi Shibata, Tsutomu Kawabata, Takuo Shibayama, Shimao Fukai, Masaaki Kawahra, Ryusei Saito. (2010) Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer 68:2, 269-272
CrossRef444
Yosuke Togashi, Katsuhiro Masago, Masahide Fukudo, Tomohiro Terada, Shiro Fujita, Kaoru Irisa, Yuichi Sakamori, Young Hak Kim, Tadashi Mio, Ken-ichi Inui, Michiaki Mishima. (2010) Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef445
Im Il Na, Du Hwan Choe, Cheol Hyeon Kim, Jae Soo Koh, Baek-Yeol Ryoo, Jae Cheol Lee, Sung Hyun Yang. (2010) Age at diagnosis predicts outcomes in gefitinib-treated female patients with non-small-cell lung cancer. Lung Cancer 68:2, 295-298
CrossRef446
Richard M. Gewanter, Kenneth E. Rosenzweig, Joe Yujiao Chang, Roy Decker, Sarita Dubey, Feng-Ming Kong, Brian E. Lally, Corey J. Langer, Hoon Ku Lee, Benjamin Movsas. (2010) ACR Appropriateness Criteria® Nonsurgical Treatment for Non-Small-Cell Lung Cancer: Good Performance Status/Definitive Intent. Current Problems in Cancer 34:3, 228-249
CrossRef447
Nobuyuki Yamamoto, Yutaka Nishiwaki, Shunichi Negoro, Haiyi Jiang, Yohji Itoh, Nagahiro Saijo, Masahiro Fukuoka. (2010) Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology1
CrossRef448
Navneet Singh, Amanjit Bal, Ashutosh N Aggarwal, Ashim Das, Digambar Behera. (2010) Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers. Future Oncology 6:5, 741-767
CrossRef449
M. L. Gatza, J. E. Lucas, W. T. Barry, J. W. Kim, Q. Wang, M. D. Crawford, M. B. Datto, M. Kelley, B. Mathey-Prevot, A. Potti, J. R. Nevins. (2010) A pathway-based classification of human breast cancer. Proceedings of the National Academy of Sciences 107:15, 6994-6999
CrossRef450
Mario E. Lacouture, Michael L. Maitland, Siegfried Segaert, Ann Setser, Robert Baran, Lindy P. Fox, Joel B. Epstein, Andrei Barasch, Lawrence Einhorn, Lynne Wagner, Dennis P. West, Bernardo L. Rapoport, Mark G. Kris, Ethan Basch, Beth Eaby, Sandra Kurtin, Elise A. Olsen, Alice Chen, Janet E. Dancey, Andy Trotti. (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Supportive Care in Cancer 18:4, 509-522
CrossRef451
Jong-Mu Sun, Joon Oh Park, Young-Woong Won, Jung-Hoon Kim, Jina Yun, Jeeyun Lee, Yeon Hee Park, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park. (2010) Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?. Journal of Thoracic Oncology 5:4, 540-545
CrossRef452
Heather-Jane Au, Jolie Ringash, Michael Brundage, Michael Palmer, Harriet Richardson, Ralph M Meyer. (2010) Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Review of Pharmacoeconomics & Outcomes Research 10:2, 119-128
CrossRef453
Emilie Pluquet, Jacques Cadranel, Anne Legendre, Michelle Beau Faller, Pierre Jean Souquet, Gerard Zalcman, Maurice Perol, Gislaine Fraboulet, Gerard Oliveiro, Florence De Fraipont, Elisabeth Quoix, Sylvie Lantuejoul, Bernard Milleron, Denis Moro-Sibilot. (2010) Osteoblastic Reaction in Non-small Cell Lung Carcinoma and its Association to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Response and Prolonged Survival. Journal of Thoracic Oncology 5:4, 491-496
CrossRef454
Michel Velez, Astrid Belalcazar, Gelenis Domingo, Marcelo Blaya, Luis E Raez, Edgardo S Santos. (2010) Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC. Expert Review of Anticancer Therapy 10:4, 549-557
CrossRef455
Z. Zhang, S. Kobayashi, A. C. Borczuk, R. S. Leidner, T. LaFramboise, A. D. Levine, B. Halmos. (2010) Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 31:4, 577-586
CrossRef456
Alain Makinson, Jean-Louis Pujol, Vincent Le Moing, Helene Peyriere, Jacques Reynes. (2010) Interactions Between Cytotoxic Chemotherapy and Antiretroviral Treatment in Human Immunodeficiency Virus-Infected Patients with Lung Cancer. Journal of Thoracic Oncology 5:4, 562-571
CrossRef457
Sreenath V. Sharma, Daniel A. Haber, Jeff Settleman. (2010) Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature Reviews Cancer 10:4, 241-253
CrossRef458
A. G. Pallis, C. Gridelli, J. P. van Meerbeeck, L. Greillier, U. Wedding, D. Lacombe, J. Welch, C. P. Belani, M. Aapro. (2010) EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Annals of Oncology 21:4, 692-706
CrossRef459
Kyoichi Kaira, Tateaki Naito, Toshiaki Takahashi, Eriko Ayabe, Rai Shimoyama, Rieko Kaira, Akira Ono, Satoshi Igawa, Takehito Shukuya, Haruyasu Murakami, Asuka Tsuya, Yukiko Nakamura, Masahiro Endo, Nobuyuki Yamamoto. (2010) Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer 68:1, 99-104
CrossRef460
Akira Ono, Tateaki Naito, Haruyasu Murakami, Toshiaki Takahashi, Yukiko Nakamura, Asuka Tsuya, Kyoichi Kaira, Satoshi Igawa, Takehiro Shukuya, Akihiro Tamiya, Rieko Kaira, Masahiro Endo, Nobuyuki Yamamoto. (2010) Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer. International Journal of Clinical Oncology 15:2, 161-165
CrossRef461
Marc C Chamberlain. (2010) Anticancer therapies and CNS relapse: overcoming blood–brain and blood–cerebrospinal fluid barrier impermeability. Expert Review of Neurotherapeutics 10:4, 547-561
CrossRef462
Daniel Renouf, Malcolm Moore. (2010) Evolution of systemic therapy for advanced pancreatic cancer. Expert Review of Anticancer Therapy 10:4, 529-540
CrossRef463
Stephen G. SPIRO, Michael NIEDERMAN, Wing W. YEW, José M. PORCEL. (2010) Year in review 2009: Respiratory infections, tuberculosis, pleural diseases and lung cancer. Respirology 15:3, 562-572
CrossRef464
Jonathan M. Street, James W. Dear. (2010) The application of mass-spectrometry-based protein biomarker discovery to theragnostics. British Journal of Clinical Pharmacology 69:4, 367-378
CrossRef465
Peter Hersey, Jeffrey Sosman, Steven O'Day, Jon Richards, Agop Bedikian, Rene Gonzalez, William Sharfman, Robert Weber, Theodore Logan, Manuela Buzoianu, Luz Hammershaimb, John M. Kirkwood, . (2010) A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin α v β 3 , ± dacarbazine in patients with stage IV metastatic melanoma. Cancer 116:6, 1526-1534
CrossRef466
P. A. Bradbury, D. Tu, L. Seymour, P. K. Isogai, L. Zhu, R. Ng, N. Mittmann, M.-S. Tsao, W. K. Evans, F. A. Shepherd, N. B. Leighl, . (2010) Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer. JNCI Journal of the National Cancer Institute 102:5, 298-306
CrossRef467
Linda E. Coate, Frances A. Shepherd. (2010) Maintenance Therapy in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef468
Lu Yang, Zhi-jie Wang, Tong-tong An, Hua Bai, Jun Zhao, Jian-chun Duan, Ping-ping Li, Mei-na Wu, Hong Sun, Li Liang, Jie Wang. (2010) A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China. Chinese Journal of Cancer Research 22:1, 1-9
CrossRef469
F. Cappuzzo, G. Tallini, G. Finocchiaro, R. S. Wilson, C. Ligorio, L. Giordano, L. Toschi, M. Incarbone, R. Cavina, L. Terracciano, M. Roncalli, M. Alloisio, M. Varella-Garcia, W. A. Franklin, A. Santoro. (2010) Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Annals of Oncology 21:3, 562-567
CrossRef470
K. N. Syrigos, J. Vansteenkiste, P. Parikh, J. von Pawel, C. Manegold, R. G. Martins, L. Simms, K. P. Sugarman, C. Visseren-Grul, G. V. Scagliotti. (2010) Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. Annals of Oncology 21:3, 556-561
CrossRef471
Yosuke Togashi, Katsuhiro Masago, Masahide Fukudo, Tomohiro Terada, Yasuaki Ikemi, Young Hak Kim, Shiro Fujita, Kaoru Irisa, Yuichi Sakamori, Tadashi Mio, Kenichi Inui, Michiaki Mishima. (2010) Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis. Journal of Thoracic Oncology1
CrossRef472
Benoît Busser, Lucie Sancey, Véronique Josserand, Carole Niang, Saadi Khochbin, Marie C Favrot, Jean-Luc Coll, Amandine Hurbin. (2010) Amphiregulin Promotes Resistance to Gefitinib in NonSmall Cell Lung Cancer Cells by Regulating Ku70 Acetylation. Molecular Therapy 18:3, 536-543
CrossRef473
Chieh-Hung Wu, Wen-Chien Fan, Yuh-Min Chen, Kun-Ta Chou, Jen-Fu Shih, Chun-Ming Tsai, Yu-Chin Lee, Ruery-Perng Perng. (2010) Second-Line Therapy for Elderly Patients with Non-small Cell Lung Cancer Who Failed Previous Chemotherapy Is as Effective as for Younger Patients. Journal of Thoracic Oncology 5:3, 376-379
CrossRef474
Luca Toschi, Federico Cappuzzo. (2010) Impact of biomarkers on non-small cell lung cancer treatment. Targeted Oncology 5:1, 5-17
CrossRef475
Christophe Le Tourneau, Véronique Diéras, Patricia Tresca, Wulfran Cacheux, Xavier Paoletti. (2010) Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. Targeted Oncology 5:1, 65-72
CrossRef476
Massimo Di Maio, Nicola Lama, Alessandro Morabito, Egbert F. Smit, Vassilis Georgoulias, Koji Takeda, Elisabeth Quoix, Dora Hatzidaki, Floris M. Wachters, Vittorio Gebbia, Chun-Ming Tsai, Carlos Camps, Wolfgang Schuette, Paolo Chiodini, Maria Carmela Piccirillo, Francesco Perrone, Ciro Gallo, Cesare Gridelli. (2010) Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials. European Journal of Cancer 46:4, 735-743
CrossRef477
Corey Langer, Jean-Charles Soria. (2010) The Role of Anti–Epidermal Growth Factor Receptor and Anti–Vascular Endothelial Growth Factor Therapies in the Treatment of Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:2, 82-90
CrossRef478
Martin Forster, Deborah Enting, Andrew G. Nicholson, Mary O’Brien, Sanjay Popat. (2010) The combination of Young's syndrome and small cell lung cancer—A spiky connection?. Lung Cancer 67:3, 372-375
CrossRef479
Young Joo Lee, Hye Jin Choi, Se Kyu Kim, Joon Chang, Jin Wook Moon, In Kyu Park, Joo-Hang Kim, Byoung Chul Cho. (2010) Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer 116:5, 1336-1343
CrossRef480
Liangping Xia, Yuming Rong, Guifang Guo, Huijuan Qiu, Feifei Zhou, Fang Wang. (2010) Efficacy of cetuximab combination with chemotherapy in non-small cell lung cancer first-line setting: the summary based on publications. The Chinese-German Journal of Clinical Oncology 9:3, 137-141
CrossRef481
Mei-Kim Ang, Say-Beng Tan, Wan-Teck Lim. (2010) Phase II clinical trials in oncology: are we hitting the target?. Expert Review of Anticancer Therapy 10:3, 427-438
CrossRef482
Adi F. Gazdar. (2010) Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer and Metastasis Reviews 29:1, 37-48
CrossRef483
Brigette BY Ma, Herbert Loong. (2010) Personalized cancer therapy coming of age: clinical highlights in 2009 and future directions. Personalized Medicine 7:2, 121-124
CrossRef484
Anne Katrin Berger, Thomas Herrmann. (2010) „Targeted therapies“ in der Behandlung solider Tumoren. Onkopipeline 3:1, 48-51
CrossRef485
Wolfram C.M. Dempke, Tamas Suto, Martin Reck. (2010) Targeted therapies for non-small cell lung cancer. Lung Cancer 67:3, 257-274
CrossRef486
Jenn-Yu Wu, Chong-Jen Yu, Jin-Yuan Shih, Chih-Hsin Yang, Pan-Chyr Yang. (2010) Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer. Lung Cancer 67:3, 348-354
CrossRef487
Joseph M. Amann, Ju-Whei Lee, Heinrich Roder, Julie Brahmer, Adriana Gonzalez, Joan H. Schiller, David P. Carbone. (2010) Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503. Journal of Thoracic Oncology 5:2, 169-178
CrossRef488
Chih-Hsin Yang, Lorinda Simms, Keunchil Park, Jin Soo Lee, Giorgio Scagliotti, Mauro Orlando. (2010) Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef489
Zachary A. Knight, Henry Lin, Kevan M. Shokat. (2010) Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer 10:2, 130-137
CrossRef490
María Martín Ureste, Regina Gironés Sarrió, Joaquín Montalar Salcedo. (2010) Biomarkers in bronchopulmonary cancer. Clinical and Translational Oncology 12:2, 92-99
CrossRef491
Joel W. Neal, Lecia V. Sequist. (2010) Targeted therapies: Optimal first-line therapy for NSCLC with EGFR mutations. Nature Reviews Clinical Oncology 7:2, 71-72
CrossRef492
Luca Toschi, Federico Cappuzzo. (2010) Clinical implications of MET gene copy number in lung cancer. Future Oncology 6:2, 239-247
CrossRef493
L.C. Heukamp, R. Büttner. (2010) Molekulardiagnostik des Lungenkarzinoms zur Therapiestratifizierung. Der Pathologe 31:1, 22-28
CrossRef494
J. T. Auman, H. L. McLeod. (2010) Now's the time to find biomarkers on purpose. Annals of Oncology 21:2, 193-194
CrossRef495
Massimo Di Maio, Ciro Gallo, Ermelinda De Maio, Alessandro Morabito, Maria Carmela Piccirillo, Cesare Gridelli, Francesco Perrone. (2010) Methodological aspects of lung cancer clinical trials in the era of targeted agents. Lung Cancer 67:2, 127-135
CrossRef496
E.-H. Tan, R. Ramlau, A. Pluzanska, H.-P. Kuo, M. Reck, J. Milanowski, J. S.-K. Au, E. Felip, P.-C. Yang, D. Damyanov, S. Orlov, M. Akimov, P. Delmar, L. Essioux, C. Hillenbach, B. Klughammer, P. McLoughlin, J. Baselga. (2010) A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Annals of Oncology 21:2, 217-222
CrossRef497
Katsuyuki Hotta, Katsuyuki Kiura, Nagio Takigawa, Hiroshige Yoshioka, Shingo Harita, Shoichi Kuyama, Toshiro Yonei, Keiichi Fujiwara, Tadashi Maeda, Keisuke Aoe, Hiroshi Ueoka, Haruhito Kamei, Shigeki Umemura, Tomonori Moritaka, Yoshihiko Segawa, Haruyuki Kawai, Akihiro Bessho, Katsuya Kato, Masahiro Tabata, Mitsune Tanimoto. (2010) Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:2, 179-184
CrossRef498
Jean Yves Douillard. (2010) Targeting the target: a step forward for the treatment of non-small-cell lung cancer. The Lancet Oncology 11:2, 104-105
CrossRef499
Elias A. Kotteas, Andriani G. Charpidou, Kostas N. Syrigos. (2010) Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors. Anti-Cancer Drugs 21:2, 151-168
CrossRef500
Junshik Hong, Sun Young Kyung, Sang Pyo Lee, Jeong Woong Park, Sung Hwan Jung, Jae-Ik Lee, Se Hoon Park, Sun Jin Sym, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee. (2010) Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer. The Korean Journal of Internal Medicine 25:3, 294
CrossRef501
Geraldine Chow, Jordi Tauler, James L. Mulshine. (2010) Cytokines and Growth Factors Stimulate Hyaluronan Production: Role of Hyaluronan in Epithelial to Mesenchymal-Like Transition in Non-Small Cell Lung Cancer. Journal of Biomedicine and Biotechnology 2010, 1-12
CrossRef502
Hyun Seung Ban, Yuko Tanaka, Wataru Nabeyama, Masako Hatori, Hiroyuki Nakamura. (2010) Enhancement of EGFR tyrosine kinase inhibition by C–C multiple bonds-containing anilinoquinazolines. Bioorganic & Medicinal Chemistry 18:2, 870-879
CrossRef503
F. Meriggi, A. Zaniboni. (2010) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer. Current Gerontology and Geriatrics Research 2010, 1-8
CrossRef504
David J. Stewart. 2010. Clinical Management of Lung Cancer. , 437-445.
CrossRef505
Kuan-Yu Chen, Jen-Hau Chen, Jin-Yuan Shih, Chih-Hsin Yang, Chong-Jen Yu, Pan-Chyr Yang. (2010) Octogenarians with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:1, 82-89
CrossRef506
Laura R. Triano, Hari Deshpande, Scott N. Gettinger. (2010) Management of Patients with Advanced Non-Small Cell Lung Cancer. Drugs 70:2, 167-179
CrossRef507
David A. Reardon, Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, Allan H. Friedman, James E. Herndon, Jennifer Marcello, Julie A. Norfleet, Roger E. McLendon, John H. Sampson, Henry S. Friedman. (2010) Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of Neuro-Oncology 96:2, 219-230
CrossRef508
Ronald Natale. 2010. Adjuvant and Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer. , 247-251.
CrossRef509
Nagahiro Saijo, Hirotsugu Kenmotsu. (2010) Recent Development of Molecular-Targeted Drugs in Lung Cancer. Internal Medicine 49:18, 1923-1934
CrossRef510
Sumithra J. Mandrekar, Yingwei Qi, Shauna L. Hillman, Katie L. Allen Ziegler, Nicholas F. Reuter, Kendrith M. Rowland, Steven A. Kuross, Randolph S. Marks, Steven E. Schild, Alex A. Adjei. (2010) Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:1, 3-9
CrossRef511
Luis Paz-Ares, Denis Soulières, Ivan Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell, Barbara Klughammer. (2010) Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. Journal of Cellular and Molecular Medicine 14:1-2, 51-69
CrossRef512
Kristina Loukeris, Madeline F. Vazquez, Gabriel Sica, Patrick Wagner, David F. Yankelevitz, Claudia I. Henschke, Matthew D. Cham, Anjali Saqi. (2010) Cytological cell blocks: Predictors of squamous cell carcinoma and adenocarcinoma subtypes. Diagnostic Cytopathologyn/a-n/a
CrossRef513
M. Dietel, P. Schirmacher. (2010) Molekularpathologische Analyse beim metastasierten NSCLC. Der Onkologe 16:1, 63-66
CrossRef514
Ewa Szutowicz, Rafał Dziadziuszko. (2010) Quantitative immunohistochemistry in lung cancer: clinical perspective. Folia Histochemica et Cytobiologica 48:1, 7-11
CrossRef515
Hiroyasu Kaneda, Isamu Okamoto, Hidetoshi Hayashi, Hiroshige Yoshioka, Masaki Miyazaki, Shinzoh Kudoh, Tatsuo Kimura, Takamune Sugiura, Toshiyuki Sawa, Koji Takeda, Yasuo Iwamoto, Miyako Satouchi, Kenji Akita, Hiroshi Saito, Isao Goto, Kazuhiko Shibata, Masahiro Fukuoka, Kazuhiko Nakagawa. (2010) Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:1, 105-109
CrossRef516
Hironori Uruga, Kazuma Kishi, Takeshi Fujii, Yuka Beika, Takahiro Enomoto, Hisashi Takaya, Atsushi Miyamoto, Nasa Morokawa, Atsuko Kurosaki, Kunihiko Yoshimura. (2010) Efficacy of Gefitinib for Elderly Patients with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Gene Mutations: A Retrospective Analysis. Internal Medicine 49:2, 103-107
CrossRef517
Nagato Sato, Junkichi Koinuma, Tomoo Ito, Eiju Tsuchiya, Satoshi Kondo, Yusuke Nakamura, Yataro Daigo. (2010) Activation of an oncogenic TBC1D7 (TBC1 domain family, member 7) protein in pulmonary carcinogenesis. Genes, Chromosomes and CancerNA-NA
CrossRef518
Chih-Hsi Kuo, Shu-Min Lin, Kang-Yun Lee, Fu-Tsai Chung, Meng-Heng Hsieh, Yueh-Fu Fang, Chih-Ten Yu, Han-Pin Kuo. (2010) Subsequent Chemotherapy Improves Survival Outcome in Advanced Non–Small-Cell Lung Cancer With Acquired Tyrosine Kinase Inhibitor Resistance. Clinical Lung Cancer 11:1, 51-56
CrossRef519
Hiroyuki Nakamura, Ryoji Horikoshi, Taikou Usui, Hyun Seung Ban. (2010) Selective inhibition of EGFR and VEGFR2 tyrosine kinases controlled by a boronic acid substituent on 4-anilinoquinazolines. MedChemComm 1:4, 282
CrossRef520
Stefan Boeck, Ursula Vehling-Kaiser, Dirk Waldschmidt, Erika Kettner, Angela Märten, Cornelia Winkelmann, Stefan Klein, Georgi Kojouharoff, Thomas Gauler, Ludwig Fischer von Weikersthal, Michael R. Clemens, Michael Geissler, Tim F. Greten, Susanna Hegewisch-Becker, Sascha Neugebauer, Volker Heinemann. (2010) Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’. Anti-Cancer Drugs 21:1, 94-100
CrossRef521
Stephen G. SPIRO, Nichole T. TANNER, Gerard A. SILVESTRI, Sam M. JANES, Eric LIM, Johan F. VANSTEENKISTE, Robert PIRKER. (2010) Lung cancer: Progress in diagnosis, staging and therapy. Respirology 15:1, 44-50
CrossRef522
Hiroshige Yoshioka, Katsuyuki Hotta, Katsuyuki Kiura, Nagio Takigawa, Hidetoshi Hayashi, Shingo Harita, Shoichi Kuyama, Yoshihiko Segawa, Haruhito Kamei, Shigeki Umemura, Akihiro Bessho, Masahiro Tabata, Mitsune Tanimoto. (2010) A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations. Journal of Thoracic Oncology 5:1, 99-104
CrossRef523
Katherine A. Lyseng-Williamson. (2010) Erlotinib. PharmacoEconomics 28:1, 75-92
CrossRef524
Lynsay L. Waller, Antonius A. Miller, W. Jeffrey Petty. (2010) Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke. Lung Cancer 67:1, 12-16
CrossRef525
Rebecca L. Toonkel, Charles A. Powell. 2010. The Gender-Specific Aspects of Lung Cancer. , 260-269.
CrossRef526
Heather Wakelee, Bill W. Loo ., Kemp H. Kernstine, Joe Bill Putnam ., Martin J. Edelman, Everett E. Vokes, Joan H. Schiller, Paul Baas, Nagahiro Saijo, Alex Adjei, Glenwood Goss, Hak Choy, David R. Gandara. (2009) Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress. Clinical Cancer Reviews 3:1, 9-18
CrossRef527
Thoralf Christoffersen, Tormod K. Guren, Karen-Lise Garm Spindler, Olav Dahl, Per Eystein Lønning, Bjørn Tore Gjertsen. (2009) Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology 625:1-3, 6-22
CrossRef528
Tanyanika Phillips Towe, Elizabeth O'Toole, Kathryn Engelhardt, Govardhanan Nagaiah, Nathan A. Berger. (2009) Changing Healthcare Practice for Older Adults with Late-Stage Non-Small Cell Lung Cancer: Practical Considerations of Targeted Therapy in Primary Care and Oncology. Journal of the American Geriatrics Society 57, s253-s258
CrossRef529
Rita S. Axelrod. (2009) Introduction: Women and Lung Cancer. Seminars in Oncology 36:6, 504-505
CrossRef530
Danielle Shafer, Kathy Albain. (2009) Lung Cancer Outcomes in Women. Seminars in Oncology 36:6, 532-541
CrossRef531
N. Kurita, N. Mise, A. Fujii, S. Ikeda, T. Sugimoto. (2009) Crescentic glomerulonephritis in a patient with advanced lung cancer during erlotinib therapy. NDT Plus 2:6, 512-513
CrossRef532
Philip C. Mack, William S. Holland, Rebekah A. Burich, Randeep Sangha, Leslie J. Solis, Yueju Li, Laurel A. Beckett, Primo N. Lara, Angela M. Davies, David R. Gandara. (2009) EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:12, 1466-1472
CrossRef533
Rowan T. Chlebowski. (2009) Menopausal Hormone Therapy, Hormone Receptor Status, and Lung Cancer in Women. Seminars in Oncology 36:6, 566-571
CrossRef534
Daniel Morgensztern, Saiama Waqar, Janakiraman Subramanian, Feng Gao, Ramaswamy Govindan. (2009) Improving Survival for Stage IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:12, 1524-1529
CrossRef535
Lisa K. Hicks, Matthew C. Cheung, Keyue Ding, Baktiar Hasan, Lesley Seymour, Aurélie Le Maître, Natasha B. Leighl, Frances A. Shepherd. (2009) Venous thromboembolism and nonsmall cell lung cancer. Cancer 115:23, 5516-5525
CrossRef536
Joline S. W. Lind, Pieter E. Postmus, Daniëlle A. M. Heideman, Erik B. Thunnissen, Otto Bekers, Egbert F. Smit. (2009) Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous Toxicity. Journal of Thoracic Oncology 4:12, 1585-1586
CrossRef537
Austin Duffy, Shivaani Kummar. (2009) Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. Targeted Oncology 4:4, 267-273
CrossRef538
Maria Patricia Rivera. (2009) Lung cancer in women: the differences in epidemiology, biology and treatment outcomes. Expert Review of Respiratory Medicine 3:6, 627-634
CrossRef539
Seema Harichand-Herdt, Suresh S. Ramalingam. (2009) Gender-Associated Differences in Lung Cancer: Clinical Characteristics and Treatment Outcomes in Women. Seminars in Oncology 36:6, 572-580
CrossRef540
Nicolas Girard, Pascale Jacoulet, Marie Gainet, Rami Elleuch, Didier Pernet, Alain Depierre, Jean-Charles Dalphin, Virginie Westeel. (2009) Third-Line Chemotherapy in Advanced Non-small Cell Lung Cancer: Identifying the Candidates for Routine Practice. Journal of Thoracic Oncology 4:12, 1544-1549
CrossRef541
V. Surmont, J.G. Aerts, E. Pouw, K.Y. Tan, R. Vernhout, J. Gras, J. Salomé, T. Pronk, P.I.M. Schmitz, H. Hoogsteden, R.J. van Klaveren. (2009) Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: A non-randomized phase II study. Lung Cancer 66:3, 333-337
CrossRef542
Hui-Young Lee, Myung-Ju Ahn, Yeon Hee Park, Jin Seok Ahn, Bong-Seog Kim, Hoon Kyo Kim, Heung Tae Kim, Hun Mo Ryoo, Sung Hwa Bae, Seung Sei Lee, Kwon Choi, Dae-Sik Hong, Kyung Hee Lee, Jung Hye Kwon, In Shil Choi, Byung-Su Kim, Nam Su Lee, Soo Jung Gong, Keunchil Park. (2009) Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: A prospective, multicenter trial. Lung Cancer 66:3, 338-343
CrossRef543
, P. Manchon Walsh, Rafael Aguiló, María Alejo, M. Mar Arnaiz, Julio Astudillo, Remei Blanco, Emili Canalís, Felip Cardenal, Víctor Curull, Enriqueta Felip, Rafael Fuentes, Ángel Gayete, Ana M. Giménez, Josep Jové, Carmen Lainez, Josep Lloreta, Ramón Marrades, José Ignacio Martínez, Xesca Martínez, M. Ángeles Montero, Cinta Pallarès, Ramón Palmero, Josep Ramírez, Nuria Rodríguez, Antoni Rosell, Josep Saumench, Nuria Viñolas, Ángel Olazábal. (2009) Lung Cancer OncoGuia. Clinical and Translational Oncology 11:12, 805-824
CrossRef544
Yufan Zhao, Michael R. Kosorok, Donglin Zeng. (2009) Reinforcement learning design for cancer clinical trials. Statistics in Medicine 28:26, 3294-3315
CrossRef545
Antoine Italiano, Alexis B. Cortot, Marius Ilie, Ghyslaine Martel-Planche, Thibault Fabas, Daniel Pop, Jérôme Mouroux, Veronique Hofman, Paul Hofman, Florence Pedeutour. (2009) EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for anti-EGFR treatment of a rare lung malignancy. International Journal of Cancer 125:10, 2479-2482
CrossRef546
Tony S. K. Mok, Suresh S. Ramalingam. (2009) Maintenance therapy in nonsmall-cell lung cancer. Cancer 115:22, 5143-5154
CrossRef547
S. E. Taube, G. M. Clark, J. E. Dancey, L. M. McShane, C. C. Sigman, S. I. Gutman. (2009) A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment. JNCI Journal of the National Cancer Institute 101:21, 1453-1463
CrossRef548
S Novello, G V Scagliotti, R Rosell, M A Socinski, J Brahmer, J Atkins, C Pallares, R Burgess, L Tye, P Selaru, E Wang, R Chao, R Govindan. (2009) Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. British Journal of Cancer 101:9, 1543-1548
CrossRef549
Edward J. Stepanski, Arthur C. Houts, Lee S. Schwartzberg, Mark S. Walker, Carolina M. Reyes, Johnetta Blakely. (2009) Second- and Third-line Treatment of Patients With Non–Small-Cell Lung Cancer With Erlotinib in the Community Setting: Retrospective Study of Patient Healthcare Utilization and Symptom Burden. Clinical Lung Cancer 10:6, 426-432
CrossRef550
Ross A Soo, Benjamin O Anderson, Byoung Chul Cho, Chih-Hsin Yang, Meilin Liao, Wan-Teck Lim, Peter Goldstraw, Tony S Mok. (2009) First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. The Lancet Oncology 10:11, 1102-1110
CrossRef551
Edward B. Garon, Steven M. Dubinett. (2009) Intracellular Signaling Molecules. Journal of Thoracic Oncology 4:Supplement 3, S1057-S1058
CrossRef552
Zheng-Tao Zhou, Xin-Hua Xu, Qing Wei, Ming-qian Lu, Jie Wang, Cai-Hong Wen. (2009) Erlotinib in advanced non-small-cell lung cancer after gefitinib failure. Cancer Chemotherapy and Pharmacology 64:6, 1123-1127
CrossRef553
Yuri Rukazenkov, Georgina Speake, Gayle Marshall, Judith Anderton, Barry R. Davies, Robert W. Wilkinson, D. Mark Hickinson, Alan Swaisland. (2009) Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?. Anti-Cancer Drugs 20:10, 856-866
CrossRef554
Antonio Rossi, Serena Ricciardi, Paolo Maione, Filippo de Marinis, Cesare Gridelli. (2009) Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer 66:2, 141-149
CrossRef555
Yoshihisa Shimada, Genichiro Ishii, Kanji Nagai, Naho Atsumi, Satoshi Fujii, Atsushi Yamada, Yuki Yamane, Tomoyuki Hishida, Mitsuyo Nishimura, Junji Yoshida, Norihiko Ikeda, Atsushi Ochiai. (2009) Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Science 100:11, 2054-2059
CrossRef556
Mechthild Krause, Kristin Gurtner, Yvonne Deuse, Michael Baumann. (2009) Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors. International Journal of Radiation Biology 85:11, 943-954
CrossRef557
Josh John Carlson, Louis P. Garrison, Scott D. Ramsey, David L. Veenstra. (2009) Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology 135:11, 1483-1493
CrossRef558
Shadia Jalal, David Waterhouse, Martin J. Edelman, Sreenivasa Nattam, Rafat Ansari, Karuna Koneru, Romnee Clark, Arthur Richards, Jingwei Wu, Menggang Yu, Brian Bottema, Angela White, Nasser Hanna. (2009) Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 4:11, 1420-1424
CrossRef559
D. I. Gregorio, M. Hollenbeck, H. Samociuk. (2009) Who's assessing tobacco use in cancer clinical trials?. Nicotine & Tobacco Research 11:11, 1354-1358
CrossRef560
Yoshitaka Totani, Yuji Saito, Masamichi Hayashi, Toshihiko Tada, Yasuo Kohashi, Yuki Mieno, Atsushi Kato, Hiromi Imizu, Yukiko Yoneda, Tami Hoshino, Yasuhiro Uchiyama, Yasuo Takeuchi, Mitsushi Okazawa, Hiroki Sakakibara. (2009) A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 64:6, 1181-1185
CrossRef561
Douglas P Clark. (2009) Ex vivo biomarkers: functional tools to guide targeted drug development and therapy. Expert Review of Molecular Diagnostics 9:8, 787-794
CrossRef562
Susana Cedrés, Aleix Prat, Pablo Martínez, Esther Pallisa, Gemma Sala, Jordi Andreu, J.M. del Campo, Isela Quispe, José Baselga, Enriqueta Felip. (2009) Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second–third line erlotinib. Lung Cancer 66:2, 257-261
CrossRef563
Heather Wakelee, Bill W. Loo ., Kemp H. Kernstine, Joe Bill Putnam ., Martin J. Edelman, Everett E. Vokes, Joan H. Schiller, Paul Baas, Nagahiro Saijo, Alex Adjei, Glenwood Goss, Hak Choy, David R. Gandara. (2009) Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress. Clinical Lung Cancer 10:6, 395-404
CrossRef564
D. Mandelker, S. B. Gabelli, O. Schmidt-Kittler, J. Zhu, I. Cheong, C.-H. Huang, K. W. Kinzler, B. Vogelstein, L. M. Amzel. (2009) A frequent kinase domain mutation that changes the interaction between PI3K and the membrane. Proceedings of the National Academy of Sciences 106:40, 16996-17001
CrossRef565
Francesc Casas, Lucyna Kepka, Jai Prakash Agarwal, D Dawotola, PM Gaye, Sherif Abdel-Wahab, L Vashkevitch, T Saghatelyan, B Perin, Branislav Jeremic. (2009) Radiochemotherapy in the elderly with lung cancer. Expert Review of Anticancer Therapy 9:10, 1405-1411
CrossRef566
Linda E Coate, Thomas John, Ming-Sound Tsao, Frances A Shepherd. (2009) Molecular predictive and prognostic markers in non-small-cell lung cancer. The Lancet Oncology 10:10, 1001-1010
CrossRef567
Lucyna Kepka, Arkadiusz Sprawka, Francesc Casas, Sherif Abdel-Wahab, Jai Prakash Agarwal, Branislav Jeremic. (2009) Combination of radiotherapy and chemotherapy in locally advanced NSCLC. Expert Review of Anticancer Therapy 9:10, 1389-1403
CrossRef568
Josh J Carlson. (2009) Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence. Expert Review of Pharmacoeconomics & Outcomes Research 9:5, 409-416
CrossRef569
Thomas E Stinchcombe, Howard L West. (2009) Maintenance therapy in non-small-cell lung cancer. The Lancet 374:9699, 1398-1400
CrossRef570
Cesare Gridelli, Paolo Maione, Antonio Rossi, Giovanni Palazzolo, Giuseppe Colantuoni, Emanuela Rossi. (2009) Management of unfit older patients with advanced NSCLC. Cancer Treatment Reviews 35:6, 517-521
CrossRef571
Amy Kluge, Snehal Dabir, Jeffrey Kern, David Nethery, Balazs Halmos, Patrick Ma, Afshin Dowlati. (2009) Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer. International Journal of Cancer 125:7, 1728-1734
CrossRef572
Michaela J Higgins, David S Ettinger. (2009) Chemotherapy for lung cancer: the state of the art in 2009. Expert Review of Anticancer Therapy 9:10, 1365-1378
CrossRef573
J.-C. Soria, F. A. Shepherd, J.-Y. Douillard, J. Wolf, G. Giaccone, L. Crino, F. Cappuzzo, S. Sharma, S. H. Gross, S. Dimitrijevic, L. Di Scala, H. Gardner, L. Nogova, V. Papadimitrakopoulou. (2009) Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Annals of Oncology 20:10, 1674-1681
CrossRef574
Mok, Tony S., Wu, Yi-Long, Thongprasert, Sumitra, Yang, Chih-Hsin, Chu, Da-Tong, Saijo, Nagahiro, Sunpaweravong, Patrapim, Han, Baohui, Margono, Benjamin, Ichinose, Yukito, Nishiwaki, Yutaka, Ohe, Yuichiro, Yang, Jin-Ji, Chewaskulyong, Busyamas, Jiang, Haiyi, Duffield, Emma L., Watkins, Claire L., Armour, Alison A., Fukuoka, Masahiro, . (2009) Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine 361:10, 947-957
Full Text575
Gazdar, Adi F., . (2009) Personalized Medicine and Inhibition of EGFR Signaling in Lung Cancer. New England Journal of Medicine 361:10, 1018-1020
Full Text576
A.G. Pallis, L. Serfass, R. Dziadziuszko, J.P. van Meerbeeck, D. Fennell, D. Lacombe, J. Welch, C. Gridelli. (2009) Targeted therapies in the treatment of advanced/metastatic NSCLC. European Journal of Cancer 45:14, 2473-2487
CrossRef577
Natasha B. Leighl, Scott A. Laurie, Xueyu E. Chen, Peter Ellis, Frances A. Shepherd, Jennifer J. Knox, Glenwood Goss, Ronald L. Burkes, Gregory R. Pond, Christopher Dick, Yun Yen, James A. Zwiebel, Malcolm J. Moore. (2009) A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:9, 1163-1169
CrossRef578
Alison K. Ramsay, Hing Y. Leung. (2009) Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy. Clinical Science 117:6, 209-228
CrossRef579
Sara A Hurvitz, Richard S Finn. (2009) What’s positive about ‘triple-negative’ breast cancer?. Future Oncology 5:7, 1015-1025
CrossRef580
Howard West, Rogerio Lilenbaum, David Harpole, Antoinette Wozniak, Lecia Sequist. (2009) Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:Supplement 2, S1029-S1039
CrossRef581
Anthony W. Tolcher. (2009) Stable Disease Is a Valid End Point in Clinical Trials. The Cancer Journal 15:5, 374-378
CrossRef582
Jacques Cadranel, Elisabeth Quoix, Laurence Baudrin, Pierre Mourlanette, Denis Moro-Sibilot, Jean-François Morere, Pierre-Jean Souquet, Jean-Charles Soria, Franck Morin, Bernard Milleron. (2009) IFCT-0401 Trial. Journal of Thoracic Oncology 4:9, 1126-1135
CrossRef583
W. N. William, K. A. Gold, E. S. Kim. (2009) Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options. Annals of Oncology 20:9, 1455-1457
CrossRef584
Fabienne Thomas, Philippe Rochaix, Melanie White-Koning, Isabelle Hennebelle, Jérôme Sarini, Adil Benlyazid, Laurence Malard, Jean-Louis Lefebvre, Etienne Chatelut, Jean Pierre Delord. (2009) Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. European Journal of Cancer 45:13, 2316-2323
CrossRef585
CIG Media Group, LP. (2009) Highlights From: The 13th World Conference on Lung Cancer. Clinical Lung Cancer 10:5, 317-321
CrossRef586
A. Osio, C. Mateus, J.-C. Soria, C. Massard, D. Malka, V. Boige, B. Besse, C. Robert. (2009) Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. British Journal of Dermatology 161:3, 515-521
CrossRef587
Yi-Sheng Huang, She-Juan An, Zhi-Hong Chen, Yi-Long Wu. (2009) Three cases of severe hepatic impairment caused by erlotinib. British Journal of Clinical Pharmacology 68:3, 464-467
CrossRef588
Chadi Nabhan, Timothy M. Lestingi, Angel Galvez, Kathy Tolzien, Susan K. Kelby, Dean Tsarwhas, Steven Newman, Jacob D. Bitran. (2009) Erlotinib Has Moderate Single-agent Activity in Chemotherapy-naïve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial. Urology 74:3, 665-671
CrossRef589
Amani Asnacios, Sylvie Naveau, Gabriel Perlemuter. (2009) Gastrointestinal toxicities of novel agents in cancer therapy. European Journal of Cancer 45, 332-342
CrossRef590
John F Deeken, Liron Pantanowitz, Bruce J Dezube. (2009) Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Current Opinion in Oncology 21:5, 445-454
CrossRef591
Neil Hawkins, David A. Scott, Beth S. Woods, Nicholas Thatcher. (2009) No Study Left Behind: A Network Meta-Analysis in Non–Small-Cell Lung Cancer Demonstrating the Importance of Considering All Relevant Data. Value in Health 12:6, 996-1003
CrossRef592
John W Powell, Elisabeth Dexter, Ernest M Scalzetti, Jeffrey A Bogart. (2009) Treatment advances for medically inoperable non-small-cell lung cancer: emphasis on prospective trials. The Lancet Oncology 10:9, 885-894
CrossRef593
Bo Peng, Jinnong Zhang, Jamile S. Woods, Wei Peng. (2009) Molecular markers and pathogenically targeted therapy in non-small cell lung cancer. Frontiers of Medicine in China 3:3, 245-255
CrossRef594
Ji Eun Uhm, Byeong-Bae Park, Myung-Ju Ahn, Jeeyun Lee, Jin Seok Ahn, Sang We Kim, Heung-Tae Kim, Jong Seog Lee, Jin Hyung Kang, Jae Yong Cho, Hong Suk Song, Se Hoon Park, Chang Hak Sohn, Sang Won Shin, Jin Hyuck Choi, Keunchil Park. (2009) Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:9, 1136-1143
CrossRef595
David F. Heigener. (2009) Tyrosinkinaseinhibitoren beim nichtkleinzelligen Lungenkarzinom. Onkopipeline 2:3, 80-85
CrossRef596
Pasi A. Jänne, Nathanael Gray, Jeff Settleman. (2009) Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nature Reviews Drug Discovery 8:9, 709-723
CrossRef597
William N. William, Fadlo R. Khuri, Frank V. Fossella, Bonnie S. Glisson, Ralph G. Zinner, J Jack Lee, Roy S. Herbst, Scott M. Lippman, Edward S. Kim. (2009) Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non–Small-Cell Lung Cancer as Frontline and Second-Line Therapy. American Journal of Clinical Oncology1
CrossRef598
T John, G Liu, M-S Tsao. (2009) Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 28, S14-S23
CrossRef599
Jennifer M. Boland, Sibel Erdogan, George Vasmatzis, Ping Yang, Lori S. Tillmans, Michele R. Erickson Johnson, Xiaoke Wang, Lisa M. Peterson, Kevin C. Halling, Andre M. Oliveira, Marie Christine Aubry, Eunhee S. Yi. (2009) Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non–small cell lung carcinomas. Human Pathology 40:8, 1152-1158
CrossRef600
R.M. Eager, C.C. Cunningham, N. Senzer, D.A. Richards, R.N. Raju, B. Jones, M. Uprichard, J. Nemunaitis. (2009) Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer. Clinical Oncology 21:6, 464-472
CrossRef601
Scott A. Kono, Marianne E. Marshall, Kathryn E. Ware, Lynn E. Heasley. (2009) The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resistance Updates 12:4-5, 95-102
CrossRef602
F R Hirsch. (2009) The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC. Oncogene 28, S1-S3
CrossRef603
Adolfo Favaretto, Giulia Pasello, Cristina Magro, Clorinda Schettino, Cesare Gridelli. (2009) Second and third line treatment in non-small cell lung cancer. Critical Reviews in Oncology/Hematology 71:2, 117-126
CrossRef604
Johnny Kao, Stuart Packer, Ha Linh Vu, Myron E. Schwartz, Max W. Sung, Richard G. Stock, Yeh-Chi Lo, Delphine Huang, Shu-Hsia Chen, Jamie A. Cesaretti. (2009) Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases. Cancer 115:15, 3571-3580
CrossRef605
Chee-Kian Tham, Su-Pin Choo, Wan-Teck Lim, Chee-Keong Toh, Swan-Swan Leong, Sze-Huey Tan, Hui-Hua Li, Eng-Huat Tan. (2009) Gefitinib in Combination with Gemcitabine and Carboplatin in Never Smokers with Non-small Cell Lung Carcinoma. Journal of Thoracic Oncology 4:8, 988-993
CrossRef606
Xin-Ling Ren, Yan-Ming Xu, Wei Bao, Hai-Jing Fu, Chang-Gui Wu, Ying Zhao, Zhi-Kui Li, Jian Zhang, Sheng-Qing Li, Wei-Qiang Chen, Tao Wang, Rui Zhang, Li-Hong Zhang, Gui-Sheng Qian, Si-Yi Chen, Lin-Tao Jia, An-Gang Yang. (2009) Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu. Cancer Letters 281:2, 134-143
CrossRef607
Kazuyuki Tsujino, Tomoya Kawaguchi, Akihito Kubo, Nana Aono, Keiko Nakao, Yasuhiro Koh, Kazunobu Tachibana, Shun-ichi Isa, Minoru Takada, Takayasu Kurata. (2009) Response Rate Is Associated with Prolonged Survival in Patients with Advanced Non-small Cell Lung Cancer Treated with Gefitinib or Erlotinib. Journal of Thoracic Oncology 4:8, 994-1001
CrossRef608
Jared Weiss, Corey Langer. (2009) NSCLC in the Elderly—The Legacy of Therapeutic Neglect. Current Treatment Options in Oncology 10:3-4, 180-194
CrossRef609
Oscar Arrieta, Miguel Angel Rios Trejo, Rosa M. Michel. (2009) Wood-Smoke Exposure as a Response and Survival Predictor in Erlotinib-Treated Nonsmall Cell Lung Cancer Patients. Journal of Thoracic Oncology 4:8, 1043
CrossRef610
H A Burris. (2009) Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene 28, S4-S13
CrossRef611
Joline S.W. Lind, Frank J. Lagerwaard, Egbert F. Smit, Suresh Senan. (2009) Phase I Study of Concurrent Whole Brain Radiotherapy and Erlotinib for Multiple Brain Metastases From Non–Small-Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 74:5, 1391-1396
CrossRef612
Brian Z Ring, Robert S Seitz, Rodney A Beck, William J Shasteen, Alex Soltermann, Stefanie Arbogast, Francisco Robert, Marshall T Schreeder, Douglas T Ross. (2009) A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Modern Pathology 22:8, 1032-1043
CrossRef613
A F Gazdar. (2009) Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28, S24-S31
CrossRef614
Tsuyoshi Suzuki, Akihiro Fujii, Junichi Ohya, Hideo Nakamura, Fumiko Fujita, Masako Koike, Masahide Fujita. (2009) Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models. Cancer Science 100:8, 1526-1531
CrossRef615
R Pérez-Soler. (2009) Individualized therapy in non-small-cell lung cancer: future versus current clinical practice. Oncogene 28, S38-S45
CrossRef616
Thomas J. Lynch, David Fenton, Vera Hirsh, David Bodkin, Edward L. Middleman, Alberto Chiappori, Balazs Halmos, Reyna Favis, Hua Liu, William L. Trepicchio, Omar Eton, Frances A. Shepherd. (2009) A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:8, 1002-1009
CrossRef617
Y Wang, C Sung, C Dartois, R Ramchandani, B P Booth, E Rock, J Gobburu. (2009) Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development. Clinical Pharmacology & Therapeutics 86:2, 167-174
CrossRef618
Riccardo Soffietti, Wallace Akerley, Randy L. Jensen, Joachim Bischoff, Anne Constanze Regierer. (2009) The Role of Intra-cerebrospinal Fluid Treatment and Prophylaxis in Patients With Solid Tumors. Seminars in Oncology 36, S55-S68
CrossRef619
M. Seike, A. Goto, T. Okano, E. D. Bowman, A. J. Schetter, I. Horikawa, E. A. Mathe, J. Jen, P. Yang, H. Sugimura, A. Gemma, S. Kudoh, C. M. Croce, C. C. Harris. (2009) MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proceedings of the National Academy of Sciences 106:29, 12085-12090
CrossRef620
Jing Li, Yan Li, Zhi-qiang Feng, Xiao-guang Chen. (2009) Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo. Cancer Letters 279:2, 213-220
CrossRef621
Andrew J. Olaharski, Hirdesh Uppal, Matthew Cooper, Stefan Platz, Tanja S. Zabka, Kyle L. Kolaja. (2009) In vitro to in vivo concordance of a high throughput assay of bone marrow toxicity across a diverse set of drug candidates. Toxicology Letters 188:2, 98-103
CrossRef622
Russell J. Schilder, Michael W. Sill, Yi-Chun Lee, Robert Mannel. (2009) A Phase II Trial of Erlotinib in Recurrent Squamous Cell Carcinoma of the Cervix. International Journal of Gynecological Cancer 19:5, 929-933
CrossRef623
Soo-Jung Um, Soo-Keol Lee, Doo Kyung Yang, Choonhee Son, Mee Sook Roh, Ki Nam Kim, Ki-Nam Lee, Pil Jo Choi. (2009) Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis. The Clinical Respiratory Journal 3:3, 181-184
CrossRef624
D. Planchard, J. Domont, E. Taranchon, I. Monnet, J. Tredaniel, R. Caliandro, P. Validire, B. Besse, J.-C. Soria, P. Fouret. (2009) The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. Annals of Oncology 20:7, 1257-1263
CrossRef625
Aubrey Jolly Graham, Anil Potti. (2009) Translating genomics into clinical practice: Applications in lung cancer. Current Oncology Reports 11:4, 263-268
CrossRef626
Songwen ZHOU, Shengxiang REN, Lianghua YAN, Ling ZHANG, Liang TANG, Jie ZHANG, Caicun ZHOU. (2009) Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. Respirology 14:5, 709-715
CrossRef627
Angela M. Davies, Cheryl Ho, Laurel Beckett, Derick Lau, Sidney A. Scudder, Primo N. Lara, Natasha Perkins, David R. Gandara. (2009) Intermittent Erlotinib in Combination with Pemetrexed. Journal of Thoracic Oncology 4:7, 862-868
CrossRef628
, Joaquín Casal Rubio, S. Vázquez, F. Vázquez, M. Amenedo, J. L. Fírvida, J. R. Mel, G. Huidobro, E. Álvarez, M. Lázaro, G. Alonso, I. Fernández. (2009) A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. Cancer Chemotherapy and Pharmacology 64:2, 379-384
CrossRef629
Helen X. Chen, Jessica N. Cleck, Rochelle Coelho, Janet E. Dancey. (2009) Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions. Current Problems in Cancer 33:4, 245-294
CrossRef630
Nathan A. Pennell, Tarek Mekhail. (2009) Investigational agents in the management of non-small cell lung cancer. Current Oncology Reports 11:4, 275-284
CrossRef631
Sarah Park, Alison J. Holmes-Tisch, Eun Yoon cho, Young Mog Shim, Jinkook Kim, Hyo Song Kim, Jeeyun Lee, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Pasi A. Jänne, Myung-Ju Ahn. (2009) Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:7, 809-815
CrossRef632
Mariano Provencio, Rosario García-Campelo, Dolores Isla, Javier Castro. (2009) Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. Clinical and Translational Oncology 11:7, 428-436
CrossRef633
Yi-He Ling, Tianhong Li, Roman Perez-Soler, Missak Haigentz. (2009) Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib. Cancer Chemotherapy and Pharmacology 64:3, 539-548
CrossRef634
Julio Sánchez De Cos Escuín. (2009) El cáncer de pulmón en España. Epidemiología, supervivencia y tratamiento actuales. Archivos de Bronconeumología 45:7, 341-348
CrossRef635
Heng-Sheng Chao, Cheng-Pei Chang, Chao-Hua Chiu, Lee-Shing Chu, Yuh-Min Chen, Chun-Ming Tsai. (2009) Bone Scan Flare Phenomenon in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib. Clinical Nuclear Medicine 34:6, 346-349
CrossRef636
Tianhong Li, Roman Perez-Soler. (2009) Skin toxicities associated with epidermal growth factor receptor inhibitors. Targeted Oncology 4:2, 107-119
CrossRef637
Margie Gerena-Lewis, Jeffrey Crawford, Philip Bonomi, Ann Marie Maddox, John Hainsworth, David E. McCune, Rakesh Shukla, Haoyue Zeigler, Paul Hurtubise, Tracy R. Chowdhury, Brandon Fletcher, Karyn Dyehouse, Richard Ghalie, Abdul R. Jazieh. (2009) A Phase II Trial of Denileukin Diftitox in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer. American Journal of Clinical Oncology 32:3, 269-273
CrossRef638
Jian Ming Xu, Yu Han, Hai Qing Duan, E. Mei Gao, Yang Zhang, Xiao Qing Liu, Jing Sheng Zhang, Luca Toschi, Domenico Galetta, Amalia Azzariti, Angelo Paradiso. (2009) EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. Journal of Cancer Research and Clinical Oncology 135:6, 771-782
CrossRef639
Katsuhiro Masago, Ryo Asato, Shiro Fujita, Shigeru Hirano, Yoshihiro Tamura, Tomoko Kanda, Tadashi Mio, Nobuyuki Katakami, Michiaki Mishima, Juichi Ito. (2009) Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. International Journal of Cancer 124:11, 2744-2749
CrossRef640
Matteo Landriscina, Annamaria Piscazzi, Annarita Fabiano, Francesca Maddalena, Eleonora Costantino, Anna Farese, Pantaleo Bufo, Mauro Cignarelli. (2009) Targeting Epidermal Growth Factor Receptor 1 Signaling in Human Thyroid-Stimulating Hormone–Independent Thyroid Carcinoma FRO Cells Results in a More Chemosensitive and Less Angiogenic Phenotype. Thyroid 19:6, 629-637
CrossRef641
Ronan J. Kelly, Bertrand Billemont, Olivier Rixe. (2009) Renal toxicity of targeted therapies. Targeted Oncology 4:2, 121-133
CrossRef642
Stuart Salmon, Heidi Chen, Shuo Chen, Roy Herbst, Anne Tsao, Hai Tran, Alan Sandler, Dean Billheimer, Yu Shyr, Ju-Whei Lee, Pierre Massion, Julie Brahmer, Joan Schiller, David Carbone, Thao P. Dang. (2009) Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen. Journal of Thoracic Oncology 4:6, 689-696
CrossRef643
G. K. Philips, S. Halabi, B. L. Sanford, D. Bajorin, E. J. Small, . (2009) A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Annals of Oncology 20:6, 1074-1079
CrossRef644
Arman Kilic, Matthew J. Schuchert, James D. Luketich, Rodney J. Landreneau, Talal El-Hefnawy. (2009) Efficacy of Signal Pathway Inhibitors Alone and in Combination With Cisplatin Varies Between Human Non-Small Cell Lung Cancer Lines. Journal of Surgical Research 154:1, 9-12
CrossRef645
M. A. Socinski, M. N. Saleh, D. F. Trent, T. W. Dobbs, L. M. Zehngebot, M. A. Levine, R. Bordoni, P. J. Stella. (2009) A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). Annals of Oncology 20:6, 1068-1073
CrossRef646
Lorenzo Daniele, Paola Cassoni, Elisa Bacillo, Susanna Cappia, Luisella Righi, Marco Volante, Fabrizio Tondat, Giorgio Inghirami, Anna Sapino, Giorgio V. Scagliotti, Mauro Papotti, Silvia Novello. (2009) Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:6, 684-688
CrossRef647
Helena Linardou, Issa J. Dahabreh, Dimitrios Bafaloukos, Paris Kosmidis, Samuel Murray. (2009) Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nature Reviews Clinical Oncology 6:6, 352-366
CrossRef648
Chin-Lun Huang, Chih-Hsin Yang, Kun-Huei Yeh, Fu-Chang Hu, Kuan-Yu Chen, Jin-Yuan Shih, Zhong-Zhe Lin, Chong-Jen Yu, Ann-Lii Cheng, Pan-Chyr Yang. (2009) EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer 64:3, 346-351
CrossRef649
Shirish M. Gadgeel, Shadan Ali, Philip A. Philip, Antoinette Wozniak, Fazlul H. Sarkar. (2009) Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Cancer 115:10, 2165-2176
CrossRef650
Sai-Hong Ignatius Ou, Coty Ho. (2009) Treatment of Advanced Lung Cancer. Clinical Pulmonary Medicine 16:3, 157-171
CrossRef651
Giulio Metro, Federico Cappuzzo. (2009) New targeted therapies for non-small-cell lung cancer. Therapy 6:3, 335-350
CrossRef652
Romano Danesi, Giuseppe Pasqualetti, Elisa Giovannetti, Francesco Crea, Giuseppe Altavilla, Mario Del Tacca, Rafael Rosell. (2009) Pharmacogenomics in non-small-cell lung cancer chemotherapy. Advanced Drug Delivery Reviews 61:5, 408-417
CrossRef653
M. Scheffler, J. Wolf. (2009) Aktuelle Entwicklungen in der Bildgebung beim nichtkleinzelligen Bronchialkarzinom. Der Onkologe 15:5, 496-501
CrossRef654
Aurélie Le Maître, Keyue Ding, Frances A. Shepherd, Natasha Leighl, Andrew Arnold, Lesley Seymour. (2009) Anticoagulation and Bleeding. Journal of Thoracic Oncology 4:5, 586-594
CrossRef655
Maura N. Dickler, Melody A. Cobleigh, Kathy D. Miller, Pamela M. Klein, Eric P. Winer. (2009) Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Research and Treatment 115:1, 115-121
CrossRef656
Marcello Tiseo, Cesare Gridelli, Stefano Cascinu, Lucio Crinò, Franco Vito Piantedosi, Francesco Grossi, Alba A. Brandes, Roberto Labianca, Salvatore Siena, Domenico Amoroso, Ornella Belvedere, Brunello Valentino, Alessandra Bearz, Paola Venturino, Andrea Ardizzoni. (2009) An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy. Lung Cancer 64:2, 199-206
CrossRef657
G. D'Addario, E. Felip, . (2009) Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv68-iv70
CrossRef658
Tammie E. Quest, Placid Bone. (2009) Caring for Patients with Malignancy in the Emergency Department: Patient–Provider Interactions. Emergency Medicine Clinics of North America 27:2, 333-339
CrossRef659
Mark S. Cragg, Claire Harris, Andreas Strasser, Clare L. Scott. (2009) Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nature Reviews Cancer 9:5, 321-326
CrossRef660
Robert Pirker, Jose R Pereira, Aleksandra Szczesna, Joachim von Pawel, Maciej Krzakowski, Rodryg Ramlau, Ihor Vynnychenko, Keunchil Park, Chih-Teng Yu, Valentyn Ganul, Jae-Kyung Roh, Emilio Bajetta, Kenneth O'Byrne, Filippo de Marinis, Wilfried Eberhardt, Thomas Goddemeier, Michael Emig, Ulrich Gatzemeier. (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. The Lancet 373:9674, 1525-1531
CrossRef661
Nagahiro Saijo, Masahiro Takeuchi, Hideo Kunitoh. (2009) Reasons for response differences seen in the V15-32, INTEREST and IPASS trials. Nature Reviews Clinical Oncology 6:5, 287-294
CrossRef662
C. Dreyer, E. Raymond, S. Faivre. (2009) Les thérapies ciblées et leurs indications dans les tumeurs solides. La Revue de Médecine Interne 30:5, 416-424
CrossRef663
Xia Qian, Jing Li, Jianhua Ding, Zhiyuan Wang, Wenjing Zhang, Gang Hu. (2009) ERLOTINIB ACTIVATES MITOCHONDRIAL DEATH PATHWAYS RELATED TO THE PRODUCTION OF REACTIVE OXYGEN SPECIES IN THE HUMAN NON-SMALL CELL LUNG CANCER CELL LINE A549. Clinical and Experimental Pharmacology and Physiology 36:5-6, 487-494
CrossRef664
Wojciech Bartminski. (2009) Araújo A, et al. Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células Rev Port Pneumol 2008; 14(6):803–827. Revista Portuguesa de Pneumologia (English Edition) 15:3, 555-559
CrossRef665
António Araújo. (2009) Araújo A, et al. Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células Rev Port Pneumol 2008; 14(6):803–827. Revista Portuguesa de Pneumologia (English Edition) 15:3, 560-566
CrossRef666
Sumithra J. Mandrekar, Daniel J. Sargent. (2009) Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All. Journal of Biopharmaceutical Statistics 19:3, 530-542
CrossRef667
Edward S. Kim, Ann M. Mauer, William N. William, Hai T. Tran, Diane Liu, Jack J. Lee, Paul Windt, Waun K. Hong, Everett E. Vokes, Roy S. Herbst. (2009) A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 115:8, 1713-1722
CrossRef668
Ghassan El Maalouf, Christophe Le Tourneau, Georges Nicolas Batty, Sandrine Faivre, Eric Raymond. (2009) Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treatment Reviews 35:2, 167-174
CrossRef669
Anne M. Traynor, Joan H. Schiller, Laura P. Stabile, Jill M. Kolesar, Jens C. Eickhoff, Sanja Dacic, Tien Hoang, Sarita Dubey, Sarah M. Marcotte, Jill M. Siegfried. (2009) Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 64:1, 51-59
CrossRef670
, Satoshi Oizumi, Koichi Yamazaki, Hiroshi Yokouchi, Jun Konishi, Fumihiro Hommura, Tetsuya Kojima, Hiroshi Isobe, Masaharu Nishimura. (2009) Phase I study of amrubicin and vinorelbine in non-small cell lung cancer previously treated with platinum-based chemotherapy. International Journal of Clinical Oncology 14:2, 125-129
CrossRef671
Chih-Ming Lin, Chih-Hung Chen, John WC Chang, Thomas CY Tsao. (2009) Phase II Study of Epirubicin in Combination With Weekly Docetaxel for Patients With Advanced NSCLC Who Have Failed or Relapsed After the Frontline Platinum-Based Chemotherapy. American Journal of Clinical Oncology 32:2, 169-173
CrossRef672
Ikuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, Hideo Kunitoh, Yuichiro Ohe, Tomohide Tamura. (2009) Comparative Chemotherapeutic Efficacy in Non-small Cell Lung Cancer Patients with Postoperative Recurrence and Stage IV Disease. Journal of Thoracic Oncology 4:4, 518-521
CrossRef673
Federico Cappuzzo, Marileila Varella-Garcia, Elisa Rossi, Sujatha Gajapathy, Marialuisa Valente, Harry Drabkin, Robert Gemmill. (2009) MYC and EIF3H Coamplification Significantly Improve Response and Survival of Non-small Cell Lung Cancer Patients (NSCLC) Treated with Gefitinib. Journal of Thoracic Oncology 4:4, 472-478
CrossRef674
Nai-Ming Cheng, Chih-Teng Yu, Kung-Chu Ho, Yi-Cheng Wu, Yuan-Chang Liu, Chih-Wei Wang, Tzu-Chen Yen. (2009) Respiration-averaged CT for attenuation correction in non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging 36:4, 607-615
CrossRef675
Anne M. Traynor, Sarita Dubey, Jens C. Eickhoff, Jill M. Kolesar, Kathleen Schell, Michael S. Huie, David L. Groteluschen, Sarah M. Marcotte, Courtney M. Hallahan, Hilary R. Weeks, George Wilding, Igor Espinoza-Delgado, Joan H. Schiller. (2009) Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:4, 522-526
CrossRef676
Marjolein Pompen, Murat Gok, Annoesjka Novák, Rob van Wuijtswinkel, Bonne Biesma, Franz Schramel, Jos Stigt, Hans Smit, Pieter Postmus. (2009) Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands. Lung Cancer 64:1, 110-116
CrossRef677
Martin Reck. (2009) Gefitinib in the treatment of advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy 9:4, 401-412
CrossRef678
Min Jae Park, Jeeyun Lee, Jung Yong Hong, Moon Ki Choi, Joon Ho Yi, Su Jin Lee, Suk Joong Oh, Jin Seok Ahn, Keunchil Park, Myung Ju Ahn. (2009) Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. Cancer 115:7, 1518-1530
CrossRef679
Suzanne WEBB, Marc THOMAS, Cecily METCALF, Amanda SEGAL, Anna K NOWAK, Jacqueline BENTEL, Michael MILLWARD. (2009) EGFR mutation testing in NSCLC: Patterns of care and outcomes in Western Australia. Asia-Pacific Journal of Clinical Oncology 5:1, 66-71
CrossRef680
Glenwood Goss, Frances A. Shepherd, Scott Laurie, Isabelle Gauthier, N. Leighl, Eric Chen, Ronald Feld, Jean Powers, Lesley Seymour. (2009) A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. European Journal of Cancer 45:5, 782-788
CrossRef681
Devalingam Mahalingam, Alain Mita, Monica M. Mita, Steffan T. Nawrocki, Francis J. Giles. (2009) Targeted Therapy for Advanced Non-small Cell Lung Cancers: Historical Perspective, Current Practices, and Future Development. Current Problems in Cancer 33:2, 73-111
CrossRef682
Yining Shi, Weidong Huang, Yuping Tan, Xueguang Jin, Rajiv Dua, Elicia Penuel, Ali Mukherjee, Jeff Sperinde, Herjit Pannu, Ahmed Chenna, Lisa DeFazio-Eli, Sailaja Pidaparthi, Youssouf Badal, Gerald Wallweber, Lili Chen, Steve Williams, Hasan Tahir, Jeff Larson, Laurie Goodman, Jeannette Whitcomb, Christos Petropoulos, John Winslow. (2009) A Novel Proximity Assay for the Detection of Proteins and Protein Complexes: Quantitation of HER1 and HER2 Total Protein Expression and Homodimerization in Formalin-fixed, Paraffin-Embedded Cell Lines and Breast Cancer Tissue. Diagnostic Molecular Pathology 18:1, 11-21
CrossRef683
Fabrice Barlési, Isabelle Nanni-Metellus, David Breen, Frédéric Fina, Philippe Astoul, Pierre-Marie Martin. (2009) Non-small cell lung cancer—Smokers or non-smokers, does it matter?. Lung Cancer 63:3, 430-432
CrossRef684
Chia-Chi Lin, Chih-Hsin Yang. (2009) Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer. Targeted Oncology 4:1, 37-44
CrossRef685
Takeo Ito, Genichiro Ishii, Kanji Nagai, Tatsuya Nagano, Masakazu Kojika, Yukinori Murata, Naho Atsumi, Yutaka Nishiwaki, Eishi Miyazaki, Toshihide Kumamoto, Atsushi Ochiai. (2009) Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies. Lung Cancer 63:3, 418-424
CrossRef686
Randeep Sangha, Primo N Lara, Philip C Mack, David R Gandara. (2009) Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Current Opinion in Oncology 21:2, 116-123
CrossRef687
Rossana Berardi, Lorena Verdecchia, Marzia Di Pietro Paolo, Riccardo Giampieri, Mario Scartozzi, Chiara Pierantoni, Maristella Bianconi, Paola Mazzanti, Stefano Cascinu. (2009) Women and lung cancer: Clinical and molecular profiling as a determinate for treatment decisions. Critical Reviews in Oncology/Hematology 69:3, 223-236
CrossRef688
Katsuyuki Hotta, Yoshiro Fujiwara, Keitaro Matsuo, Katsuyuki Kiura, Nagio Takigawa, Masahiro Tabata, Mitsune Tanimoto. (2009) Time to Progression as a Surrogate Marker for Overall Survival in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:3, 311-317
CrossRef689
João Paulo da Silveira Nogueira Lima, Lucas Vieira dos Santos, Emma Chen Sasse, Andre Deeke Sasse. (2009) Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis. European Journal of Cancer 45:4, 601-607
CrossRef690
Giuseppe Giaccone, Renee B. Iacona, Abderrahim Fandi, Mette Janas, Judith S. Ochs, Roy S. Herbst, David H. Johnson. (2009) Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. Journal of Cancer Research and Clinical Oncology 135:3, 467-476
CrossRef691
Chun-Ru Chien, Tony Hsiu-Hsi Chen. (2009) A Bayesian Model for Age, Period, and Cohort Effects on Mortality Trends for Lung Cancer, in Association with Gender-Specific Incidence and Case–Fatality Rates. Journal of Thoracic Oncology 4:2, 167-171
CrossRef692
Alejandro Forner, Carmen Ayuso, María Varela, Jordi Rimola, Amelia J. Hessheimer, Carlos Rodriguez de Lope, María Reig, Luís Bianchi, Josep M. Llovet, Jordi Bruix. (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma. Cancer 115:3, 616-623
CrossRef693
Ikuo Sekine. (2009) Is there a need to take ethnicity into account when considering lung cancer treatment?. Expert Review of Respiratory Medicine 3:1, 1-4
CrossRef694
Xishan Xiong, Lili Fu, Li Wang, Houan Cai, Lin Li, Hualiang Jiang, Wenhu Duan, Changlin Mei. (2009) Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo. Investigational New Drugs 27:1, 1-11
CrossRef695
Alejandro Forner, Carmen Ayuso, María Isabel Real, Javier Sastre, Ricardo Robles, Bruno Sangro, María Varela, Manuel de la Mata, María Buti, Luís Martí-Bonmatí, Concepció Bru, Josep Tabernero, Josep M Llovet, Jordi Bruix. (2009) Diagnóstico y tratamiento del carcinoma hepatocelular. Medicina Clínica 132:7, 272-287
CrossRef696
Thomas E. Stinchcombe, Mark A. Socinski. (2009) Treatment Paradigms for Advanced Stage Non-small Cell Lung Cancer in the Era of Multiple Lines of Therapy. Journal of Thoracic Oncology 4:2, 243-250
CrossRef697
Wallace Akerley, Kenneth M. Boucher, Joel S. Bentz, Kylee Arbogast, Theodore Walters. (2009) A Phase II Study of Erlotinib as Initial Treatment for Patients with Stage IIIB-IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:2, 214-219
CrossRef698
Jin Kyung Rho, Yun Jung Choi, Jin Kyung Lee, Baek-Yeol Ryoo, Im Il Na, Sung Hyun Yang, Cheol Hyeon Kim, Jae Cheol Lee. (2009) Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63:2, 219-226
CrossRef699
Amir T Fathi, Mark Levis. (2009) Lestaurtinib: a multi-targeted FLT3 inhibitor. Expert Review of Hematology 2:1, 17-26
CrossRef700
C.-H. Gow, Y.-L. Chang, Y.-C. Hsu, M.-F. Tsai, C.-T. Wu, C.-J. Yu, C.-H. Yang, Y.-C. Lee, P.-C. Yang, J.-Y. Shih. (2009) Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Annals of Oncology 20:4, 696-702
CrossRef701
S. E. Witta, R. Dziadziuszko, K. Yoshida, K. Hedman, M. Varella-Garcia, P. A. Bunn, F. R. Hirsch. (2009) ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). Annals of Oncology 20:4, 689-695
CrossRef702
Toyoaki Hida, Shizu Ogawa, Jang Chul Park, Ji Young Park, Junichi Shimizu, Yoshitsugu Horio, Kimihide Yoshida. (2009) Gefitinib for the treatment of non-small-cell lung cancer. Expert Review of Anticancer Therapy 9:1, 17-35
CrossRef703
Kenji Tamura. (2009) EGFR and VEGF-targeted drugs: clinical evidence for their effects from evaluation of biomarkers. Folia Pharmacologica Japonica 133:2, 69-72
CrossRef704
Martin Reck, Lucio Crinò. (2009) Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer 63:1, 1-9
CrossRef705
Antonio Rossi. (2009) Non-small-cell lung cancer: targeted therapies. Therapy 6:1, 95-98
CrossRef706
Jin Hwa Lee, Kyoung Eun Lee, Yon Ju Ryu, Eun Mi Chun, Jung Hyun Chang. (2009) Comparison of Gefitinib and Erlotinib for Patients with Advanced Non-Small-Cell Lung Cancer. Tuberculosis and Respiratory Diseases 66:4, 280
CrossRef707
Gyu Jin Lee, Mann Hong Jung, Tae Won Jang, Chul Ho Ok, Hyun Joo Jung. (2009) Efficacy and Safety of Pemetrexed in Advanced Non-Small Cell Lung Carcinoma. Tuberculosis and Respiratory Diseases 67:2, 121
CrossRef708
Amir Harandi, Aisha S. Zaidi, Abigail M. Stocker, Damian A. Laber. (2009) Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. Journal of Oncology 2009, 1-14
CrossRef709
Jason M. Foster, Zoran Gatalica, Stan Lilleberg, Gleb Haynatzki, Brian W. Loggie. (2009) Novel and Existing Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor are Predictors of Optimal Resectability in Malignant Peritoneal Mesothelioma. Annals of Surgical Oncology 16:1, 152-158
CrossRef710
Josh J. Carlson, Louis P. Garrison, Scott D. Ramsey, David L. Veenstra. (2009) The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer. Value in Health 12:1, 20-27
CrossRef711
Se Hoon Park, Seung Yeon Ha, Jae-Ik Lee, Hyewon Lee, Hoyong Sim, Young Saing Kim, Junshik Hong, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee. (2009) Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung. Journal of Korean Medical Science 24:3, 448
CrossRef712
Kikuo Nakano, Takeshi Masuda, Takashi Yoshida, Kazuhide Fukuhara. (2009) Terminating Chemotherapy and Transition to Palliative Care for Patients with Recurrent Non-small Cell Lung Cancer in the Terminal Stage. Haigan 49:6, 836-843
CrossRef713
Miyako Satouchi. (2009) Selective Use of Gefitinib and Erlotinib on Non-small Cell Lung Cancer Patients. Haigan 49:6, 950-956
CrossRef714
Hyun Seung Ban, Taikou Usui, Wataru Nabeyama, Hidetoshi Morita, Kaori Fukuzawa, Hiroyuki Nakamura. (2009) Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase. Organic & Biomolecular Chemistry 7:21, 4415
CrossRef715
Rebecca Suk Heist, David Christiani. (2009) EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics 10:1, 59-68
CrossRef716
Prashanth Kandaswamy, Meindert Boysen, Carole Longson, Andrew Stevens. (2009) Erlotinib for the treatment of non-small-cell lung cancer. The Lancet Oncology 10:1, 15-16
CrossRef717
Aarati Ranganathan, David Lee, Sabeeha Muneer, Marissa Shrader, David R. Gandara, Primo N. Lara, Roy S. Herbst. (2009) Highlights from: The 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology. Clinical Lung Cancer 10:1, 13-19
CrossRef718
Choel-Kyu Park, Kyu-Sik Kim, In-Jae Oh, Manaljav Tseden-Ish, Yoo-Duk Choi, Yong-Soo Kwon, Yoo-Il Kim, Sung-Chul Lim, Young-Chul Kim. (2009) Efficacy of Pemetrexed in Relapsed Non-Small Cell Lung Cancer and Thymidylate Synthase Expression. Tuberculosis and Respiratory Diseases 67:3, 191
CrossRef719
Cesare Gridelli, Paolo Maione, Antonio Rossi, Marzia Falanga, Marianna Bareschino, Clorinda Schettino, Giuseppe Colantuoni, Ciro Guerriero, Dario Nicolella, Emanuela Rossi, Marianna Luciana Ferrara, Giovanni Palazzolo. (2009) New avenues for second-line treatment of metastatic non-small-cell lung cancer. Expert Review of Anticancer Therapy 9:1, 115-124
CrossRef720
M. Sebastian, A. Schad, S. Schadmand-Fischer, F. Post, S. Meier, E. Springer, J. Makowski, C. Taube, R. Wiewrodt, B. Fischer, R. Buhl. (2009) Hämorrhagischer Perikarderguss mit multiplen pulmonalen Rundherden bei einem 37-jährigen „Nie-Raucher“. Der Internist 50:1, 91-94
CrossRef721
Rachel E Sanborn, Angela M Davies. (2009) Erlotinib: applications in therapy and current status of research. Expert Review of Clinical Pharmacology 2:1, 15-36
CrossRef722
I Sekine, N Yamamoto, K Nishio, N Saijo. (2008) Emerging ethnic differences in lung cancer therapy. British Journal of Cancer 99:11, 1757-1762
CrossRef723
Rachel E. Sanborn. (2008) Cisplatin Versus Carboplatin in NSCLC: Is There One “Best” Answer?. Current Treatment Options in Oncology 9:4-6, 326-342
CrossRef724
Genni M. Newnham, David M. Thomas, Sue Anne McLachlan, Gavin Wright, Matthew Conron. (2008) Molecular Profiling of Non-Small Cell Lung Cancer: Of What Value in Clinical Practice?. Heart, Lung and Circulation 17:6, 451-462
CrossRef725
Sandro Barni, Mary Cabiddu, F Petrelli. (2008) Toxicity of targeted therapies in elderly patients. Expert Review of Anticancer Therapy 8:12, 1965-1976
CrossRef726
Taofeek K. Owonikoko, Suresh Ramalingam. (2008) The Role of Targeted Agents in the Treatment of Elderly Patients with Non-Small Cell Lung Cancer (NSCLC). Current Treatment Options in Oncology 9:4-6, 313-325
CrossRef727
April Scott, Ravi Salgia. (2008) Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. Biomarkers in Medicine 2:6, 577-586
CrossRef728
Kaoru Kubota, Masaaki Kawahara, Mitsumasa Ogawara, Yutaka Nishiwaki, Kiyoshi Komuta, Koichi Minato, Yuka Fujita, Satoshi Teramukai, Masanori Fukushima, Kiyoyuki Furuse. (2008) Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. The Lancet Oncology 9:12, 1135-1142
CrossRef729
Kaoru Kubota, Yutaka Nishiwaki, Tomohide Tamura, Kazuhiko Nakagawa, Kaoru Matsui, Koshiro Watanabe, Toyoaki Hida, Masaaki Kawahara, Nobuyuki Katakami, Koji Takeda, Akira Yokoyama, Kazumasa Noda, Masahiro Fukuoka, Nagahiro Saijo. (2008) Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:12, 1439-1445
CrossRef730
Cesare Gridelli, Antonio Rossi, Paolo Maione, Giovanni Palazzolo, Paola Claudia Sacco, Maria Anna Bareschino, Clorinda Schettino. (2008) Overview of clinical trials for lung cancer in the elderly. Aging Health 4:6, 629-642
CrossRef731
Marianna Aita, Gianpiero Fasola, Carlotta Defferrari, Annalisa Brianti, Maria Giovanna Dal Bello, Alessandro Follador, Graziella Sinaccio, Paolo Pronzato, Francesco Grossi. (2008) Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Critical Reviews in Oncology/Hematology 68:3, 183-196
CrossRef732
Claus-Peter Schneider, David Heigener, Kathrin Schott-von-Römer, Sylvia Gütz, Eckart Laack, Werner Digel, Wolf-Rüdiger Guschall, Andreas Franke, Heinrich Bodenstein, Claudia Schmidtgen, Martin Reck. (2008) Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:12, 1446-1453
CrossRef733
Kazım Uygun, Gorkem Aksu, Irfan Cicin, Hakan Karagol, Zafer Kocak, Merdan Fayda, Ahmet Binici, Fernaz Uzunoglu. (2008) The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma. Medical Oncology 25:4, 408-414
CrossRef734
Patrick C. Ma, Maria S. Tretiakova, Alexander C. MacKinnon, Nithya Ramnath, Candace Johnson, Sascha Dietrich, Tanguy Seiwert, James G. Christensen, Ramasamy Jagadeeswaran, Thomas Krausz, Everett E. Vokes, Aliya N. Husain, Ravi Salgia. (2008) Expression and mutational analysis of MET in human solid cancers. Genes, Chromosomes and Cancer 47:12, 1025-1037
CrossRef735
Cesare Guida, Paolo Maione, Antonio Rossi, Marianna Bareschino, Clorinda Schettino, Domenico Barzaghi, Massimo Elmo, Cesare Gridelli. (2008) Combined chemo-radiotherapy for locally advanced non-small cell lung cancer: Current status and future development. Critical Reviews in Oncology/Hematology 68:3, 222-232
CrossRef736
Chiun Hsu, Sung-Hsin Kuo, Fu-Chang Hu, Ann-Lii Cheng, Jin-Yuan Shih, Chong-Jen Yu, Chia-Chi Lin, Tsu-Chen Huang, Pan-Chyr Yang, Chih-Hsin Yang. (2008) Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma—A randomized phase II trial. Lung Cancer 62:3, 334-343
CrossRef737
Fred R. Hirsch, Anna Spreafico, Silvia Novello, Mary Dugan Wood, Lorinda Simms, Mauro Papotti. (2008) The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:12, 1468-1481
CrossRef738
Nilesh Vora, Karen L. Reckamp. (2008) Non-Small Cell Lung Cancer in the Elderly: Defining Treatment Options. Seminars in Oncology 35:6, 590-596
CrossRef739
Ryotaro Morinaga, Isamu Okamoto, Yoshihiko Fujita, Tokuzo Arao, Masaru Sekijima, Kazuto Nishio, Hiroyuki Ito, Masahiro Fukuoka, Jun-ichi Kadota, Kazuhiko Nakagawa. (2008) Association of epidermal growth factor receptor ( EGFR ) gene mutations with EGFR amplification in advanced non-small cell lung cancer. Cancer Science 99:12, 2455-2460
CrossRef740
A. U. Ahmed, R. L. Schmidt, C. H. Park, N. R. Reed, S. E. Hesse, C. F. Thomas, J. R. Molina, C. Deschamps, P. Yang, M. C. Aubry, A. H. Tang. (2008) Effect of Disrupting Seven-in-Absentia Homolog 2 Function on Lung Cancer Cell Growth. JNCI Journal of the National Cancer Institute 100:22, 1606-1629
CrossRef741
J.-M. Sun, K.-W. Lee, J. H. Kim, Y. J. Kim, H. I. Yoon, J.-H. Lee, C.-T. Lee, J. S. Lee. (2008) Efficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancer. Japanese Journal of Clinical Oncology 39:1, 27-32
CrossRef742
Niels Reinmuth, Anna Jauch, Elizabeth Chang Xu, Thomas Muley, Martin Granzow, Hans Hoffmann, Hendrik Dienemann, Esther Herpel, Philipp A. Schnabel, Felix J.F. Herth, Sandra Gottschling, Harald Lahm, Martin Steins, Michael Thomas, Michael Meister. (2008) Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. Lung Cancer 62:2, 193-201
CrossRef743
Michael Cullen, Nicholas Thatcher. (2008) Gefitinib or docetaxel in advanced non-small-cell lung cancer. The Lancet 372:9652, 1785-1786
CrossRef744
C. Chouaid, A. Moser, C. Coudray-Omnès, A. Vergnenègre. (2008) Conséquences économiques de l’erlotinib dans le traitement des cancers bronchopulmonaires non à petites cellules. Revue des Maladies Respiratoires 25:9, 1096-1103
CrossRef745
Joaquin Garcia, Gregory J. Riely, Khedoudja Nafa, Marc Ladanyi. (2008) KRAS mutational testing in the selection of patients for EGFR-targeted therapies. Seminars in Diagnostic Pathology 25:4, 288-294
CrossRef746
Hossein Borghaei, Corey J. Langer, Michael Millenson, Karen J. Ruth, Samuel Litwin, Holly Tuttle, Judie Sylvester Seldomridge, Marc Rovito, David Mintzer, Roger Cohen, Joseph Treat. (2008) Phase II Study of Paclitaxel, Carboplatin, and Cetuximab as First Line Treatment, for Patients with Advanced Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 3:11, 1286-1292
CrossRef747
Rogerio C. Lilenbaum, Roy S. Herbst. (2008) Advances in the Treatment of Metastatic Non–Small-Cell Lung Cancer With Chemotherapy and Targeted Agents. Clinical Pulmonary Medicine 15:6, 352-358
CrossRef748
Edward S Kim, Vera Hirsh, Tony Mok, Mark A Socinski, Radj Gervais, Yi-Long Wu, Long-Yun Li, Claire L Watkins, Mark V Sellers, Elizabeth S Lowe, Yan Sun, Mei-Lin Liao, Kell Østerlind, Martin Reck, Alison A Armour, Frances A Shepherd, Scott M Lippman, Jean-Yves Douillard. (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. The Lancet 372:9652, 1809-1818
CrossRef749
Evangelos Cholongitas, George Kokolakis, Despina Ioannidou. (2008) How important is the pus culture obtained from epithelial growth factor receptor (EGFR) inhibitors’ associated rash?. International Journal of Dermatology 47:11, 1203-1204
CrossRef750
Gregory J. Riely, Marc Ladanyi. (2008) KRAS Mutations. The Journal of Molecular Diagnostics 10:6, 493-495
CrossRef751
Brandon H. Tieu, Rachel E. Sanborn, Charles R. Thomas. (2008) Neoadjuvant Therapy for Resectable Non–Small Cell Lung Cancer with Mediastinal Lymph Node Involvement. Thoracic Surgery Clinics 18:4, 403-415
CrossRef752
A. Araújo, B. Parente, R. Sotto-Mayor, E. Teixeira, T. Almodôvar, F. Barata, H. Queiroga, C. Pereira, H. Pereira, F. Negreiro, C. Silva. (2008) Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células. Revista Portuguesa de Pneumologia (English Edition) 14:6, 803-827
CrossRef753
R. de Boer, Y. Humblet, J. Wolf, L. Nogova, K. Ruffert, T. Milenkova, R. Smith, A. Godwood, J. Vansteenkiste. (2008) An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Annals of Oncology 20:3, 486-491
CrossRef754
M. A. Pantaleo, M. Nannini, A. Maleddu, S. Fanti, C. Nanni, S. Boschi, F. Lodi, G. Nicoletti, L. Landuzzi, P. L. Lollini, G. Biasco. (2008) Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Annals of Oncology 20:2, 213-226
CrossRef755
A.-C. Toffart, E. Pluquet, J.-F. Timsit, S. Diab, D. Moro-Sibilot. (2008) Cancer bronchopulmonaire et réanimation. Revue de Pneumologie Clinique 64:5, 250-256
CrossRef756
Rebecca Suk Heist, Panos Fidias, Mark Huberman, Blair Ardman, Lecia V. Sequist, Jennifer S. Temel, Thomas J. Lynch. (2008) A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:10, 1153-1158
CrossRef757
Reury-Perng Perng, Chih-Hsin Yang, Yuh-Min Chen, Gee-Chen Chang, Meng-Chih Lin, Ruey-Kuen Hsieh, Nei-Min Chu, Ruay-Sheng Lai, Wu-Chou Su, Chao-Jung Tsao, Te-Chun Hsia, Hao-Cheng Chen, Chih-Hung Chen, Ming-Shyan Huang, Jui-Long Wang, Ming-Lin Ho, Chih-Yuan Chung, Chong-Jen Yu, Wen-Cheng Chang, Han-Pin Kuo, Chih-Teng Yu, Zhong-Zhe Lin, Woei-Yau Kao. (2008) High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer 62:1, 78-84
CrossRef758
Cesare Gridelli, Antonio Rossi, Paolo Maione. (2008) The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Critical Reviews in Oncology/Hematology 68:1, 29-36
CrossRef759
Silvia Novello, Tiziana Vavalà. (2008) Lung cancer and women. Future Oncology 4:5, 705-716
CrossRef760
Sharon Barr, Stuart Thomson, Elizabeth Buck, Suzanne Russo, Filippo Petti, Izabela Sujka-Kwok, Alexandra Eyzaguirre, Maryland Rosenfeld-Franklin, Neil W. Gibson, Mark Miglarese, David Epstein, Kenneth K. Iwata, John D. Haley. (2008) Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clinical & Experimental Metastasis 25:6, 685-693
CrossRef761
Alexandra Eyzaguirre, Elizabeth Buck, Kenneth K. Iwata, John D. Haley, Mark R. Miglarese. (2008) Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies. Targeted Oncology 3:4, 235-243
CrossRef762
O N Ikediobi. (2008) Somatic pharmacogenomics in cancer. The Pharmacogenomics Journal 8:5, 305-314
CrossRef763
Katsuhiro Masago, Shiro Fujita, Tadashi Mio, Masataka Ichikawa, Keiichiro Sakuma, Young Hak Kim, Yukimasa Hatachi, Akiko Fukuhara, Kiyofumi Kamiyama, Makoto Sonobe, Ryo Miyahara, Hiroshi Date, Michiaki Mishima. (2008) Accuracy of epidermal growth factor receptor gene mutation analysis by direct sequencing method based on small biopsy specimens from patients with non-small cell lung cancer: analysis of results in 19 patients. International Journal of Clinical Oncology 13:5, 442-446
CrossRef764
Frank Griesinger. (2008) Das fortgeschrittene nichtkleinzellige Lungenkarzinom. best practice onkologie 3:5, 26-36
CrossRef765
Josep M. Llovet, Jordi Bruix. (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:4, 1312-1327
CrossRef766
Marcello Tiseo, Marzia Capelletti, Giuseppe De Palma, Vittorio Franciosi, Andrea Cavazzoni, Paola Mozzoni, Roberta R. Alfieri, Matteo Goldoni, Maricla Galetti, Beatrice Bortesi, Cecilia Bozzetti, Maura Loprevite, Luca Boni, Roberta Camisa, Guido Rindi, Pier Giorgio Petronini, Andrea Ardizzoni. (2008) Epidermal Growth Factor Receptor Intron-1 Polymorphism Predicts Gefitinib Outcome in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:10, 1104-1111
CrossRef767
M. A. Pantaleo, S. Fanti, M. Nannini, S. Boschi, C. Nanni, A. Maleddu, D. Rubello, G. Biasco. (2008) What oncologists need and require from nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging 35:10, 1761-1765
CrossRef768
Nagahiro Saijo. (2008) Advances in the treatment of non-small cell lung cancer. Cancer Treatment Reviews 34:6, 521-526
CrossRef769
Giannis Mountzios, Pierre Fouret, Jean-Charles Soria. (2008) Mechanisms of Disease: signal transduction in lung carcinogenesis—a comparison of smokers and never-smokers. Nature Clinical Practice Oncology 5:10, 610-618
CrossRef770
Grace K. Dy, Alex A. Adjei. (2008) Systemic cancer therapy: Evolution over the last 60 years. Cancer 113:S7, 1857-1887
CrossRef771
Herbst, Roy S., Heymach, John V., Lippman, Scott M., . (2008) Lung Cancer. New England Journal of Medicine 359:13, 1367-1380
Full Text772
Y K Zee, T Eisen. (2008) Survival from lung cancer in England and Wales up to 2001. British Journal of Cancer 99, S43-S46
CrossRef773
Z Tang, R Du, S Jiang, C Wu, D S Barkauskas, J Richey, J Molter, M Lam, C Flask, S Gerson, A Dowlati, L Liu, Z Lee, B Halmos, Y Wang, J A Kern, P C Ma. (2008) Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. British Journal of Cancer 99:6, 911-922
CrossRef774
Nicholas W. Choong, Ann M. Mauer, Daniel J. Haraf, Eric Lester, Philip C. Hoffman, Mark Kozloff, Shang Lin, Janet E. Dancey, Livia Szeto, Tatyana Grushko, Olufunmilayo I. Olopade, Ravi Salgia, Everett E. Vokes. (2008) Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:9, 1003-1011
CrossRef775
Kadoaki Ohashi, Kammei Rai, Yoshiro Fujiwara, Masahiro Osawa, Seiki Hirano, Katsuyoshi Takata, Eisaku Kondo, Tadashi Yoshino, Minoru Takata, Mitsune Tanimoto, Katsuyuki Kiura. (2008) Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter. Cancer Science 99:9, 1747-1753
CrossRef776
Paul J. Hesketh, Kari Chansky, Antoinette J. Wozniak, Fred R. Hirsch, Anna Spreafico, James Moon, Philip C. Mack, Benjamin T. Marchello, Wilbur A. Franklin, John J. Crowley, David R. Gandara. (2008) Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2. Journal of Thoracic Oncology 3:9, 1026-1031
CrossRef777
Chao Hui Huang, Michael M. Millenson, Eric J. Sherman, Hossein Borghaei, David M. Mintzer, Roger B. Cohen, Arthur P. Staddon, Judi Seldomridge, Ocn Joseph Treat, Holly Tuttle, Karen J. Ruth, Corey J. Langer. (2008) Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy. Journal of Thoracic Oncology 3:9, 1032-1038
CrossRef778
Aaron P. Brown, Deborah E. Citrin, Kevin A. Camphausen. (2008) Clinical biomarkers of angiogenesis inhibition. Cancer and Metastasis Reviews 27:3, 415-434
CrossRef779
Seema Harichand-Herdt, Suresh S. Ramalingam. (2008) Targeted Therapy for the Treatment of Non-Small Cell Lung Cancer: Focus on Inhibition of Epidermal Growth Factor Receptor. Seminars in Thoracic and Cardiovascular Surgery 20:3, 217-223
CrossRef780
David E. Gerber. (2008) EGFR inhibition in the treatment of non-small cell lung cancer. Drug Development Research 69:6, 359-372
CrossRef781
Kai-Keen Shiu, David SP Tan, Jorge S Reis-Filho. (2008) Development of therapeutic approaches to ‘triple negative’ phenotype breast cancer. Expert Opinion on Therapeutic Targets 12:9, 1123-1137
CrossRef782
Laura K. Zerbe, Lori D. Dwyer-Nield, Jason M. Fritz, Elizabeth F. Redente, Robert J. Shroyer, Elizabeth Conklin, Shawn Kane, Chris Tucker, S. Gail Eckhardt, Daniel L. Gustafson, Kenneth K. Iwata, Alvin M. Malkinson. (2008) Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemotherapy and Pharmacology 62:4, 605-620
CrossRef783
A. Kretzschmar. (2008) Prognoseadaptierte Therapie beim fortgeschrittenen CUP-Syndrom. Der Onkologe 14:9, 920-930
CrossRef784
Mechthild Krause, Michael Baumann. (2008) Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. Cancer and Metastasis Reviews 27:3, 387-402
CrossRef785
Yilong Wu, Jinji Yang, Yujuan Huang, Qin Zhou, Yisheng Huang, Chongrui Xu. (2008) Docetaxel as salvage chemotherapy in patients with advanced non-small cell lung cancer after failure of cytotoxic agents and gefitinib treatment. The Chinese-German Journal of Clinical Oncology 7:9, 495-499
CrossRef786
Joline S. W. Lind, Egbert F. Smit, Katrien Grünberg, Suresh Senan, Frank J. Lagerwaard. (2008) Fatal Interstitial Lung Disease After Erlotinib for Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:9, 1050-1053
CrossRef787
Shinji Atagi, Masaaki Kawahara, Yoko Kusunoki, Minoru Takada, Tomoya Kawaguchi, Kyoiti Okishio, Akihito Kubo, Kazutaka Uehira, Katsuyuki Yumine, Yoshio Tomizawa, Ryusei Saito, Shimao Fukai, Hikotaro Komatsu. (2008) Phase I/II Study of Docetaxel and S-1 in Patients with Previously Treated Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:9, 1012-1017
CrossRef788
Balázs Döme, Melinda Magyar. (2008) A daganatos érhálózat mint terápiás célpont nem kissejtes tüdőrákban. Magyar Onkológia 52:3, 247-259
CrossRef789
Aminah Jatoi, Kendrith Rowland, Jeff A. Sloan, Howard M. Gross, Paul A. Fishkin, Stephen P. Kahanic, Paul J. Novotny, Paul L. Schaefer, David B. Johnson, Loren K. Tschetter, Charles L. Loprinzi. (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes. Cancer 113:4, 847-853
CrossRef790
Jennifer S. Temel, Jessica McCannon, Joseph A. Greer, Vicki A. Jackson, Patricia Ostler, William F. Pirl, Thomas J. Lynch, J. Andrew Billings. (2008) Aggressiveness of care in a prospective cohort of patients with advanced NSCLC. Cancer 113:4, 826-833
CrossRef791
David M. Jackman, Hedy L. Kindler, Beow Y. Yeap, Panos Fidias, Ravi Salgia, Joan Lucca, Linda K. Morse, Patricia A. Ostler, Bruce E. Johnson, Pasi A. Jänne. (2008) Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 113:4, 808-814
CrossRef792
Keith D. Eaton, Deborah A. Frieze. (2008) Cancer pain: Perspectives of a medical oncologist. Current Pain and Headache Reports 12:4, 270-276
CrossRef793
Giovanni Silvano, Grazia Lazzari, Monica Lovecchio, Carmela Palazzo. (2008) Acute and fatal diarrhoea after erlotinib plus abdominal palliative hypofractionated radiotherapy in a metastatic non-small cell lung cancer patient: A case report. Lung Cancer 61:2, 270-273
CrossRef794
Raymond Ng, Michael Loreto, Roy Lee, Natasha B. Leighl. (2008) Brief report: Retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. Lung Cancer 61:2, 262-265
CrossRef795
Oscar Arrieta, Luis Martinez-Barrera, Sergio Treviño, Enrique Guzman, Patricia Castillo-Gonzalez, Miguel Angel Rios-Trejo, Diana Flores-Estrada, Eduardo Téllez, Cesar Gonzalez, Johny de la Cruz Vargas, Claudia Haydee Gonzalez-De la Rosa, Norma Hernandez-Pedro, Rafael Morales-Barrera, Jaime De la Garza. (2008) Wood-Smoke Exposure as a Response and Survival Predictor in Erlotinib-treated Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology 3:8, 887-893
CrossRef796
Samuel Murray, Issa J. Dahabreh, Helena Linardou, Menelaos Manoloukos, Dimitrios Bafaloukos, Paris Kosmidis. (2008) Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database. Journal of Thoracic Oncology 3:8, 832-839
CrossRef797
Enrico Vasile, Carmelo Tibaldi, Antonio Chella, Alfredo Falcone. (2008) Erlotinib after Failure of Gefitinib in Patients with Advanced Non-small Cell Lung Cancer Previously Responding to Gefitinib. Journal of Thoracic Oncology 3:8, 912-914
CrossRef798
Scott R Plotkin, Marybeth A Singh, Caroline C O'Donnell, Gordon J Harris, Andrea I McClatchey, Chris Halpin. (2008) Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nature Clinical Practice Oncology 5:8, 487-491
CrossRef799
Kerby Shedden, Jeremy M G Taylor, Steven A Enkemann, Ming-Sound Tsao, Timothy J Yeatman, William L Gerald, Steven Eschrich, Igor Jurisica, Thomas J Giordano, David E Misek, Andrew C Chang, Chang Qi Zhu, Daniel Strumpf, Samir Hanash, Frances A Shepherd, Keyue Ding, Lesley Seymour, Katsuhiko Naoki, Nathan Pennell, Barbara Weir, Roel Verhaak, Christine Ladd-Acosta, Todd Golub, Michael Gruidl, Anupama Sharma, Janos Szoke, Maureen Zakowski, Valerie Rusch, Mark Kris, Agnes Viale, Noriko Motoi, William Travis, Barbara Conley, Venkatraman E Seshan, Matthew Meyerson, Rork Kuick, Kevin K Dobbin, Tracy Lively, James W Jacobson, David G Beer, Kerby Shedden, Jeremy M G Taylor, Steven A Enkemann, Ming-Sound Tsao, Timothy J Yeatman, William L Gerald, Steven Eschrich, Igor Jurisica, Thomas J Giordano, David E Misek, Andrew C Chang, Chang Qi Zhu, Daniel Strumpf, Samir Hanash, Frances A Shepherd, Keyue Ding, Lesley Seymour, Katsuhiko Naoki, Nathan Pennell, Barbara Weir, Roel Verhaak, Christine Ladd-Acosta, Todd Golub, Michael Gruidl, Anupama Sharma, Janos Szoke, Maureen Zakowski, Valerie Rusch, Mark Kris, Agnes Viale, Noriko Motoi, William Travis, Barbara Conley, Venkatraman E Seshan, Matthew Meyerson, Rork Kuick, Kevin K Dobbin, Tracy Lively, James W Jacobson, David G Beer. (2008) Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine 14:8, 822-827
CrossRef800
Chiung-Ing Wong, Hui-Ling Yap, Seng-Gee Lim, Jia-Yi Guo, Boon-Cher Goh, Soo-Chin Lee. (2008) Lack of somatic ErbB2 tyrosine kinase domain mutations in hepatocellular carcinoma. Hepatology Research 38:8, 838-841
CrossRef801
Yuh-Min Chen, Reury-Perng Perng, Jen-Fu Shih, Jacqueline Whang-Peng. (2008) A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly. Lung Cancer 61:2, 214-219
CrossRef802
D. H. Lee, S.-W. Kim, C. Suh, D. H. Yoon, E. J. Yi, J.-S. Lee. (2008) Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Annals of Oncology 19:12, 2039-2042
CrossRef803
K. Ding, J. Pater, M. Whitehead, L. Seymour, F.A. Shepherd. (2008) Validation of treatment induced specific adverse effect as a predictor of treatment benefit: A case study of NCIC CTG BR21. Contemporary Clinical Trials 29:4, 527-536
CrossRef804
R.M. Huber. (2008) Therapie des Lungenkarzinoms. Der Pneumologe 5:4, 259-266
CrossRef805
Dae Ho Lee, Ji‐Youn Han, Heung Tae Kim, Sung Jin Yoon, Hong Ryull Pyo, Kwan Ho Cho, Sang‐Hoon Shin, Heon Yoo, Seung‐Hoon Lee, Jin Soo Lee. (2008) Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole‐brain radiotherapy administered first. Cancer 113:1, 143-149
CrossRef806
Christian Manegold. (2008) Antiangiogenic treatments of advanced non-small cell lung cancer. Targeted Oncology 3:3, 187-196
CrossRef807
Janakiraman Subramanian, Ramaswamy Govindan. (2008) Molecular genetics of lung cancer in people who have never smoked. The Lancet Oncology 9:7, 676-682
CrossRef808
Diego Dongiovanni, Lorenzo Daniele, Carla Barone, Vincenzo Dongiovanni, Camilla Fissore, Anna Sapino, Luigia Macrì, Giovanni Bussolati, Lucio Buffoni, Fabio Gaspari, Raffaella Grillo, Nadia Birocco, Alfredo Addeo, Libero Ciuffreda, Marina Schena. (2008) Gefitinib (ZD1839): Therapy in selected patients with non-small cell lung cancer (NSCLC)?. Lung Cancer 61:1, 73-81
CrossRef809
M. Reck, U. Gatzemeier. (2008) Advanced non-small cell lung cancer therapy: historical and future perspectives. Targeted Oncology 3:3, 135-147
CrossRef810
Raffaele Califano, Fiona H. Blackhall, Giovanna Finocchiaro, Luca Toschi, Nicholas Thatcher, Federico Cappuzzo, Lucio Crinò. (2008) EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?. Targeted Oncology 3:3, 173-186
CrossRef811
Benjamin B. Bridges, Leno Thomas, Petr F. Hausner, L. Austin Doyle, Michelle Bedor, Ruth Smith, Julie Brahmer, Martin J. Edelman. (2008) Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer. Lung Cancer 61:1, 61-66
CrossRef812
Francesco Grossi, Cesare Gridelli, Marianna Aita, Filippo De Marinis. (2008) Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer. Critical Reviews in Oncology/Hematology 67:1, 16-26
CrossRef813
Paul Baas, A Szczęsna, I Albert, J Milanowski, E Juhász, Z Sztancsik, J von Pawel, R Oyama, S Burgers. (2008) Phase I/II Study of a 3 Weekly Oral Taxane (DJ-927) in Patients with Recurrent, Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:7, 745-750
CrossRef814
Patricia M LoRusso, Joseph Paul Eder. (2008) Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. Expert Opinion on Investigational Drugs 17:7, 1013-1028
CrossRef815
David R. Spigel, Ming Lin, Vincent O'Neill, John D. Hainsworth. (2008) Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer 112:12, 2749-2755
CrossRef816
P A Vasey, M Gore, R Wilson, G Rustin, H Gabra, J-P Guastalla, E P Lauraine, J Paul, K Carty, S Kaye. (2008) A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. British Journal of Cancer 98:11, 1774-1780
CrossRef817
Kwok-Kin Wong. (2008) Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. Lung Cancer 60, S10-S18
CrossRef818
Lecia V. Sequist. (2008) First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Mutation. Journal of Thoracic Oncology 3:Supplement 2, S143-S145
CrossRef819
Gregory J. Riely. (2008) Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:Supplement 2, S146-S149
CrossRef820
Caio M. Rocha-Lima. (2008) New directions in the management of advanced pancreatic cancer: a review. Anti-Cancer Drugs 19:5, 435-446
CrossRef821
M. Filipits, R. Pirker. (2008) Adjuvant therapy in non-small cell lung cancer: Current status and future perspectives. memo - Magazine of European Medical Oncology 1:2, 57-60
CrossRef822
S. E. Rosenbaum, S. Wu, M. A. Newman, D. P. West, T. Kuzel, M. E. Lacouture. (2008) Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Supportive Care in Cancer 16:6, 557-566
CrossRef823
Marie Florescu, Baktiar Hasan, Lesley Seymour, Keyue Ding, Frances A. Shepherd. (2008) A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Thoracic Oncology 3:6, 590-598
CrossRef824
Takashi Seto, Takeharu Yamanaka, Makiko Nakano, Mayuko Ota, Riichiroh Maruyama, Tatsuro Okamoto, Hiroshi Wataya, Kazutsugu Uematsu, Nobuhiko Seki, Kenji Eguchi, Hiroshi Semba, Yukito Ichinose. (2008) Tegafur-Uracil Plus Gemcitabine Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Platinum. Journal of Thoracic Oncology 3:6, 637-642
CrossRef825
Anne Horgan, Ronald Feld, Natasha B Leighl. (2008) Gefitinib: a consideration of cost. Expert Review of Pharmacoeconomics & Outcomes Research 8:3, 223-232
CrossRef826
Pasi A. Jänne. (2008) Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer 60, S3-S9
CrossRef827
Ann M. Mauer, Ezra E. W. Cohen, Patrick C. Ma, Mark F. Kozloff, Lee Schwartzberg, Andrew I. Coates, Jiang Qian, Anne E. Hagey, Gary B. Gordon. (2008) A Phase II Study of ABT-751 in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:6, 631-636
CrossRef828
Chih-Hsin Yang. (2008) EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer 60, S23-S30
CrossRef829
Gregory J. Riely. (2008) The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. Lung Cancer 60, S19-S22
CrossRef830
Fred R. Hirsch, Rafal Dziadziuszko, Marileila Varella-Garcia, Wilbur A. Franklin, David R. Gandara, Paul A. Bunn. (2008) First-Generation Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer: Clinical Impact of the Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization Assay. Journal of Thoracic Oncology 3:Supplement 2, S138-S142
CrossRef831
Ugur Coskun, Ali Osman Kaya, Süleyman Buyukberber, Mustafa Benekli, Aytug Uner, Mustafa Dikilitas, Banu Ozturk, Ramazan Yildiz, Secil Ozkan, Emel Yaman, Deniz Yamac. (2008) Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens. Medical Oncology 25:2, 133-136
CrossRef832
Tianhong Li, Yi-He Ling, Roman Perez-Soler. (2008) Tumor Dependence on the EGFR Signaling Pathway Expressed by the p-EGFR:p-AKT Ratio Predicts Erlotinib Sensitivity in Human Non-small Cell Lung Cancer (NSCLC) Cells Expressing Wild-Type EGFR Gene. Journal of Thoracic Oncology 3:6, 643-647
CrossRef833
Marta Guix, Anthony C. Faber, Shizhen Emily Wang, Maria Graciela Olivares, Youngchul Song, Sherman Qu, Cammie Rinehart, Brenda Seidel, Douglas Yee, Carlos L. Arteaga, Jeffrey A. Engelman. (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. Journal of Clinical Investigation
CrossRef834
J. Horti, E. Juhasz, Z. Monostori, K. Maeda, S. Eckhardt, I. Bodrogi. (2008) Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 62:1, 173-180
CrossRef835
Nobuhisa Ishikawa, Noboru Hattori, Akihoto Yokoyama, Sonosuke Tanaka, Ryohei Nishino, Koji Yoshioka, Shinichiro Ohshimo, Kazunori Fujitaka, Hiroshi Ohnishi, Hironobu Hamada, Koji Arihiro, Nobuoki Kohno. (2008) Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. International Journal of Cancer 122:11, 2612-2620
CrossRef836
Vittorio Gebbia. (2008) Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?. Expert Opinion on Pharmacotherapy 9:8, 1321-1337
CrossRef837
Helen Su, Yann Seimbille, Gregory Z. Ferl, Claudia Bodenstein, Barbara Fueger, Kevin J. Kim, Yu-Tien Hsu, Steven M. Dubinett, Michael E. Phelps, Johannes Czernin, Wolfgang A. Weber. (2008) Evaluation of [18F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. European Journal of Nuclear Medicine and Molecular Imaging 35:6, 1089-1099
CrossRef838
Karen Kelly, Chao Huang. (2008) Biological Agents in Non-small Cell Lung Cancer: A Review of Recent Advances and Clinical Results with a Focus on Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor. Journal of Thoracic Oncology 3:6, 664-673
CrossRef839
Mark A. Socinski. (2008) The Current Status and Evolving Role of Sunitinib in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:Supplement 2, S119-S123
CrossRef840
Pankaj Gupta, Luni Emdad, Irina V. Lebedeva, Devanand Sarkar, Paul Dent, David T. Curiel, Jeffrey Settleman, Paul B. Fisher. (2008) Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva. Journal of Cellular Physiology 215:3, 827-836
CrossRef841
J. M. Llovet, A. M. Di Bisceglie, J. Bruix, B. S. Kramer, R. Lencioni, A. X. Zhu, M. Sherman, M. Schwartz, M. Lotze, J. Talwalkar, G. J. Gores, . (2008) Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. JNCI Journal of the National Cancer Institute 100:10, 698-711
CrossRef842
L Paz-Ares, H Ross, M O'Brien, A Riviere, U Gatzemeier, J Von Pawel, E Kaukel, L Freitag, W Digel, H Bischoff, R García-Campelo, N Iannotti, P Reiterer, I Bover, J Prendiville, A J Eisenfeld, F B Oldham, B Bandstra, J W Singer, P Bonomi. (2008) Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. British Journal of Cancer 98:10, 1608-1613
CrossRef843
G. Gravis, F. Bladou, N. Salem, A. Goncalves, B. Esterni, J. Walz, S. Bagattini, M. Marcy, S. Brunelle, P. Viens. (2008) Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Annals of Oncology 19:9, 1624-1628
CrossRef844
M. Navarro Martín, C. Rodríguez Sánchez, C. Delgado Fernández, L. Mezquita Pérez, J.J. Cruz Hernández. (2008) Erupción acneiforme en mujer con adenocarcinoma de pulmón. Revista Clínica Española 208:5, 251-252
CrossRef845
C. Wilhelm, A. Neubauer. (2008) Molekulare Tumortherapie. Der Internist 49:5, 581-592
CrossRef846
N. V. Zhukov, S. A. Tjulandin. (2008) Targeted therapy in the treatment of solid tumors: Practice contradicts theory. Biochemistry (Moscow) 73:5, 605-618
CrossRef847
Yohann Loriot, Gabriel Perlemuter, David Malka, Frédérique Penault-Lorca, Valérie Boige, Eric Deutsch, Christophe Massard, Jean Pierre Armand, Jean-Charles Soria. (2008) Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nature Clinical Practice Oncology 5:5, 268-278
CrossRef848
C. Gridelli, P. Maione, D. Amoroso, M. Baldari, A. Bearz, V. Bettoli, E. Cammilluzzi, L. Crinò, F. De Marinis, F.A. Di Pietro, F. Grossi, D. Innocenzi, G. Micali, F.V. Piantedosi, M. Scartozzi. (2008) Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an Experts Panel Meeting. Critical Reviews in Oncology/Hematology 66:2, 155-162
CrossRef849
Nicolas de Prost, Armelle Lavolé, Laurent Taillade, Marie Wislez, Jacques Cadranel. (2008) Gefitinib-Associated Propionibacterium acnes Pleural Empyema. Journal of Thoracic Oncology 3:5, 556-557
CrossRef850
Adrian Yun-San Yip, Eleanor Yuen-Yuen Ong, Louis Wing-Cheong Chow. (2008) Vinflunine: clinical perspectives of an emerging anticancer agent. Expert Opinion on Investigational Drugs 17:4, 583-591
CrossRef851
E Cholongitas, GP Kokolakis, D Ioannidou. (2008) Painful pustular eruption in the groin and the scrotum induced by erlotinib. Journal of the European Academy of Dermatology and Venereology 22:4, 507-508
CrossRef852
Amer H. Zureikat, Mark D. McKee. (2008) Targeted Therapy for Solid Tumors: Current Status. Surgical Oncology Clinics of North America 17:2, 279-301
CrossRef853
Martin H Fenner, Gernot Beutel, Viktor Grünwald. (2008) Targeted therapies for patients with germ cell tumors. Expert Opinion on Investigational Drugs 17:4, 511-522
CrossRef854
Clorinda Schettino, Maria Anna Bareschino, Vincenzo Ricci, Fortunato Ciardiello. (2008) Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. Expert Review of Respiratory Medicine 2:2, 167-178
CrossRef855
Michèle Beau-Faller, Anne-Marie Ruppert, Anne-Claire Voegeli, Agnès Neuville, Nicolas Meyer, Eric Guerin, Michèle Legrain, Bertrand Mennecier, Jean-Marie Wihlm, Gilbert Massard, Elisabeth Quoix, Pierre Oudet, Marie P. Gaub. (2008) MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort. Journal of Thoracic Oncology 3:4, 331-339
CrossRef856
Enric Carcereny Costa, Núria Viñolas Segarra, Pere Gascón Vilaplana. (2008) Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC). Clinical and Translational Oncology 10:4, 198-203
CrossRef857
Diego Cortinovis, Paolo Bidoli, Daniela Cullurà, Vito Lorusso, Antonio Ardizzoia, Vito Amoroso, Mauro Bandera, Enrico Aitini, Alberto Fusi, Nicoletta Zilembo, Daniela Radula, Emilio Bajetta. (2008) Is Irinotecan Plus Docetaxel Useful as Second-Line Therapy in Advanced Non-small Cell Lung Cancer?. Journal of Thoracic Oncology 3:4, 405-411
CrossRef858
Peter Nygren, Rolf Larsson. (2008) Predictive tests for individualization of pharmacological cancer treatment. Expert Opinion on Medical Diagnostics 2:4, 349-360
CrossRef859
Ramón San Miguel, Ana María López-González, Eduardo Sanchez-Iriso, Javier Mar, Juan M. Cabasés. (2008) Measuring health-related quality of life in drug clinical trials: is it given due importance?. Pharmacy World & Science 30:2, 154-160
CrossRef860
Katsuyuki Kiura, Kazuhiko Nakagawa, Tetsu Shinkai, Kenji Eguchi, Yuichiro Ohe, Nobuyuki Yamamoto, Masahiro Tsuboi, Soichiro Yokota, Takashi Seto, Haiyi Jiang, Kazuto Nishio, Nagahiro Saijo, Masahiro Fukuoka. (2008) A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 3:4, 386-393
CrossRef861
Jair Bar, Amir Onn. (2008) Combined anti-proliferative and anti-angiogenic strategies for cancer. Expert Opinion on Pharmacotherapy 9:5, 701-715
CrossRef862
Alvin S. Wong, Richie Soong, Serena Bee-Kee Seah, Siew-Woon Lim, Khoon-Leong Chuah, Min-En Nga, Tan-Min Chin, Ross A. Soo. (2008) Evidence for Disease Control with Erlotinib after Gefitinib Failure in Typical Gefitinib-Sensitive Asian Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:4, 400-404
CrossRef863
Gary M. Clark. (2008) Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib. Molecular Oncology 1:4, 406-412
CrossRef864
Shang-Gin Wu, Jin-Yuan Shih, Chong-Jen Yu, Pan-Chyr Yang. (2008) Lung Adenocarcinoma with Good Response to Erlotinib after Gefitinib Treatment Failure and Acquired T790M Mutation. Journal of Thoracic Oncology 3:4, 451-452
CrossRef865
Cesare Gridelli, Andrea Ardizzoni, Fortunato Ciardiello, Nasser Hanna, John V. Heymach, Francesco Perrone, Rafael Rosell, Frances A. Shepherd, Nick Thatcher, Johan Vansteenkiste, Luigi De Petris, Massimo Di Maio, Filippo De Marinis. (2008) Second-Line Treatment of Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:4, 430-440
CrossRef866
Philipp C. Manegold, Georg Lurje, Alexandra Pohl, Yan Ning, Wu Zhang, Heinz-Josef Lenz. (2008) Can we predict the response to epidermal growth factor receptor targeted therapy?. Targeted Oncology 3:2, 87-99
CrossRef867
Ciardiello, Fortunato, Tortora, Giampaolo, . (2008) EGFR Antagonists in Cancer Treatment. New England Journal of Medicine 358:11, 1160-1174
Full Text868
K Tamura, I Okamoto, T Kashii, S Negoro, T Hirashima, S Kudoh, Y Ichinose, N Ebi, K Shibata, T Nishimura, N Katakami, T Sawa, E Shimizu, J Fukuoka, T Satoh, M Fukuoka. (2008) Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). British Journal of Cancer 98:5, 907-914
CrossRef869
Maria C Shoshan, Stig Linder. (2008) Target specificity and off-target effects as determinants of cancer drug efficacy. Expert Opinion on Drug Metabolism & Toxicology 4:3, 273-280
CrossRef870
Fred R. Hirsch, Rafal Dziadziuszko, Nick Thatcher, Helen Mann, Claire Watkins, Dinah V. Parums, Georgina Speake, Brian Holloway, Paul A. Bunn, Wilbur A. Franklin. (2008) Epidermal growth factor receptor immunohistochemistry. Cancer 112:5, 1114-1121
CrossRef871
Ferenc Pinter, Judit Papay, Andrea Almasi, Zoltan Sapi, Edit Szabo, Melinda Kanya, Anna Tamasi, Balazs Jori, Edit Varkondi, Judit Moldvay, Klara Szondy, Gyorgy Keri, Massimo Dominici, Pierfranco Conte, Sandor Eckhardt, Laszlo Kopper, Richard Schwab, Istvan Petak. (2008) Epidermal Growth Factor Receptor (EGFR) High Gene Copy Number and Activating Mutations in Lung Adenocarcinomas Are Not Consistently Accompanied by Positivity for EGFR Protein by Standard Immunohistochemistry. The Journal of Molecular Diagnostics 10:2, 160-168
CrossRef872
Suresh Ramalingam, Judy Forster, Cynthia Naret, Terry Evans, Matt Sulecki, Haolan Lu, Paola Teegarden, Martin R. Weber, Chandra P. Belani. (2008) Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients with Refractory Non-small Cell Lung Cancer (NSCLC): A Phase I Study. Journal of Thoracic Oncology 3:3, 258-264
CrossRef873
Takayuki Fukui, Tetsuya Mitsudomi. (2008) Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. General Thoracic and Cardiovascular Surgery 56:3, 97-103
CrossRef874
Cesare Gridelli. (2008) Targeted therapy developments in the treatment of non-small cell lung cancer: a promising but long and winding road. Current Opinion in Oncology 20:2, 145-147
CrossRef875
Paul Wheatley-Price, Frances A Shepherd. (2008) Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Current Opinion in Oncology 20:2, 162-175
CrossRef876
V Gregorc, M Hidalgo, A Spreafico, G Cusatis, V Ludovini, RG Ingersoll, S Marsh, SM Steinberg, MG Viganò, D Ghio, E Villa, A Sparreboom, SD Baker. (2008) Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib. Clinical Pharmacology & Therapeutics 83:3, 477-484
CrossRef877
Noboru Yamamoto, Atsushi Horiike, Yasuhito Fujisaka, Haruyasu Murakami, Tatsu Shimoyama, Yasuhide Yamada, Tomohide Tamura. (2008) Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemotherapy and Pharmacology 61:3, 489-496
CrossRef878
Thomas Fong, Daniel Morgensztern, Ramaswamy Govindan. (2008) EGFR Inhibitors as First-Line Therapy in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:3, 303-310
CrossRef879
Alex Y Chang. (2008) The role of gefitinib in the management of Asian patients with non-small cell lung cancer. Expert Opinion on Investigational Drugs 17:3, 401-411
CrossRef880
F. Grossi, A. Brianti, C. Defferrari, P. Pronzato. (2008) Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations. memo - Magazine of European Medical Oncology 1:1, 13-16
CrossRef881
Jie Ling, Scott Fettner, Bert L. Lum, Myriam Riek, Ashok Rakhit. (2008) Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anti-Cancer Drugs 19:2, 209-216
CrossRef882
Yataro Daigo, Yusuke Nakamura. (2008) From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. General Thoracic and Cardiovascular Surgery 56:2, 43-53
CrossRef883
Chris Twelves, José M. Trigo, Rob Jones, Flavio De Rosa, Ashok Rakhit, Scott Fettner, Tonya Wright, José Baselga. (2008) Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: A dose-escalation study. European Journal of Cancer 44:3, 419-426
CrossRef884
Karen L. Reckamp, Brian K. Gardner, Robert A. Figlin, David Elashoff, Kostyantyn Krysan, Mariam Dohadwala, Jenny Mao, Sherven Sharma, Landon Inge, Ayyappan Rajasekaran, Steven M. Dubinett. (2008) Tumor Response to Combination Celecoxib and Erlotinib Therapy in Non-small Cell Lung Cancer Is Associated with a Low Baseline Matrix Metalloproteinase-9 and a Decline in Serum-Soluble E-Cadherin. Journal of Thoracic Oncology 3:2, 117-124
CrossRef885
Sanjay Popat, Yolanda Barbachano, Sue Ashley, Alison Norton, Mary O’Brien. (2008) Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer. Lung Cancer 59:2, 227-231
CrossRef886
Floris A. de Jong, Alex Sparreboom, Jaap Verweij, Ron H.J. Mathijssen. (2008) Lifestyle habits as a contributor to anti-cancer treatment failure. European Journal of Cancer 44:3, 374-382
CrossRef887
Lecia V. Sequist, Thomas J. Lynch. (2008) EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story. Annual Review of Medicine 59:1, 429-442
CrossRef888
Daniela D. Rosa, Gustavo Ismael, Lissandra Dal Lago, Ahmad Awada. (2008) Molecular-targeted therapies: Lessons from years of clinical development. Cancer Treatment Reviews 34:1, 61-80
CrossRef889
Daniel Morgensztern, Boone Goodgame, Maria Q. Baggstrom, Feng Gao, Ramaswamy Govindan. (2008) The Effect of FDG-PET on the Stage Distribution of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:2, 135-139
CrossRef890
S Savic, C Tapia, B Grilli, A Rufle, M P Bihl, A de Vito Barascud, M Herzog, L Terracciano, F Baty, L Bubendorf. (2008) Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. British Journal of Cancer 98:1, 154-160
CrossRef891
Christopher G. Azzoli, Bernard J. Park, William Pao, Maureen Zakowski, Mark G. Kris. (2008) Molecularly Tailored Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:1, 84-93
CrossRef892
Ashok Rakhit, Michael P. Pantze, Scott Fettner, Hannah M. Jones, Jean-Eric Charoin, Myriam Riek, Bert L. Lum, Marta Hamilton. (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition. European Journal of Clinical Pharmacology 64:1, 31-41
CrossRef893
Katsuyuki Kiura, Nagio Takigawa, Isao Oze, Masayuki Yasugi, Nobuaki Ochi, Daijiro Harada, Mitsune Tanimoto. (2008) Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 119:3, 285-292
CrossRef894
Afshin Dowlati, Amy Kluge, David Nethery, Balazs Halmos, Jeffrey A. Kern. (2008) SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2. Anti-Cancer Drugs 19:1, 9-16
CrossRef895
Lisa A. Hammond-Thelin. (2008) Cutaneous Reactions Related to Systemic Immunomodulators and Targeted Therapeutics. Dermatologic Clinics 26:1, 121-159
CrossRef896
Dae Sik Kim, Jae Sook Sung, Eun Soon Shin, Jeong-Seon Ryu, In Keun Choi, Kyong Hwa Park, Yong Park, Eui Bae Kim, Seh Jong Park, Yeul Hong Kim. (2008) Association of Single Nucleotide Polymorphisms in PIM-1 Gene with the Risk of Korean Lung Cancer. Cancer Research and Treatment 40:4, 190
CrossRef897
Joachim von Pawel, Horst Wagner, Thomas Duell, Barbara Poellinger. (2008) Erlotinib in Patients with Previously Irradiated, Recurrent Brain Metastases from Non-Small Cell Lung Cancer: Two Case Reports. Onkologie 31:3, 123-126
CrossRef898
Inderpal S. Sarkaria, Maureen F. Zakowski, Duykhanh Pham, Michael Hezel, Michael I. Ebright, Shaokun Chuai, Ennapadam S. Venkatraman, Mark G. Kris, Valerie W. Rusch, Bhuvanesh Singh. (2008) Epidermal Growth Factor Receptor Signaling in Adenocarcinomas With Bronchioloalveolar Components. The Annals of Thoracic Surgery 85:1, 216-223
CrossRef899
Madeleine Duvic. (2008) EGFR Inhibitor-Associated Acneiform Folliculitis. American Journal of Clinical Dermatology 9:5, 285-294
CrossRef900
María Sereno, Antonella Brunello, Alberto Chiappori, Jorge Barriuso, Enrique Casado, Cristóbal Belda, Javier Castro, Jaime Feliu, Manuel González-Barón. (2008) Cardiac toxicity: old and new issues in anti-cancer drugs. Clinical and Translational Oncology 10:1, 35-46
CrossRef901
Wolfgang A Weber, Johannes Czernin, Michael E Phelps, Harvey R Herschman. (2008) Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nature Clinical Practice Oncology 5:1, 44-54
CrossRef902
Franklin L. Chen, Andrew J. Armstrong, Daniel J. George. (2008) Cell Signaling Modifiers in Prostate Cancer. The Cancer Journal 14:1, 40-45
CrossRef903
Kun-ta Chou, Yuh-Min Chen, Jen-Fu Shih, Reury-Perng Perng, Chun-Ming Tsai, Jacqueline Whang-Peng. (2008) Phase II randomized study of weekly docetaxel alone or plus UFUR treatment in non-small cell lung cancer patients who failed previous chemotherapy. Lung Cancer 59:1, 64-68
CrossRef904
Peter Ebeling, Lewin Eisele, Philipp Schuett, Sebastian Bauer, Jochen Schuette, Thomas Moritz, Siegfried Seeber, Michael Flasshove. (2008) Docetaxel and Gemcitabine in the Treatment of Soft Tissue Sarcoma – A Single-Center Experience. Onkologie 31:1-2, 11-16
CrossRef905
Rachel E. Sanborn, David A. Sauer. (2008) Cutaneous Reactions to Chemotherapy: Commonly Seen, Less Described, Little Understood. Dermatologic Clinics 26:1, 103-119
CrossRef906
Kye Young Lee. (2008) Targeted Therapy of Lung Cancer. Journal of the Korean Medical Association 51:5, 483
CrossRef907
Isabelle Madelaine, Pierre Faure, Pierre Faure, Julie Berthou. 2008. Traitement des cancers bronchique, colorectal, du sein et de l'ovaire. , 621-644.
CrossRef908
Shirish M. Gadgeel, Shadan Ali, Philip A. Philip, Fakhara Ahmed, Antoinette Wozniak, Fazlul H. Sarkar. (2007) Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor. Cancer 110:12, 2775-2784
CrossRef909
A G Pallis, A Voutsina, Ar Kalikaki, J Souglakos, E Briasoulis, S Murray, A Koutsopoulos, M Tripaki, E Stathopoulos, D Mavroudis, V Georgoulias. (2007) ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. British Journal of Cancer 97:11, 1560-1566
CrossRef910
Shay Ashouri, Agustin A. Garcia. (2007) Current Status of Signal Transduction Modulators in the Treatment of Gynecologic Malignancies. Current Treatment Options in Oncology 8:6, 383-392
CrossRef911
Emmanuelle Wesarg, Sandra Hoffarth, Rainer Wiewrodt, Monika Kröll, Stefan Biesterfeld, Christoph Huber, Martin Schuler. (2007) Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. International Journal of Cancer 121:11, 2387-2394
CrossRef912
José Jimeno. (2007) Role of target expression as inclusion criteria. European Journal of Cancer Supplements 5:9, 41-42
CrossRef913
Valérie Gounant, Marie Wislez, Virginie Poulot, Antoine Khalil, Armelle Lavole, Jacques Cadranel, Bernard Milleron. (2007) Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer. Lung Cancer 58:3, 425-428
CrossRef914
John Wen-Cheng Chang, Chun-Liang Chou, Shiu-Feng Huang, Hung-Ming Wang, Jia-Juan Hsieh, Todd Hsu, Yun-Chung Cheung. (2007) Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer. Lung Cancer 58:3, 414-417
CrossRef915
Tsuyoshi Suzuki, Akihiro Fujii, Junichi Ohya, Yusaku Amano, Yasunori Kitano, Daisuke Abe, Hideo Nakamura. (2007) Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor. Cancer Science 98:12, 1977-1984
CrossRef916
Paul M. Armistead, Jason Salganick, Jae S. Roh, Dejka M. Steinert, Shreyaskumar Patel, Mark Munsell, Adel K. El-Naggar, Robert S. Benjamin, Wei Zhang, Jonathan C. Trent. (2007) Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma. Cancer 110:10, 2293-2303
CrossRef917
S. H. Kardaun, K. F. van Duinen. (2007) Erlotinib-induced florid acneiform rash complicated by extensive impetiginization. Clinical and Experimental Dermatology 0:0, 071106211831001-???
CrossRef918
Emma J Dean, Malcolm Ranson, Fiona Blackhall, Caroline Dive. (2007) X-linked inhibitor of apoptosis protein as a therapeutic target. Expert Opinion on Therapeutic Targets 11:11, 1459-1471
CrossRef919
Tae-You Kim, Sae-Won Han, Yung-Jue Bang. (2007) Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. Expert Review of Molecular Diagnostics 7:6, 821-836
CrossRef920
Yuichi Takiguchi, Tetsuro Moriya, Yoshiko Asaka-Amano, Tatsuo Kawashima, Katsushi Kurosu, Yuji Tada, Keiichi Nagao, Takayuki Kuriyama. (2007) Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer. Lung Cancer 58:2, 253-259
CrossRef921
H. Labrosse, B. Favier, J. Fayette. (2007) Pharmacologie des thérapeutiques ciblées. Oncologie 9:11, 773-777
CrossRef922
Howard A. Fine. (2007) Promising New Therapies for Malignant Gliomas. The Cancer Journal 13:6, 349-354
CrossRef923
Alexander Knabl. (2007) TRUST-Studie: Praxisrelevante Daten zu Erlotinib beim NSCLC. Wiener Medizinische Wochenschrift 157:21-22, 579-580
CrossRef924
David Osoba, Andrea Bezjak, Michael Brundage, Joseph Pater. (2007) Evaluating Health-Related Quality of Life in Cancer Clinical Trials: The National Cancer Institute of Canada Clinical Trials Group Experience. Value in Health 10, S138-S145
CrossRef925
Geoffrey R. Oxnard, Panos Fidias, Alona Muzikansky, Lecia V. Sequist. (2007) Non-small Cell Lung Cancer in Octogenarians: Treatment Practices and Preferences. Journal of Thoracic Oncology 2:11, 1029-1035
CrossRef926
Ferdinand Ploner. (2007) NSCLC: Update der 2nd line Therapie nach ASCO 2007. Wiener Medizinische Wochenschrift 157:21-22, 540-544
CrossRef927
Georg Pall, Wolfgang Hilbe. (2007) "Targeted Therapies" beim NSCLC – Gegenwart und Zukunft. Wiener Medizinische Wochenschrift 157:21-22, 545-553
CrossRef928
Bharat B. Aggarwal, Gautam Sethi, Veera Baladandayuthapani, Sunil Krishnan, Shishir Shishodia. (2007) Targeting cell signaling pathways for drug discovery: An old lock needs a new key. Journal of Cellular Biochemistry 102:3, 580-592
CrossRef929
Giuseppe Giaccone, Egbert Smit, Suresh Senan, Rick Paul. 2007. Multidisciplinary Team Management of Lung Cancer. .
CrossRef930
George K. Philips, Susan Halabi, Ben L. Sanford, Dean Bajorin, Eric J. Small, . (2007) A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU International 0:0, 071008070648004-???
CrossRef931
L. V. Rubinstein, J. E. Dancey, E. L. Korn, M. A. Smith, J. J. Wright. (2007) Early Average Change in Tumor Size in a Phase 2 Trial: Efficient Endpoint or False Promise?. JNCI Journal of the National Cancer Institute 99:19, 1422-1423
CrossRef932
T. G. Karrison, M. L. Maitland, W. M. Stadler, M. J. Ratain. (2007) Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute 99:19, 1455-1461
CrossRef933
Rob J. Jones, Tamsin Boyce, Michael Fennell, Vivien Jacobs, Francesco Pinto, Emma Duffield, Glen Clack, Tim Green, John Kelly, John Robertson. (2007) The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers. Cancer Chemotherapy and Pharmacology 61:1, 23-32
CrossRef934
Cesare Gridelli. (2007) Elderly lung cancer patients: what treatment strategies?. Expert Review of Anticancer Therapy 7:10, 1331-1334
CrossRef935
Manrique Alvarez, Eloy Roman, Edgardo S Santos, Luis E Raez. (2007) New targets for non-small-cell lung cancer therapy. Expert Review of Anticancer Therapy 7:10, 1423-1437
CrossRef936
Kiyotaka Yoh, Kaoru Kubota, Ryutaro Kakinuma, Hironobu Ohmatsu, Koichi Goto, Seiji Niho, Nagahiro Saijo, Yutaka Nishiwaki. (2007) Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy. Lung Cancer 58:1, 73-79
CrossRef937
M. Pérol, D. Arpin. (2007) Les inhibiteurs de tyrosine kinase de l’EGFR dans le traitement du CBNPC. Revue des Maladies Respiratoires 24:8, 188-197
CrossRef938
P.-J. Souquet. (2007) Cancer bronchique non à petites cellules : du traitement de la rechute aux traitements des rechutes. Revue des Maladies Respiratoires 24:8, 108-113
CrossRef939
Minggui Pan, Monica Santamaria, David B Wollman. (2007) CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. Nature Clinical Practice Oncology 4:10, 603-607
CrossRef940
Paraic A Kenny. (2007) Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. Expert Opinion on Therapeutic Targets 11:10, 1287-1298
CrossRef941
Sophie Sun, Joan H. Schiller, Adi F. Gazdar. (2007) Lung cancer in never smokers — a different disease. Nature Reviews Cancer 7:10, 778-790
CrossRef942
Daniel B. Costa, Susumu Kobayashi, Daniel G. Tenen, Mark S. Huberman. (2007) Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58:1, 95-103
CrossRef943
Sophie Sun, Joan H. Schiller, Monica Spinola, John D. Minna. (2007) New molecularly targeted therapies for lung cancer. Journal of Clinical Investigation 117:10, 2740-2750
CrossRef944
Cesare Gridelli, Antonio Rossi, Paolo Maione, Giuseppe Colantuoni, Filomena Del Gaizo, Carmine Ferrara, Dario Nicolella, Ciro Guerriero. (2007) Erlotinib in non-small-cell lung cancer. Expert Opinion on Pharmacotherapy 8:15, 2579-2592
CrossRef945
Giovanna Finocchiaro, Luca Toschi, Isabella Garassino, Fabio De Vincenzo, Elisabetta Campagnoli, Paolo Zucali, Raffaele Cavina, Giovanni L Ceresoli, Armando Santoro, Federico Cappuzzo. (2007) EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?. Expert Opinion on Medical Diagnostics 1:2, 183-191
CrossRef946
D. Moro-Sibilot, E. Pluquet, G. Zalcman, J.-M. Bréchot, P.-J. Souquet, D. Debieuvre, F. Morin, J.-F. Morère. (2007) Quel traitement pour un patient de PS-2/3 ayant un cancer bronchique non à petites cellules (CBNPC). Revue des Maladies Respiratoires 24:8, 120-124
CrossRef947
C.-C. Lin, K. P. Papadopoulos. (2007) Novel targeted therapies for advanced esophageal cancer. Diseases of the Esophagus 20:5, 365-371
CrossRef948
Aya Jakobovits, Rafael G Amado, Xiaodong Yang, Lorin Roskos, Gisela Schwab. (2007) From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nature Biotechnology 25:10, 1134-1143
CrossRef949
C Massard, J-J Voigt, A Laplanche, S Culine, A Lortholary, R Bugat, C Theodore, F Priou, M-C Kaminsky, T Lesimple, X Pivot, B Coudert, J-Y Douillard, Y Merrouche, K Fizazi. (2007) Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?. British Journal of Cancer
CrossRef950
Piyush K Agarwal, Peter C Black, David J McConkey, Colin PN Dinney. (2007) Emerging drugs for targeted therapy of bladder cancer. Expert Opinion on Emerging Drugs 12:3, 435-448
CrossRef951
Enriqueta Felip, Mariacarmela Santarpia, Rafael Rosell. (2007) Emerging drugs for non-small-cell lung cancer. Expert Opinion on Emerging Drugs 12:3, 449-460
CrossRef952
Junichi Soh, Shinichi Toyooka, Shuji Ichihara, Yoshiro Fujiwara, Katsuyuki Hotta, Hiroshi Suehisa, Naruyuki Kobayashi, Kouichi Ichimura, Keisuke Aoe, Motoi Aoe, Katsuyuki Kiura, Hiroshi Date. (2007) Impact ofHER2 andEGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer. International Journal of Cancer 121:5, 1162-1167
CrossRef953
Yaara Zwang, Yosef Yarden. (2007) Growth factor signalling: ample opportunities for pharmaceutical interventions in oncology. European Journal of Cancer Supplements 5:5, 427-429
CrossRef954
Peter C. Black, Piyush K. Agarwal, Colin P.N. Dinney. (2007) Targeted therapies in bladder cancer—an update. Urologic Oncology: Seminars and Original Investigations 25:5, 433-438
CrossRef955
Janakiraman Subramanian, Vamsidhar Velcheti, Feng Gao, Ramaswamy Govindan. (2007) Presentation and Stage-Specific Outcomes of Lifelong Never-smokers with Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 2:9, 827-830
CrossRef956
Jerry M. Maniate, Sri Navaratnam, Mary Cheang, Sat Sharma. (2007) Outcome of Lung Cancer Patients Admitted to the Intensive Care Unit. Clinical Pulmonary Medicine 14:5, 281-285
CrossRef957
Tal Grenader, Maya Gipps, Linda Shavit, Alberto Gabizon. (2007) Significant drug interaction: Phenytoin toxicity due to erlotinib. Lung Cancer 57:3, 404-406
CrossRef958
Victoria A Joshi, Raju Kucherlapati. (2007) Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies. Pharmacogenomics 8:9, 1211-1220
CrossRef959
Maria Q. Baggstrom, Thomas E. Stinchcombe, Daniel B. Fried, Charles Poole, Thomas A. Hensing, Mark A. Socinski. (2007) Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis. Journal of Thoracic Oncology 2:9, 845-853
CrossRef960
Veronika Sárosi, Zoltán Balikó. (2007) Erlotinib (Tarceva <sup>®</sup> ) in Second/Third Line Treatment for Non-Small Cell Lung Cancer (NSCLC) – Case Description. Hungarian Medical Journal 1:3, 307-313
CrossRef961
Elwyn Cabebe, Heather Wakelee. (2007) Role of Anti-angiogenesis Agents in Treating NSCLC: Focus on Bevacizumab and VEGFR Tyrosine Kinase Inhibitors. Current Treatment Options in Oncology 8:1, 15-27
CrossRef962
Christine L. Hann, Julie R. Brahmer. (2007) “Who Should Receive Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer and When?”. Current Treatment Options in Oncology 8:1, 28-37
CrossRef963
Gowri L Kanthan, Jay Jayamohan, Desmond Yip, R Max Conway. (2007) Management of metastatic carcinoma of the uveal tract: an evidence-based analysis. Clinical & Experimental Ophthalmology 35:6, 553-565
CrossRef964
Marin Marinov, Barbara Fischer, Alexandre Arcaro. (2007) Targeting mTOR signaling in lung cancer. Critical Reviews in Oncology/Hematology 63:2, 172-182
CrossRef965
J Nemunaitis, J S Vorhies, B Pappen, N Senzer. (2007) 10-year follow-up of gene-modified adenoviral-based therapy in 146 non-small-cell lung cancer patients. Cancer Gene Therapy 14:8, 762-763
CrossRef966
Cesare Gridelli, Paolo Maione, Domenico Galetta, Guiseppe Colantuoni, Filomena Del Gaizo, Carmine Ferrara, Ciro Guerriero, Dario Nicolella, Antonio Rossi. (2007) Three Cases of Long-Lasting Tumor Control with Erlotinib after Progression with Gefitinib in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 2:8, 758-761
CrossRef967
Veronika Sárosi, Zoltán Balikó. (2007) Erlotinib a nem kissejtes tüdőrák második-harmadik vonalbeli kezelésében. Orvosi Hetilap 148:32, 1525-1529
CrossRef968
James MG Larkin, Simon Chowdhury, Martin E Gore. (2007) Drug Insight: advances in renal cell carcinoma and the role of targeted therapies. Nature Clinical Practice Oncology 4:8, 470-479
CrossRef969
Dany Gholam, Amale Chebib, Dominique Hauteville, Marie-Pierre Bralet, Claude Jasmin. (2007) Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer. Anti-Cancer Drugs 18:7, 835-837
CrossRef970
Bilal Piperdi, Yi-He Ling, Roman Perez-Soler. (2007) Schedule-Dependent Interaction between the Proteosome Inhibitor Bortezomib and the EGFR-TK Inhibitor Erlotinib in Human Non-small Cell Lung Cancer Cell Lines. Journal of Thoracic Oncology 2:8, 715-721
CrossRef971
Tony S. Mok. (2007) Salvage therapy for NSCLC. Journal of Thoracic Oncology 2:Supplement 4, S289-290
CrossRef972
Rafal Dziadziuszko, Fred R. Hirsch. (2007) Selecting lung cancer patients to targeted therapies based on protein expression by immunohistochemistry. Journal of Thoracic Oncology 2:Supplement 4, S157-S158
CrossRef973
Andrew X. Zhu, Keith Stuart, Lawrence S. Blaszkowsky, Alona Muzikansky, Donald P. Reitberg, Jeffrey W. Clark, Peter C. Enzinger, Pankaj Bhargava, Jeffrey A. Meyerhardt, Kerry Horgan, Charles S. Fuchs, David P. Ryan. (2007) Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110:3, 581-589
CrossRef974
Anastassios V. Koutsopoulos, Dimitris Mavroudis, Konstantina I. Dambaki, John Souglakos, Eleni G. Tzortzaki, John Drositis, George S. Delides, Vassilis Georgoulias, Efstathios N. Stathopoulos. (2007) Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: Correlation with clinical outcome. Lung Cancer 57:2, 193-200
CrossRef975
Andrew H. Ko. (2007) Future Strategies for Targeted Therapies and Tailored Patient Management in Pancreatic Cancer. Seminars in Oncology 34:4, 354-364
CrossRef976
Weitian Liu, Frederick L. Makrauer, Amir A. Qamar, Pasi A. Jänne, Robert D. Odze. (2007) Fulminant Hepatic Failure Secondary to Erlotinib. Clinical Gastroenterology and Hepatology 5:8, 917-920
CrossRef977
Giovanni Selvaggi, Giorgio Vittorio Scagliotti. (2007) Perspectives in adjuvant chemotherapy in NSCLC. Expert Review of Respiratory Medicine 1:1, 99-110
CrossRef978
Y Minami, T Shimamura, K Shah, T LaFramboise, K A Glatt, E Liniker, C L Borgman, H J Haringsma, W Feng, B A Weir, A M Lowell, J C Lee, J Wolf, G I Shapiro, K-K Wong, M Meyerson, R K Thomas. (2007) The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 26:34, 5023-5027
CrossRef979
Martin Sebastian, Bernward Passlick, Hilke Friccius-Quecke, Michael Jäger, Horst Lindhofer, Frank Kanniess, Rainer Wiewrodt, Eckhard Thiel, Roland Buhl, Alexander Schmittel. (2007) Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study. Cancer Immunology, Immunotherapy 56:10, 1637-1644
CrossRef980
Sera Tort, Dolores Gallardo, Fergus MacBeth, Maria Cinta Pallarès, Ivan Solà, Sera Tort. 2007. Erlotinib for advanced non-small cell lung cancer. .
CrossRef981
Christos Chouaid, Isabelle Monnet, Gilles Robinet, Maurice Perol, Pierre Fournel, Alain Vergnenegre. (2007) Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis. Current Medical Research and Opinion 23:7, 1509-1515
CrossRef982
Rosalyn Juergens, Julie Brahmer. (2007) Targeting the epidermal growth factor receptor in non-small-cell lung cancer: Who, which, when, and how?. Current Oncology Reports 9:4, 255-264
CrossRef983
Dan J Raz, Jae Y Kim, David M Jablons. (2007) Diagnosis and treatment of bronchioloalveolar carcinoma. Current Opinion in Pulmonary Medicine 13:4, 290-296
CrossRef984
David R. Gandara, Heather Wakelee, Royce Calhoun, David Jablons. (2007) Adjuvant Chemotherapy of Stage I Non-small Cell Lung Cancer in North America. Journal of Thoracic Oncology 2:Supplement 3, S125-S127
CrossRef985
Danan Li, Takeshi Shimamura, Hongbin Ji, Liang Chen, Henry J. Haringsma, Kate McNamara, Mei-Chih Liang, Samanthi A. Perera, Sara Zaghlul, Christa L. Borgman, Shigeto Kubo, Masaya Takahashi, Yanping Sun, Lucian R. Chirieac, Robert F. Padera, Neal I. Lindeman, Pasi A. Jänne, Roman K. Thomas, Matthew L. Meyerson, Michael J. Eck, Jeffrey A. Engelman, Geoffrey I. Shapiro, Kwok-Kin Wong. (2007) Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy. Cancer Cell 12:1, 81-93
CrossRef986
Francesco Grossi, Marianna Aita. (2007) Bevacizumab and non-small-cell lung cancer. Expert Opinion on Biological Therapy 7:7, 1107-1119
CrossRef987
B. Alt-Epping, W. Jung, F. Nauck. (2007) Symptomkontrollierende Effekte der Chemotherapie. Der Onkologe 13:7, 619-624
CrossRef988
Fernando J. Barata, Ana Filipa Costa. (2007) Carcinoma do pulmão de pequenas células – Estado da arte e perspectivas futuras. Revista Portuguesa de Pneumologia (English Edition) 13:4, 587-604
CrossRef989
Angela M Davies, Cheryl Ho, Paul J Hesketh, Laurel A Beckett, Primo N Lara, Derick HM Lau, David R Gandara. (2007) Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study. Investigational New Drugs 25:4, 351-355
CrossRef990
F. Taguchi, B. Solomon, V. Gregorc, H. Roder, R. Gray, K. Kasahara, M. Nishio, J. Brahmer, A. Spreafico, V. Ludovini, P. P. Massion, R. Dziadziuszko, J. Schiller, J. Grigorieva, M. Tsypin, S. W. Hunsucker, R. Caprioli, M. W. Duncan, F. R. Hirsch, P. A. Bunn, D. P. Carbone. (2007) Mass Spectrometry to Classify Non-Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study. JNCI Journal of the National Cancer Institute 99:11, 838-846
CrossRef991
Ken Y. Yoneda, David K. Shelton, Laurel A. Beckett, David R. Gandara. (2007) Independent Review of Interstitial Lung Disease Associated with Death in TRIBUTE (Paclitaxel and Carboplatin with or without Concurrent Erlotinib) in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:6, 537-543
CrossRef992
J. Cadranel, M. Wislez, V. Gounant, A. Lavolé, M. Antoine, B. Milleron. (2007) Prise en charge thérapeutique des adénocarcinomes de type bronchiolo-alvéolaires étendus : chimiothérapie ou inhibiteurs de la tyrosine kinase du récepteur de l’epidermal growth factor ?. Revue de Pneumologie Clinique 63:3, 147-154
CrossRef993
Nathan A Pennell, Lecia V Sequist. (2007) Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors. Biomarkers in Medicine 1:1, 203-207
CrossRef994
Stephen A Welch, Malcolm J Moore. (2007) Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer. Future Oncology 3:3, 247-254
CrossRef995
Frances A Shepherd, Rafael Rosell. (2007) Weighing Tumor Biology in Treatment Decisions for Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:Suppl 2, S68-S76
CrossRef996
Rafael Rosell, Miquel Taron, Jose Javier Sanchez, Luis Paz-Ares. (2007) Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Oncology 3:3, 277-283
CrossRef997
Alison ARMOUR. (2007) Gefitinib in advanced non-small cell lung cancer: Clinical experience in patients of Asian origin. Asia-Pacific Journal of Clinical Oncology 3:2, 66-78
CrossRef998
Jia-Lin Yang, Xian-Jun Qu, Vanessa M. Hayes, Phillip C. Brenner, Pamela J. Russell, David Goldstein. (2007) Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-?. BJU International 99:6, 1539-1545
CrossRef999
Aleix Prat, Josep Baselga. (2007) Bioterapia: aplicaciones actuales y futuras en oncología. Medicina Clínica 129:5, 184-193
CrossRef1000
Michael Baumann, Mechthild Krause, Ekkehard Dikomey, Klaus Dittmann, Wolfgang Dörr, Ulla Kasten-Pisula, H. Peter Rodemann. (2007) EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms. Radiotherapy and Oncology 83:3, 238-248
CrossRef1001
Kiyoshi Mori, Yukari Kamiyama, Tetsuro Kondo, Yasuhiko Kano, Tetsuro Kodama. (2007) Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology 60:2, 189-195
CrossRef1002
Takashi Hirose, Takao Shirai, Hiroo Ishida, Kohichi Ando, Tomohide Sugiyama, Sojiro Kusumoto, Takamichi Hosaka, Masanao Nakashima, Tohru Ohmori, Mitsuru Adachi. (2007) Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 60:2, 267-274
CrossRef1003
Anthony W. Tolcher, Anthony W. Tolcher. 2007. Other Novel Targeted Therapies in Lung Cancer. , 123-148.
CrossRef1004
Rafal Dziadziuszko, Barbara Szostakiewicz, Fred R. Hirsch. 2007. Epidermal Growth Factor Receptor Targeted Therapy—Markers of Sensitivity and Response. , 97-122.
CrossRef1005
Federico Cappuzzo, Claudio Ligorio, Luca Toschi, Elisa Rossi, Rocco Trisolini, Daniela Paioli, Elisabetta Magrini, Giovanna Finocchiaro, Stefania Bartolini, Alessandra Cancellieri, Fred R. Hirsch, Lucio Crino, Marileila Varella-Garcia. (2007) EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 2:5, 423-429
CrossRef1006
Katsuyuki Hotta, Yoshiro Fujiwara, Katsuyuki Kiura, Nagio Takigawa, Masahiro Tabata, Hiroshi Ueoka, Mitsune Tanimoto. (2007) Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in 143 Phase III Trials. Journal of Thoracic Oncology 2:5, 402-407
CrossRef1007
T Macarulla, J Tabernero. 2007. Safety of targeted therapies. , 141-155.
CrossRef1008
Leora Horn, Alan Sandler. (2007) Lung Cancer Adjuvant Therapy. The Cancer Journal 13:3, 210-216
CrossRef1009
Yi-Long Wu, Wen-Zhao Zhong, Long-Yun Li, Xiao-Tong Zhang, Li Zhang, Cai-Cun Zhou, Wei Liu, Bin Jiang, Xin-Lin Mu, Jia-Ying Lin, Qing Zhou, Chong-Rui Xu, Zhen Wang, Guo-Chun Zhang, Tony Mok. (2007) Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China. Journal of Thoracic Oncology 2:5, 430-439
CrossRef1010
Andrea Ardizzoni, Marcello Tiseo. (2007) Combination of Target Agents: Challenges and Opportunities. Journal of Thoracic Oncology 2:Supplement 1, S4-S6
CrossRef1011
Lela E. Buckingham, John S. Coon, Larry E. Morrison, Kristine K. B. Jacobson, Susan S. Jewell, Kelly A. Kaiser, Ann M. Mauer, Tariq Muzzafar, Clayton Polowy, Sanjib Basu, Meryl Gale, Victoria M. Villaflor, Philip Bonomi. (2007) The Prognostic Value of Chromosome 7 Polysomy in Non-small Cell Lung Cancer Patients Treated with Gefitinib. Journal of Thoracic Oncology 2:5, 414-422
CrossRef1012
Sae-Won Han, Yoon Kyung Jeon, Kyung-Hun Lee, Bhumsuk Keam, Pil Gyu Hwang, Do-Youn Oh, Se-Hoon Lee, Dong-Wan Kim, Seock-Ah Im, Doo Hyun Chung, Dae Seog Heo, Yung-Jue Bang, Tae-You Kim. (2007) Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. Pharmacogenetics and Genomics 17:5, 313-319
CrossRef1013
Janet E. Dancey. 2007. Early Clinical Trial Design Issues: Patient Populations, End Points, and Barriers. , 25-44.
CrossRef1014
Maria Anna Bareschino, Floriana Morgillo, Fortunato Ciardiello. (2007) Combination of Standard Chemotherapy and Targeted Agents. Journal of Thoracic Oncology 2:Supplement 1, S19-S23
CrossRef1015
BC Kuenen, G Giaccone. 2007. Combination treatment. , 135-140.
CrossRef1016
Federico Cappuzzo. (2007) Predictive Factors for Response and for Resistance to Tyrosine Kinase Inhibitor Therapy in Lung Cancer. Journal of Thoracic Oncology 2:Supplement 1, S12-S14
CrossRef1017
Antonio Jimeno, Manuel Hidalgo. 2007. Epidermal Growth Factor Receptor Inhibition in Non–Small Cell Lung Cancer. , 81-96.
CrossRef1018
Wolfgang Hilbe, Kurt Aigner, Christian Dittrich, Josef Eckmayr, Michael Fiegl, Martin Flicker, Bernhard Forstner, Richard Greil, Herbert Jamnig, Gerhard Krajnik, Alois Lang, Andrea Mohn-Staudner, Herwig Schinko, Michael Studnicka, Robert Pirker, Ferdinand Ploner, Johannes Rothmund, Lothar Schiller, August Zabernigg, Sabine Zöchbauer-Müller. (2007) Expertenempfehlung 2006 zur rationalen Zweitlinien-Therapie beim nicht-kleinzelligen Bronchuskarzinom. Wiener klinische Wochenschrift 119:7-8, 259-266
CrossRef1019
Manuel Cobo, Vanesa Gutiérrez, Julia Alcaide, Inmaculada Alés, Esther Villar, Silvia Gil, Gema Durán, Joaquina Martínez, Francisco Carabantes, Juan J. Bretón, Manuel Benavides. (2007) A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status. Lung Cancer 56:2, 255-262
CrossRef1020
Amalia Milano, Rosario Vincenzo Iaffaioli, Francesco Caponigro. (2007) The proteasome: A worthwhile target for the treatment of solid tumours?. European Journal of Cancer 43:7, 1125-1133
CrossRef1021
James Spicer, Simon Chowdhury, Peter Harper. (2007) Targeting novel and established therapies for non-small cell lung cancer. Cancer Letters 250:1, 9-16
CrossRef1022
Siu, Lillian L., . (2007) Clinical Trials in the Elderly — A Concept Comes of Age. New England Journal of Medicine 356:15, 1575-1576
Full Text1023
G. Robinet, F. Barlesi, P. Fournel, H. Berard, R. Corre, A. Vergnenegre, L. Falchero, P-J. Souquet, A. Tisseron-Carrasco, C. Chouaid. (2007) Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study. Targeted Oncology 2:2, 63-71
CrossRef1024
Mitsuo Sato, David S. Shames, Adi F. Gazdar, John D. Minna. (2007) A Translational View of the Molecular Pathogenesis of Lung Cancer. Journal of Thoracic Oncology 2:4, 327-343
CrossRef1025
Philip Bonomi. (2007) Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy 7:4, 415-422
CrossRef1026
Shirish M. Gadgeel, John C. Ruckdeschel, Elisabeth I. Heath, Lance K. Heilbrun, Raghu Venkatramanamoorthy, Antoinette Wozniak. (2007) Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 2:4, 299-305
CrossRef1027
Andrew J. Graham, Fiona M. Shrive, William A. Ghali, Braden J. Manns, Sean C. Grondin, Richard J. Finley, Joanne Clifton. (2007) Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis. The Annals of Thoracic Surgery 83:4, 1257-1264
CrossRef1028
Sanjay Popat, Sarah Hughes, Panos Papadopoulos, Anna Wilkins, Sally Moore, Kathy Priest, Linda Meehan, Alison Norton, Mary O’Brien. (2007) Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung Cancer 56:1, 135-137
CrossRef1029
Rogerio Lilenbaum, Mark Rubin, Joyce Samuel, Laszlo Boros, Tarek Chidiac, Leonard Seigel, Afshin Dowlati, Patricia Graham, Jennifer Beaumont, Hongyan Du. (2007) A Randomized Phase II Trial of Two Schedules of Docetaxel in Elderly or Poor Performance Status Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:4, 306-311
CrossRef1030
Emma J. Dean, Malcolm Ranson, Fiona Blackhall, Sarah V. Holt, Caroline Dive. (2007) Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic. Cancer Treatment Reviews 33:2, 203-212
CrossRef1031
H Uramoto, T Mitsudomi. (2007) Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?. British Journal of Cancer 96:6, 857-863
CrossRef1032
Thorsten Schlomm, Andreas Erbersdobler, Martina Mirlacher, Guido Sauter. (2007) Molecular staging of prostate cancer in the year 2007. World Journal of Urology 25:1, 19-30
CrossRef1033
Shuji Ichihara, Shinichi Toyooka, Yoshiro Fujiwara, Katsuyuki Hotta, Hisayuki Shigematsu, Masaki Tokumo, Junichi Soh, Hiroaki Asano, Kouichi Ichimura, Keisuke Aoe, Motoi Aoe, Katsuyuki Kiura, Kenji Shimizu, Hiroshi Date, Nobuyoshi Shimizu. (2007) The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. International Journal of Cancer 120:6, 1239-1247
CrossRef1034
C E Ford, S K Lau, C Q Zhu, T Andersson, M S Tsao, W F Vogel. (2007) Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. British Journal of Cancer 96:5, 808-814
CrossRef1035
F. Weissinger, D. Fabbro, H. Einsele. (2007) Signalübermittlungsinhibitoren. Der Onkologe 13:3, 213-226
CrossRef1036
Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman, Daniel A. Haber. (2007) Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer 7:3, 169-181
CrossRef1037
M.V. Seiden, H.A. Burris, U. Matulonis, J.B. Hall, D.K. Armstrong, J. Speyer, J.D.A. Weber, F. Muggia. (2007) A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecologic Oncology 104:3, 727-731
CrossRef1038
David Berz, Thomas Miner, Elise McCormack, Howard Safran. (2007) HER family inhibitors in pancreatic cancer: current status and future directions. Expert Opinion on Therapeutic Targets 11:3, 337-347
CrossRef1039
Jamie A. Weydert, Michael B. Cohen. (2007) Small Peripheral Pulmonary Adenocarcinoma. Advances in Anatomic Pathology 14:2, 120-128
CrossRef1040
K. Bencardino, M. Manzoni, S. Delfanti, A. Riccardi, M. Danova, G. R. Corazza. (2007) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues. Internal and Emergency Medicine 2:1, 3-12
CrossRef1041
Fiona H Blackhall, Frances A Shepherd. (2007) Small cell lung cancer and targeted therapies. Current Opinion in Oncology 19:2, 103-108
CrossRef1042
Cesare Gridelli. (2007) Targeted therapies and non-small-cell lung cancer: new developments. Current Opinion in Oncology 19:2, 75-77
CrossRef1043
David M Jackman, Pasi A Jänne. (2007) Does erlotinib improve symptoms in patients with lung cancer?. Nature Clinical Practice Oncology 4:3, 146-147
CrossRef1044
Tina Cascone, Cesare Gridelli, Fortunato Ciardiello. (2007) Combined targeted therapies in non-small cell lung cancer: a winner strategy?. Current Opinion in Oncology 19:2, 98-102
CrossRef1045
Luciano J. Costa, Robert M. Gemmill, Harry A. Drabkin. (2007) Upstream Signaling Inhibition Enhances Rapamycin Effect on Growth of Kidney Cancer Cells. Urology 69:3, 596-602
CrossRef1046
Jianping Chen, Melissa Smith, Kenneth Kolinsky, Violeta Adames, Nila Mehta, Luke Fritzky, Mohammad Rashed, Eric Wheeldon, Michael Linn, Brian Higgins. (2007) Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models. Cancer Chemotherapy and Pharmacology 59:5, 651-659
CrossRef1047
Kim L. Wang, Tsung-Teh Wu, In Seon Choi, Huamin Wang, Erika Resetkova, Arlene M. Correa, Wayne L. Hofstetter, Stephen G. Swisher, Jaffer A. Ajani, Asif Rashid, Constance T. Albarracin. (2007) Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas. Cancer 109:4, 658-667
CrossRef1048
Im Il Na, Hye Jin Kang, Soo Youn Cho, Jae Soo Koh, Jin Kyung Lee, Byeong Cheol Lee, Guk Haeng Lee, Yong Sik Lee, Hyung Jun Yoo, Baek-Yeol Ryoo, Sung Hyun Yang, Yoon Sang Shim. (2007) EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. European Journal of Cancer 43:3, 520-526
CrossRef1049
Neeltje Steeghs, Johan W. R. Nortier, Hans Gelderblom. (2007) Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments. Annals of Surgical Oncology 14:2, 942-953
CrossRef1050
Yonatan Y Mahller, Sachin S Vaikunth, Mark A Currier, Shyra J Miller, Maria C Ripberger, Ya-Hsuan Hsu, Ruty Mehrian-Shai, Margaret H Collins, Timothy M Crombleholme, Nancy Ratner, Timothy P Cripe. (2007) Oncolytic HSV and Erlotinib Inhibit Tumor Growth and Angiogenesis in a Novel Malignant Peripheral Nerve Sheath Tumor Xenograft Model. Molecular Therapy 15:2, 279-286
CrossRef1051
Minnelly Luu, Susan E. Lai, Jyoti Patel, Joan Guitart, Mario E. Lacouture. (2007) Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatology, Photoimmunology & Photomedicine 23:1, 42-45
CrossRef1052
Gregory J. Riely, Shirish Gadgeel, Ivan Rothman, Bruce Saidman, Kert Sabbath, Kevie Feit, Mark G. Kris, Naiyer A. Rizvi. (2007) A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer 55:2, 181-185
CrossRef1053
Suresh Ramalingam, Chandra P Belani. (2007) Recent advances in targeted therapy for non-small cell lung cancer. Expert Opinion on Therapeutic Targets 11:2, 245-257
CrossRef1054
Toru Itaya, Nobuyuki Yamaoto, Masahiko Ando, Masako Ebisawa, Yukiko Nakamura, Haruyasu Murakami, Gyo Asai, Masahiro Endo, Toshiaki Takahashi. (2007) Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. Cancer Science 98:2, 226-230
CrossRef1055
Sudhir Srivastava, Paul D Wagner. (2007) Risk-based and diagnostics-linked personalized medicine for cancer. Personalized Medicine 4:1, 33-43
CrossRef1056
Roy S Herbst, John V Heymach, Michael S O’Reilly, Amir Onn, Anderson J Ryan. (2007) Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opinion on Investigational Drugs 16:2, 239-249
CrossRef1057
Matthew G. Fury, David B. Solit, Yungpo Bernard Su, Neal Rosen, F. M. Sirotnak, Robert P. Smith, Christopher G. Azzoli, Jorge E. Gomez, Vincent A. Miller, Mark G. Kris, Barbara A. Pizzo, Roxanne Henry, David G. Pfister, Naiyer A. Rizvi. (2007) A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 59:4, 467-475
CrossRef1058
Mebea Aklilu, David H. Ilson. (2007) Targeted Agents and Esophageal Cancer—The Next Step?. Seminars in Radiation Oncology 17:1, 62-69
CrossRef1059
Junji Tsurutani, Seth M. Steinberg, Marc Ballas, Matthew Robertson, Jaclyn LoPiccolo, Hiroshi Soda, Shigeru Kohno, Valgardur Egilsson, Phillip A. Dennis. (2007) Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer 55:1, 115-121
CrossRef1060
Michael F Press, Heinz-Josef Lenz. (2007) EGFR, HER2 and VEGF Pathways. Drugs 67:14, 2045-2075
CrossRef1061
Im II Na, Jin Kyung Rho, Yun Jung Choi, Cheol Hyeon Kim, Jae Soo Koh, Baek-Yeol Ryoo, Sung Hyun Yang, Jae Cheol Lee. (2007) Clinical Features Reflect Exon Sites of EGFR Mutations in Patients with Resected Non-Small-Cell Lung Cancer. Journal of Korean Medical Science 22:3, 393
CrossRef1062
Alessandra Bearz, Lucia Fratino, Simon Spazzapan, Massimiliano Berretta, Annalisa Giacalone, Cecilia Simonelli, Umberto Tirelli. (2007) Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 55:1, 125-127
CrossRef1063
N.H. Hanna. (2007) Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Yearbook of Oncology 2007, 210-211
CrossRef1064
Martin Reck. (2007) Treating Non-Small-Cell Lung Cancer First Line with Erlotinib Monotherapy in Elderly Patients: Discussion of a Case Series. Onkologie 30:10, 515-518
CrossRef1065
Fred R. Hirsch. (2007) EGFR Inhibitors in the Treatment of Lung Cancer. Onkologie 30:10, 476-476
CrossRef1066
Keisei TAKU, Narikazu BOKU. (2007) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 38:6, 393-400
CrossRef1067
Richard J Gralla, Ulrich Gatzemeier, Vittorio Gebbia, Rudolf Huber, Mary O???Brien, Christian Puozzo. (2007) Oral Vinorelbine in the Treatment of Non-Small Cell Lung Cancer. Drugs 67:10, 1403-1410
CrossRef1068
N.H. Hanna. (2007) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Yearbook of Oncology 2007, 207-210
CrossRef1069
Chandra P. Belani, Sherry Marts, Joan Schiller, Mark A. Socinski. (2007) Women and lung cancer: Epidemiology, tumor biology, and emerging trends in clinical research. Lung Cancer 55:1, 15-23
CrossRef1070
Rupert Bartsch, Catharina Wenzel, Christoph C Zielinski, Guenther G Steger. (2007) HER-2-Positive Breast Cancer. BioDrugs 21:2, 69-77
CrossRef1071
Jie Zhang, Shailaja Kalyankrishna, Marie Wislez, Nishan Thilaganathan, Babita Saigal, Wei Wei, Long Ma, Ignacio I. Wistuba, Faye M. Johnson, Jonathan M. Kurie. (2007) Src-Family Kinases Are Activated in Non-Small Cell Lung Cancer and Promote the Survival of Epidermal Growth Factor Receptor-Dependent Cell Lines. The American Journal of Pathology 170:1, 366-376
CrossRef1072
L.T. Tanoue. (2007) Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. Yearbook of Pulmonary Disease 2007, 144-146
CrossRef1073
J Nemunaitis, J Nemunaitis. (2007) A review of vaccine clinical trials for non-small cell lung cancer. Expert Opinion on Biological Therapy 7:1, 89-102
CrossRef1074
Hoon-Kyo Kim, Myeong Im Ahn, Jinyoung Yoo, Chi Hong Kim, Hong-Jun Yang, Byoung Yong Shim. (2007) Sequential Responses of Adenocarcinoma of the Lung to Erlotinib after Gefitinib in Never Smoker Korean Woman. Cancer Research and Treatment 39:1, 37
CrossRef1075
Cesare Gridelli, Paolo Maione, Domenico Galetta, Antonio Rossi. (2007) Safety Profile of Erlotinib in Patients with Advanced Non-small Cell Lung Cancer with Chronic Renal Failure. Journal of Thoracic Oncology 2:1, 96-98
CrossRef1076
Raffaella Salmi, Piergiorgio Gaudenzi, Filippo Di Todaro, Pierluigi Morandi, Ingrid Nielsen, Roberto Manfredini. (2007) Massive Thrombosis of Brachiocephalic Veins and Superior Vena Cava Syndrome in a Patient with Non-Small Cell Lung Cancer Treated with the Epidermal Growth Factor Receptor Inhibitor Erlotinib. Clinical Drug Investigation 27:7, 499-503
CrossRef1077
J. Li, M. O. Karlsson, J. Brahmer, A. Spitz, M. Zhao, M. Hidalgo, S. D. Baker. (2006) CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors. JNCI Journal of the National Cancer Institute 98:23, 1714-1723
CrossRef1078
A. Zoller, S.G. Schäd, G.E. Gross. (2006) Erlotinib-associated skin reactions ? case report and proposal for classification. British Journal of Dermatology 155:6, 1293-1295
CrossRef1079
Tawee Tanvetyanon, Gerold Bepler. (2006) Commentary: Concomitant chemotherapy and radiation for limited stage small cell lung cancer and benefit of adding additional drug into chemotherapy regimen for advanced non-small cell lung cancer. Cancer Treatment Reviews 32:8, 656-657
CrossRef1080
B. You, V. Trillet-Lenoir. (2006) Thérapeutiques anticancéreuses ciblées. La Revue de Médecine Interne 27, S285-S288
CrossRef1081
Hatem A. Azim, Apar Kishor Ganti. (2006) Targeted therapy in advanced non-small cell lung cancer (NSCLC): Where do we stand?. Cancer Treatment Reviews 32:8, 630-636
CrossRef1082
Francesco Caponigro, Amalia Milano, Alessandro Ottaiano, Rosario Vincenzo Iaffaioli. (2006) Epidermal growth factor receptor as a major anticancer drug target. Expert Opinion on Therapeutic Targets 10:6, 877-888
CrossRef1083
Federico Cappuzzo. (2006) Should every lung cancer patient be tested for EGFR mutation?. Expert Opinion on Therapeutic Targets 10:6, 789-791
CrossRef1084
Antonio Jimeno, Manuel Hidalgo. (2006) Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1766:2, 217-229
CrossRef1085
F. Stenner-Liewen, A. Zippelius, B. C. Pestalozzi, A. Knuth. (2006) Molekular zielgerichtete Therapie. Der Chirurg 77:12, 1118-1125
CrossRef1086
S. Khanduri, G. Gerrard, R. Barton, P. Mulvenna, S.M. Lee. (2006) Clinical Trials Assessing the Optimal Management of Brain Metastases — the State of Play. Clinical Oncology 18:10, 744-746
CrossRef1087
Nicholas W Choong, Ezra EW Cohen. (2006) Forthcoming receptor tyrosine kinase inhibitors. Expert Opinion on Therapeutic Targets 10:6, 793-797
CrossRef1088
James M.G. Larkin, Tim Eisen. (2006) Kinase inhibitors in the treatment of renal cell carcinoma. Critical Reviews in Oncology/Hematology 60:3, 216-226
CrossRef1089
Tefurumi KATO, Kazuto NISHIO. (2006) Clinical aspects of epidermal growth factor receptor inhibitors: Benefit and risk. Respirology 11:6, 693-698
CrossRef1090
J. de Castro Carpeño, C. Belda-Iniesta, J. Feliu Batlle, M. González Barón. (2006) Cáncer de pulmón (II). Tratamiento médico. Medicine - Programa de Formación Médica Continuada Acreditado 9:66, 4265-4269
CrossRef1091
Bruce E. Johnson, David Jackman, Pasi A. Jänne. (2006) Impact of EGFR mutations on treatment of non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 58:S1, 5-9
CrossRef1092
Wei-Chun Lin, Chao-Hua Chiu, Jia-Ling Liou, Yuh-Min Chen, Reury-Perng Perng, Chun-Ming Tsai. (2006) Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung Cancer 54:2, 193-199
CrossRef1093
Sae-Won Han, Tae-You Kim, Kyung-Hun Lee, Pil Gyu Hwang, Yoon Kyung Jeon, Do-Youn Oh, Se-Hoon Lee, Dong-Wan Kim, Seock-Ah Im, Doo Hyun Chung, Dae Seog Heo, Yung-Jue Bang. (2006) Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. Lung Cancer 54:2, 201-207
CrossRef1094
Alberto A. Chiappori, Peter M. Ellis, John Turner Hamm, Jacob David Bitran, Irene Eiseman, Jennifer Lovalvo, Diana Burnett, Stephen Olson, Peter Lenehan, Ralph Goldman Zinner. (2006) A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 1:9, 1010-1019
CrossRef1095
J Noble, P M. Ellis, J A. Mackay, W K. Evans. (2006) Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline. Journal of Thoracic Oncology 1:9, 1042-1058
CrossRef1096
Miranda Payne, Paul Ellis, David Dunlop, Malcolm Ranson, Sarah Danson, Lee Schacter, Denis Talbot. (2006) DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter Trial. Journal of Thoracic Oncology 1:9, 984-990
CrossRef1097
Dae Ho Lee, Ji-Youn Han, Sun Young Yu, Hyae Young Kim, Byung-Ho Nam, Eun Kyung Hong, Heung Tae Kim, Jin Soo Lee. (2006) The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study. Journal of Thoracic Oncology 1:9, 965-971
CrossRef1098
Jyoti D Patel. (2006) Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies. Current Opinion in Oncology 18:6, 609-614
CrossRef1099
Michael Davies, Bryan Hennessy, Gordon B Mills. (2006) Point mutations of protein kinases and individualised cancer therapy. Expert Opinion on Pharmacotherapy 7:16, 2243-2261
CrossRef1100
Syed M. AHMED, Ravi SALGIA. (2006) Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology 11:6, 687-692
CrossRef1101
F Oshita, S Matsukuma, M Yoshihara, Y Sakuma, N Ohgane, Y Kameda, H Saito, K Yamada, E Tsuchiya, Y Miyagi. (2006) Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. British Journal of Cancer 95:8, 1070-1075
CrossRef1102
H Asahina, K Yamazaki, I Kinoshita, N Sukoh, M Harada, H Yokouchi, T Ishida, S Ogura, T Kojima, Y Okamoto, Y Fujita, H Dosaka–akita, H Isobe, M Nishimura. (2006) A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. British Journal of Cancer 95:8, 998-1004
CrossRef1103
Helen J. Ross, Lowell L. Hart, Paul M. Swanson, Mark U. Rarick, Robert A. Figlin, Andrew D. Jacobs, David E. McCune, Arthur H. Rosenberg, Ari D. Baron, Laurie E. Grove, Michael D. Thorn, Dennis M. Miller, Jonathan G. Drachman, Charles M. Rudin. (2006) A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung Cancer 54:1, 69-77
CrossRef1104
Amir Onn, Burton F Dickey. (2006) A better crystal ball to predict lung-cancer survival?. The Lancet Oncology 7:10, 789-790
CrossRef1105
M Nazir Ibrahim, Zarina Abdullah, Michael J Martin. (2006) Recent developments in the chemotherapeutic options for nonsmall cell lung cancer. Expert Review of Anticancer Therapy 6:10, 1397-1410
CrossRef1106
Alex Chang, Purvish Parikh, Sumitra Thongprasert, Eng Huat Tan, Reury-Perng Perng, Domingo Ganzon, Chih-Hsin Yang, Chao-Jung Tsao, Claire Watkins, Nick Botwood, Nick Thatcher. (2006) Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. Journal of Thoracic Oncology 1:8, 847-855
CrossRef1107
C. Gridelli, A. Rossi, P. Maione. (2006) New antiangiogenetic agents and non-small cell lung cancer. Critical Reviews in Oncology/Hematology 60:1, 76-86
CrossRef1108
J. Feliu, G. Martín, J. Castro, A. Sundlov, A. Rodriguez-Jaráiz, E. Casado, M. Lomas, C. Madroñal, A. Galán, C. Belda, M. Gonzalez-Barón. (2006) Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 58:4, 527-531
CrossRef1109
Balvindar S Johal, Janessa Laskin. (2006) A new era for bronchioloalveolar carcinoma: current state of the art and recent advances in biologically targeted therapy. Expert Review of Anticancer Therapy 6:10, 1411-1419
CrossRef1110
Gary M. Clark, Denni M. Zborowski, Jennifer L. Culbertson, Marlo Whitehead, Michelle Savoie, Lesley Seymour, Frances A. Shepherd. (2006) Clinical Utility of Epidermal Growth Factor Receptor Expression for Selecting Patients with Advanced Non-small Cell Lung Cancer for Treatment with Erlotinib. Journal of Thoracic Oncology 1:8, 837-846
CrossRef1111
John Marshall. (2006) Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107:6, 1207-1218
CrossRef1112
Daniel T. Milton, Christopher G. Azzoli, Robert T. Heelan, Ennapadam Venkatraman, Jorge E. Gomez, Mark G. Kris, Lee M. Krug, William Pao, Naiyer A. Rizvi, Megan Dunne, Vincent A. Miller. (2006) A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer 107:5, 1034-1041
CrossRef1113
Lecia V. Sequist, Rafal Dziadziuszko. (2006) Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer. Journal of Thoracic Oncology 1:7, 740-743
CrossRef1114
Luis E Raez, Joseph D Rosenblatt, Eckhard R Podack. (2006) Present and future of lung cancer vaccines. Expert Opinion on Emerging Drugs 11:3, 445-459
CrossRef1115
Dae Ho Lee, Ji-Youn Han, Heung Tae Kim, Jin Soo Lee. (2006) Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: Retrospective analysis of 575 Korean patients. Lung Cancer 53:3, 339-345
CrossRef1116
John Nemunaitis, Nevin Murray. (2006) Immune-Modulating Vaccines in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 1:7, 756-761
CrossRef1117
Jose Baselga. (2006) Epidermal growth factor receptor pathway inhibitors. Update on Cancer Therapeutics 1:3, 299-310
CrossRef1118
Kohzoh Imai, Akinori Takaoka. (2006) Comparing antibody and small-molecule therapies for cancer. Nature Reviews Cancer 6:9, 714-727
CrossRef1119
E. A. Sausville. (2006) Respecting Cancer Drug Transportability: A Basis for Successful Lead Selection. JNCI Journal of the National Cancer Institute 98:16, 1098-1099
CrossRef1120
Sumithra J. Mandrekar, Steven E. Schild, Shauna L. Hillman, Katie L. Allen, Randolph S. Marks, James A. Mailliard, James E. Krook, Andrew W. Maksymiuk, Kari Chansky, Karen Kelly, Alex A. Adjei, James R. Jett. (2006) A prognostic model for advanced stage nonsmall cell lung cancer. Cancer 107:4, 781-792
CrossRef1121
Niels Reinmuth, Michael Meister, Thomas Muley, Martin Steins, Michael Kreuter, Felix J.F. Herth, Hans Hoffmann, Hendrik Dienemann, Michael Thomas. (2006) Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer. International Journal of Cancer 119:4, 727-734
CrossRef1122
Heung T. Kim, Ji-Youn Han, Dae H. Lee, Jong H. Chun, Hong G. Lee, Jae J. Lee, Hyae Y. Kim, Sung Y. Lee, Jin S. Lee. (2006) A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy. Cancer 107:4, 799-805
CrossRef1123
Christine L. Hann, Julie R. Brahmer. (2006) Second-line therapy for advanced non-small-cell lung cancer. Current Oncology Reports 8:4, 243-247
CrossRef1124
Antonio Jimeno, Manuel Hidalgo. (2006) Multitargeted therapy: Can promiscuity be praised in an era of political correctness?. Critical Reviews in Oncology/Hematology 59:2, 150-158
CrossRef1125
Coralia Bueno Muíño, José Ángel García-Sáenz, Sara López Tarruella, Laura Rodríguez Lajustica, Eduardo Díaz-Rubio. (2006) New target-based agents involve new clinical trial designs. Clinical and Translational Oncology 8:8, 581-587
CrossRef1126
I Bernard Weinstein, Andrew K Joe. (2006) Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. Nature Clinical Practice Oncology 3:8, 448-457
CrossRef1127
Smitha Patiyil, S. Ni Chan, Aminah Jatoi. (2006) New agents, new rashes: An update on skin complications from cancer chemotherapy. Current Oncology Reports 8:4, 269-274
CrossRef1128
Nickolas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein. (2006) The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nature Biotechnology 24:8, 985-995
CrossRef1129
B. M. Fischer, W. Eberhardt, R. Buhl, R. Pirker, N. Niederle. (2006) Molekular zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms. Der Onkologe 12:8, 769-779
CrossRef1130
Tetsuya Mitsudomi, Takayuki Kosaka, Yasushi Yatabe. (2006) Biological and clinical implications of EGFR mutations in lung cancer. International Journal of Clinical Oncology 11:3, 190-198
CrossRef1131
Yuh-Min Chen, Reury-Perng Perng, Jen-Fu Shih, Chun-Ming Tsai, Jacqueline Whang-Peng. (2006) Salvage Therapy for Chinese Non-small Cell Lung Cancer Patients Who Failed Previous Chemotherapy. Journal of Thoracic Oncology 1:6, 545-550
CrossRef1132
Shizhen Emily Wang, Archana Narasanna, Marianela Perez-Torres, Bin Xiang, Frederick Y. Wu, Seungchan Yang, Graham Carpenter, Adi F. Gazdar, Senthil K. Muthuswamy, Carlos L. Arteaga. (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:1, 25-38
CrossRef1133
Nancy E. Hynes, Thomas Schlange. (2006) Targeting ADAMS and ERBBs in lung cancer. Cancer Cell 10:1, 7-11
CrossRef1134
Pablo M. Bedano, Nasser H. Hanna. (2006) Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 1:6, 582-587
CrossRef1135
Gilberto de Castro, Ahmad Awada. (2006) Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies). Current Opinion in Oncology 18:4, 307-315
CrossRef1136
Hak Choy. (2006) Satraplatin: an orally available platinum analog for the treatment of cancer. Expert Review of Anticancer Therapy 6:7, 973-982
CrossRef1137
Ranee Mehra. (2006) The second annual symposium on the future of lung cancer: a translational focus. Expert Opinion on Therapeutic Targets 10:3, 475-480
CrossRef1138
F B J M Thunnissen, O C J Schuurbiers, M A den Bakker. (2006) A critical appraisal of prognostic and predictive factors for common lung cancers. Histopathology 48:7, 779-786
CrossRef1139
Derick Lau, Linlang Guo, Ruiwu Liu, Jan Marik, Kit Lam. (2006) Peptide ligands targeting integrin α3β1 in non-small cell lung cancer. Lung Cancer 52:3, 291-297
CrossRef1140
Yuh-Min Chen, Reury-Perng Perng, Chun-Ming Tsai, Jacqueline Whang-Peng. (2006) A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Lung Cancer 52:3, 333-338
CrossRef1141
Nagahiro Saijo. (2006) Recent trends in the treatment of advanced lung cancer. Cancer Science 97:6, 448-452
CrossRef1142
Guillermo Guhl, Ana González-De Arriba, Esteban Daudén. (2006) Efectos cutáneos de los inhibidores del receptor del factor de crecimiento epidérmico. Actas Dermo-Sifiliográficas 97:5, 296-310
CrossRef1143
Fred R. Hirsch. (2006) EGFR: A Prognostic and/or a Predictive Marker?. Journal of Thoracic Oncology 1:5, 395-397
CrossRef1144
Giorgio V Scagliotti. (2006) Can advanced non-small-cell lung cancer be treated with weekly instead of 3-weekly docetaxel?. Nature Clinical Practice Oncology 3:6, 294-295
CrossRef1145
C. Jochims, U. Mazitschek, D. Jäger, H. Goldschmidt. (2006) Zielgerichtete Therapie bei soliden Tumoren und in der Hämatoonkologie. Der Internist 47:6, 633-641
CrossRef1146
Giorgio Scagliotti. (2006) Proteasome inhibitors in lung cancer. Critical Reviews in Oncology/Hematology 58:3, 177-189
CrossRef1147
D. Garfield. (2006) Lung Cancer 52:3, 373
CrossRef1148
J Bennouna, J-L Breton, J-M Tourani, C Ottensmeier, M O'Brien, P Kosmidis, T E Huat, M-C Pinel, C Colin, J-Y Douillard. (2006) Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. British Journal of Cancer 94:10, 1383-1388
CrossRef1149
Heather A. Wakelee, Patricia Bernardo, David H. Johnson, Joan H. Schiller. (2006) Changes in the natural history of nonsmall cell lung cancer (NSCLC)—Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer 106:10, 2208-2217
CrossRef1150
Sarita Dubey, Jill M Siegfried, Anne M Traynor. (2006) Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. The Lancet Oncology 7:5, 416-424
CrossRef1151
Leticia R Villela, Brad L Stanford, Sachin R Shah. (2006) Pemetrexed, a Novel Antifolate Therapeutic Alternative for Cancer Chemotherapy. Pharmacotherapy 26:5, 641-654
CrossRef1152
Ron Feld, Srikala S. Sridhar, Frances A. Shepherd, Jean A. Mackay, William K. Evans. (2006) Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review. Journal of Thoracic Oncology 1:4, 367-376
CrossRef1153
Robert J Cersosimo. (2006) Gefitinib: an adverse effects profile. Expert Opinion on Drug Safety 5:3, 469-479
CrossRef1154
Luis E Raez, Rogerio Lilenbaum. (2006) New developments in chemotherapy for advanced non-small cell lung cancer. Current Opinion in Internal Medicine 5:3, 305-310
CrossRef1155
Hannelore Goeminne, Jan P van Meerbeeck. (2006) Pemetrexed in thoracic cancer. Expert Opinion on Pharmacotherapy 7:7, 917-928
CrossRef1156
C A Townsley, P Major, L L Siu, J Dancey, E Chen, G R Pond, T Nicklee, J Ho, D Hedley, M Tsao, M J Moore, A M Oza. (2006) Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. British Journal of Cancer 94:8, 1136-1143
CrossRef1157
Christophe A Dooms, Karin E Pat, Johan F Vansteenkiste. (2006) The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer. Expert Review of Anticancer Therapy 6:4, 531-544
CrossRef1158
Jonathan E Dowell, John D Minna. (2006) EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. Nature Clinical Practice Oncology 3:4, 170-171
CrossRef1159
Yoshiro Fujiwara, Katsuyuki Kiura, Shinichi Toyooka, Nagio Takigawa, Masaki Tokumo, Katsuyuki Hotta, Motoi Aoe, Masahiro Tabata, Keitaro Matsuo, Hiroshi Date, Mitsune Tanimoto. (2006) Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 52:1, 99-103
CrossRef1160
Daniel Morgensztern, Ramaswamy Govindan. (2006) Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474. Expert Review of Anticancer Therapy 6:4, 545-551
CrossRef1161
(2006) Bad patients meet good drugs. Clinical & Translational Oncology 8:4, 225-227
CrossRef1162
Marc-Eric Halatsch, Ursula Schmidt, Julianne Behnke-Mursch, Andreas Unterberg, Christian Rainer Wirtz. (2006) Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treatment Reviews 32:2, 74-89
CrossRef1163
Hans-Stefan Hofmann. (2006) The wind of change in the therapy of lung cancer. Expert Review of Anticancer Therapy 6:4, 469-472
CrossRef1164
Tanja Cufer, Eduard Vrdoljak, Rabab Gaafar, Inci Erensoy, Kristine Pemberton. (2006) Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anti-Cancer Drugs 17:4, 401-409
CrossRef1165
H Eugene LIU, Ken-Hong LIM, Ming-Jer HUANG, Biing-Shiun HUANG. (2006) Targeting epidermal growth factor receptor in lung cancer: Perspective from the Asia-Pacific region. Asia-Pacific Journal of Clinical Oncology 2:1, 22-31
CrossRef1166
Alex Y CHANG. (2006) Targeted cancer therapy: The prime time show in oncology. Asia-Pacific Journal of Clinical Oncology 2:1, 1-2
CrossRef1167
Cesare Gridelli. (2006) Targeted therapies and non-small-cell lung cancer: work in progress?. Current Opinion in Oncology 18:2, 132-134
CrossRef1168
Rafael Rosell, Mauricio Cuello, Fabiana Cecere, Mariacarmela Santarpia, Noemi Reguart, Enriqueta Felip, Miquel Taron. (2006) Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Current Opinion in Oncology 18:2, 135-143
CrossRef1169
Atul Kumar, Heather Wakelee. (2006) Second- and third-line treatments in non-small cell lung cancer. Current Treatment Options in Oncology 7:1, 37-49
CrossRef1170
Martin Reck. (2006) Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. Future Oncology 2:1, 47-51
CrossRef1171
Patricia A Tang, Ming-Sound Tsao, Malcolm J Moore. (2006) A review of erlotinib and its clinical use. Expert Opinion on Pharmacotherapy 7:2, 177-193
CrossRef1172
Amy P. Abernethy, Robert M. Arnold. (2006) PC-FACS: A Real-Time Evidence Resource for Busy Palliative Care Clinicians. Journal of Palliative Medicine 9:1, 24-28
CrossRef1173
Michael Cullen. (2006) Second-Line Treatment Options in Advanced Non–Small Cell Lung Cancer: Current Status. Seminars in Oncology 33, 3-8
CrossRef1174
Filippo de Marinis, Stefano De Santis, Luigi De Petris. (2006) Second-Line Treatment Options in Non–Small Cell Lung Cancer: A Comparison of Cytotoxic Agents and Targeted Therapies. Seminars in Oncology 33, 17-24
CrossRef1175
Fabrice Barlési, William Jacot, Philippe Astoul, Jean-Louis Pujol. (2006) Second-line treatment for advanced non-small cell lung cancer: A systematic review. Lung Cancer 51:2, 159-172
CrossRef1176
Martin J. Edelman, Ikuo Sekine, Tomohide Tamura, Nagahiro Saijo. (2006) Geographic Variation in the Second-Line Treatment of Non–Small Cell Lung Cancer. Seminars in Oncology 33, 39-44
CrossRef1177
Antonio Saha, Robin Rudd. (2006) Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer?. Expert Review of Anticancer Therapy 6:2, 165-173
CrossRef1178
Christopher M. Booth, Frances A. Shepherd. (2006) Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 1:2, 180-187
CrossRef1179
Vincent A. Miller. (2006) Optimizing Therapy in Previously Treated Non–Small Cell Lung Cancer. Seminars in Oncology 33, 25-31
CrossRef1180
Raymond Liu Chai, Jennifer Rubin Grandis. (2006) Advances in molecular diagnostics and therapeutics in head and neck cancer. Current Treatment Options in Oncology 7:1, 3-11
CrossRef1181
Natasha B. Leighl, W. Stephen Tsao, Dianne L. Zawisza, Mahsan Nematollahi, Frances A. Shepherd. (2006) A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer 51:1, 115-121
CrossRef1182
Young-Chul Kim, Kyu-Sik Kim. (2006) Drugs for Lung Cancer Treatment. Tuberculosis and Respiratory Diseases 60:2, 123
CrossRef1183
Michael Bergqvist, Sverre S??renson, Daniel Brattstr??m, Tony Mok, Roger Henriksson. (2006) Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer. American Journal of Cancer 5:4, 223-244
CrossRef1184
Michael Fanucchi, Fadlo R Khuri. (2006) Taxanes in the Treatment of Non-Small Cell Lung Cancer. Treatments in Respiratory Medicine 5:3, 181-191
CrossRef1185
C. Gridelli, A. Rossi, P. Maione, C. Ferrara, F. Gaizo, D. Nicolella, C. Guerriero, G. Colantuoni. (2006) Erlotinib in a previously treated advanced non-small cell lung cancer elderly patient: a clinical case. Targeted Oncology 1:1, 56-58
CrossRef1186
Kathryn J Strand, Hanif Khalak, Jeffrey W Strovel, Reinhard Ebner, Meena Augustus. (2006) Expression biomarkers for clinical efficacy and outcome prediction in cancer. Pharmacogenomics 7:1, 105-115
CrossRef1187
C. Gridelli, P. Maione, A. Rossi, C. Ferrara, G. Colantuoni, F. Gaizo, D. Nicolella, C. Guerriero. (2006) Targeted therapies in the treatment of advanced non-small cell lung cancer elderly patients. Targeted Oncology 1:1, 13-22
CrossRef1188
Justin Stebbing, Mark Bower. (2006) Comparative pharmacogenomics of antiretroviral and cytotoxic treatments. The Lancet Oncology 7:1, 61-68
CrossRef1189
T. Macarulla, C. Valverde, F. J. Ramos, E. Casado, E. Martinelli, J. Tabernero, A. Cervantes. (2006) Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies. Targeted Oncology 1:1, 23-33
CrossRef1190
Nico van Zandwijk. (2006) Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics. Lung Cancer 51:1, 137-138
CrossRef1191
Athanassios Argiris, Thomas Hensing, Anjana Yeldandi, Smita Patel, Adekunle Raji, Charles Sturgis, Gregory Masters, William Gooding, Michael Pins, Jill Kolesar. (2006) Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non???Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. Journal of Thoracic Oncology 1:1, 52-60
CrossRef1192
Junji Tsurutani, Marc Ballas, Seth M Steinberg, Valgardur Egilsson, Phillip A Dennis. (2006) Gefitinib for refractory advanced non-small-cell lung cancer. The Lancet 367:9507, 300
CrossRef1193
Amy D'Orazio, G. Kesava Reddy, Eric Nadler, David R. Gandara, Vinay K. Jain. (2006) 2005 Highlights From: First Annual Lung Cancer Symposium, New York, NY, November 2005. Clinical Lung Cancer 7:4, 235-240
CrossRef1194
Taro Shibata. (2006) Regulatory Points to Consider on Multiplicity Issues in Clinical Trials of New Drug Applications. Japanese Journal of Biometrics 27:Special_Issue, S78-S87
CrossRef1195
F Cappuzzo, L Toschi, I Domenichini, S Bartolini, G L Ceresoli, E Rossi, V Ludovini, A Cancellieri, E Magrini, L Bemis, W A Franklin, L Crino, P A Bunn, F R Hirsch, M Varella-Garcia. (2005) HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. British Journal of Cancer 93:12, 1334-1340
CrossRef1196
Suresh Ramalingam, Chandra P Belani. (2005) Molecularly-targeted therapies for non-small cell lung cancer. Expert Opinion on Pharmacotherapy 6:15, 2667-2679
CrossRef1197
Pasi A. Jänne. (2005) Ongoing First-Line Studies of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Select Patient Populations. Seminars in Oncology 32, 9-15
CrossRef1198
Thomas Lynch, Edward Kim. (2005) Optimizing chemotherapy and targeted agent combinations in NSCLC. Lung Cancer 50, S25-S32
CrossRef1199
Martin J. Edelman. (2005) An Update on the Role of Epidermal Growth Factor Receptor Inhibitors in Non–Small Cell Lung Cancer. Seminars in Oncology 32, 3-8
CrossRef1200
Giorgio Scagliotti. (2005) An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy 6:16, 2855-2866
CrossRef1201
Giuseppe Giaccone, Jose Antonio Rodriguez. (2005) EGFR inhibitors: what have we learned from the treatment of lung cancer?. Nature Clinical Practice Oncology 2:11, 554-561
CrossRef1202
E.A. EISENHAUER. (2005) Trial design for testing new therapies in ovarian cancer. International Journal of Gynecological Cancer 15:s3, 258-265
CrossRef1203
(2005) Erlotinib in Lung Cancer. New England Journal of Medicine 353:16, 1739-1741
Full Text1204
Ewan R Brown, Frances A Shepherd. (2005) Erlotinib in the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy 5:5, 767-775
CrossRef1205
Floriana Morgillo, Ho-Young Lee. (2005) Resistance to epidermal growth factor receptor-targeted therapy. Drug Resistance Updates 8:5, 298-310
CrossRef1206
Janine Smith. (2005) Erlotinib: Small-molecule targeted therapy in the treatmentof non-small-cell lung cancer. Clinical Therapeutics 27:10, 1513-1534
CrossRef1207
Janessa J Laskin. (2005) Adjuvant chemotherapy for non-small cell lung cancer: the new standard of care. Future Oncology 1:5, 619-623
CrossRef1208
Eric M. Toloza, Thomas A. D’Amico. (2005) Targeted Therapy for Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery 17:3, 199-204
CrossRef1209
Tsao, Ming-Sound, Sakurada, Akira, Cutz, Jean-Claude, Zhu, Chang-Qi, Kamel-Reid, Suzanne, Squire, Jeremy, Lorimer, Ian, Zhang, Tong, Liu, Ni, Daneshmand, Manijeh, Marrano, Paula, da Cunha Santos, Gilda, Lagarde, Alain, Richardson, Frank, Seymour, Lesley, Whitehead, Marlo, Ding, Keyue, Pater, Joseph, Shepherd, Frances A., . (2005) Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome. New England Journal of Medicine 353:2, 133-144
Full Text1210
Krause, Daniela S., Van Etten, Richard A., . (2005) Tyrosine Kinases as Targets for Cancer Therapy. New England Journal of Medicine 353:2, 172-187
Full Text1211
Doroshow, James H., . (2005) Targeting EGFR in Non–Small-Cell Lung Cancer. New England Journal of Medicine 353:2, 200-202
Full Text1212
C. Manegold. (2005) Zukünftige klinische Entwicklung von Bevacizumab und Erlotinib. Der Onkologe 11:S01, 49-52
CrossRef1213
D.A. HABER, D.W. BELL, R. SORDELLA, E.L. KWAK, N. GODIN-HEYMANN, S.V. SHARMA, T.J. LYNCH, J. SETTLEMAN. (2005) Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR Inhibitors. Cold Spring Harbor Symposia on Quantitative Biology 70:1, 419-426
CrossRef1214
L.C. AMLER, A.D. GODDARD, K.J. HILLAN. (2005) Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors. Cold Spring Harbor Symposia on Quantitative Biology 70:1, 483-488
CrossRef
- Letters
